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A population-based study in South East Wales (population 668,100) 
identified 69 families with 135 affected members with von Recklinghausen 
neurofibromatosis (NF-1), giving a disease prevalence of 20/105 of 
population. In these families penetrance of the NF-1 gene was 100% by the 
age of five years. 41/135 cases were judged to represent new disease 
mutations and the mutation rate was estimated to lie between 3.1x10-5 and 
10.4x10-5. A parental age effect for new mutations was not demonstrated, 
nor was a maternal effect on disease severity. 
The clinical features and natural history of NF-1 in this cohort were 
used to derive data for genetic counselling and recommendations for the 
management of affected individuals. For counselling purposes the 
complications of NF-1 can be usefully divided into 4 categories (the 
frequency of each, based on this study, are shown in parentheses): 
intellectual handicap (33% overall, moderate/severe retardation 3.2%, 
minimal retardation/ learning difficulties 29.8%); complications developing 
in childhood and causing lifelong morbidity, e. g. facial plexiform 
neurofibromas, scoliosis, pseudoarthrosis (8.5%); 'treatable' complications 
which can develop at any age, e. g. benign disorders of the nervous system, 
visceral and endocrine tumours, renal artery stenosis (15.7%) and malignant 
or CNS tumours (4.4-5.2%). 
The study population indicates that sufferers are not being diagnosed 
sufficiently early, nor receiving appropriate follow-up and counselling. 
It is recommended that patients with NF-1 have regular clinical assessments 
to monitor for the development of complications, although none occur often 
enough to warrant biochemical or radiological screening. As many of the 
complications develop early in life, children should have biannual review; 
in adults, unless a particular complication indicates more frequent review, 
11 
annual clinical examination is sufficient. 
Alongside the population survey, genetic linkage studies were 
undertaken in selected large families to determine the chromosomal 
localisation of the NF-1 gene. At the outset of this work, two families 
had been reported in which NF-1 and Myotonic Dystrophy (DM) appeared to 
co-segregate, suggesting that the two genes were closely linked and on 
chromosome 19. However, linkage studies of 3 chromosome 19 markers linked 
to DM showed significantly negative lod scores, therefore excluding this 
possibility. Other chromosomes were then studied using random unique 
sequence DNA probes and samples from the largest families were made 
available to collaborators in the USA for linkage studies using possible 
candidate genes (ß nerve growth factor and oncogenes). No marker studied 
showed evidence of linkage. 
The negative data were used to produce an exclusion map for NF-1, using 
the computer program 'EXCLUDE'. The presentation of this work was one of 
the factors which precipitated the formation of an international consortium 
for NF-1 linkage in February 1987; the first task of the consortium was to 
produce an expanded exclusion map. A small positive lod score for a marker 
on chromosome 17, taken with the exclusion data, showed that NF-1 was seven 
times more likely to be on chromosome 17 than any other chromosome; this 
was rapidly confirmed by two North American groups, one of which was using 
samples from the 5 largest families presented in the thesis. Subsequent 
linkage analysis of pericentromeric chromosome 17 markers in the Welsh 
family panel showed no evidence of non-allelic heterogeneity and identified 
closely linked flanking markers for the NF-1 gene suitable for 
prenatal/presymptomatic diagnosis. The chromosomal localisation of NF-i 
represents a major step towards the eventual understanding of the disease 
pathogenesis and the development of possible treatments. 
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PART 1 
CLINICAL AND GENETIC STUDIES OF VON RECKLINGHAUSEN 
NEUROFIBROMATOSIS IN SOUTH EAST WALES 
CHAPTER 1 Von Recklinghausen neurofibromatosis - literature review 
and aims of present study 
1. Introduction 
"So you see that it is not an idle whim of mine to talk and 
write so often about these phakomatoses*, but. that the study of 
them can be of great advantage for our patients and of great 
value for our knowledge. " 
Van der Hoeve, 
Doyne Memorial Lecture, 1932. 
Von Recklinghausen or type 1 neurofibromatosis (NF-1) is one of 
the commonest autosomal dominant disorders of man; Crowe et al (1956) 
estimated that the birth incidence may be in the region of 
1/2500-3300. The major features of the disease are cafe au lait 
(CAL) spots, peripheral neurofibromas and Lisch nodules (pigmented 
iris hamartomas). The morbidity and mortality caused by NF-1 is 
largely dictated by the occurrence of its complications; these are 
numerous and can involve any of the body systems. 
In embarking on the present study of NF-1, the primary interest 
was in mapping the disease gene by family linkage studies; this work 
is presented in part 2 of this thesis. Reviewing the literature at 
the outset, it became apparent that there were many unanswered 
questions about various clinical and genetic aspects of the disease; 
there had been no major survey of NF-1 in the British population. 
Alongside linkage studies, a population-based study of the disease in 
South East Wales was therefore undertaken. 
* Van der Hoeve coined the term phakomatosis in 1923 to epitomise 
NF-1 and tuberous sclerosis; "phakos" is the Greek for birth mark. 
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In this chapter an overview of the NF-1 literature is presented 
and the unresolved questions addressed by the population study 
outlined. 
2. Literature review 
(A) Clinical aspects - The clinical features of NF-1 are summarised 
in Table 1-1. The disease complications are based on the findings of 
previous large population- or hospital-based surveys (Borberg 1951; 
Crowe et al 1956; Brasfield & Das Gupta 1972; Riccardi & Kleiner 
1977; Bader & Miller 1978; McKeen et al 1978; Carey et al 1979; 
Samuelsson 1981; Riccardi & Eichner 1986). 
From a historical viewpoint, the first descriptions are of adult 
patients with multiple dermal tumours found in the eighteenth century 
literature (Akenside 1768; Ludwig & Tilesius 1793). By 1849 Smith 
was able to cite 75 references in a review of the literature; he 
presented two further cases and postulated, although was unable to 
prove, that the tumours arise from the fibrous connective tissue 
sheath of small nerves. Thirty-three years later, von Recklinghausen 
(1882) demonstrated that this was indeed the case and named the 
tumours neurofibromas. Von Recklinghausen also emphasised that one 
of his two cases had an affected sibling and realised the disease was 
not acquired. Following this important work, the disease became 
known as von Recklinghausen's disease. 
Von Recklinghausen (1882) also described "innumerable brown 
pigmentation spots" in one of his cases, but did not appreciate their 
significance. The credit for this falls to Marie & Bernard (1896) 
14 
Table 1-1 The clinical features of NF-1 
Major defining features 






Complications (by body system) 
















Lateral thoracic meningocoele 
Lambdoidal suture defects 











Renal artery stenosis 
Cerebrovascular disease 
f) Respiratory 





Atypical forms of childhood 
leukaemia 
* Indicates some doubt whether definite increased frequency 
** NFS = neurofibromas 
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and Chauffard (1896). Although it was not until the study of Crowe 
et al (1956) that it was accepted that CAL spots were the first 
manifestations of the disease to appear, some authors prior to this 
had described young patients with only CAL spots as having a "forme 
fruste" of the disease (Parkes Weber 1909). Much later, Crowe (1964) 
reported that axillary freckling was a clinical feature unique to 
NF-1. 
Abnormalities of the iris in NF-1 were first reported clinically 
by Waardenburg in 1918; he described small wart-like iris lesions 
which he presumed to be neurofibromas. Goldstein & Wexler (1930) 
demonstrated multiple melanocytic tumours of the iris in the eyes of 
a patient with NF-2 at necropsy. In 1937 Lisch reported 3 cases of 
NF-1 all of which had nodular lesions of the iris which had a 
distinct appearance. He concluded that they were pathognomic of the 
disease and that if the irides of more NF-1 patients were examined, 
they would be a frequent finding. His hypothesis was not tested 
until 1981 and was then found to be correct; Lewis & Riccardi found 
Lisch nodules to be present in 56/61 (92%) of patients >5 years of 
age. 
After the recognition of NF-1 as a distinct entity, clinical 
reports of complications affecting most of the body systems began to 
appear in the literature, but it was only with the first large 
clinical studies of Borberg (1951) and Crowe et al (1956) that the 
spectrum and prevalence of complications became more clear. Since 
that time there have been four further large surveys of patients with 
NF-1 (Brasfield & Das Gupta 1972; Carey et al 1979; Samuelsson 1981; 
Riccardi & Eichner 1986). The prevalence of the major complications 
found in the six studies are given in Table 1-2. There are 
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4 
made between NF-1 and the other forms of neurofibromatosis (Crowe et 
al 1956; Carey et al 1979; Samuelsson 1981). In others, the study 
sample was not population-based and therefore the frequency of 
complications may be an over-estimate, resulting from referral of 
more severely affected cases for specialist referral (Borberg 1951; 
Brasfield & Das Gupta 1972; Carey et al 1979; Riccardi & Eichner 
1986). These differences in diagnostic classification and patient 
ascertainment mean that combining the findings of the various studies 
to give an overall estimate of complications is not possible and 
highlight the need for further studies looking at the frequency of 
complications in a series of patients with well-defined NF-1 
ascertained in a relatively unbiased manner. 
There is no specific preventive treatment available for any of 
the manifestations of NF-1; the majority of complications are treated 
in the same way as when they occur in isolation. In reviewing the 
NF-1 literature, it is apparent that all major clinical specialties 
are involved in the care of sufferers; reports of disease features in 
individual cases or groups of patients can be found in the journals 
of many different disciplines. The fact that most of the 
complications of NF-1 are individually rare has meant that no one 
specialty has had to take responsibility for the overall care of NF-1 
sufferers. This undoubtedly has resulted in a lack of systematic 
clinical and laboratory investigation of the disease until relatively 
recently. 
In the last decade, however, there has been an increasing 
awareness of the problems encountered by NF-1 sufferers and there has 
been pressure on the medical profession from the lay organisations 
for disease sufferers (e. g. the National Neurofibromatosis Foundation 
in the USA, formed in 1978; LINK in the UK, formed in 1981) to begin 
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to take an overview of the care of NF-1 sufferers, with particular 
regard to co-ordination of their medical care and the need for 
improved counselling about the clinical and genetic aspects of the 
disease. In the USA several centres have responded to this need by 
establishing neurofibromatosis clinics and have begun to formulate 
protocols for the assessment and follow-up of NF-1 sufferers. 
Riccardi, who established one of the first neurofibromatosis clinics, 
suggested the following protocol in a review article in 1981 
(Riccardi 1981a): 
"... all persons with neurofibromatosis or at risk for it should 
routinely undergo an extensive evaluation aimed at confirming the 
diagnosis, identifying complications, and monitoring progression. 
The evaluation should include the following procedures: 
intelligence-quotient measurement and psychological testing; 
electroencephalography; audiography; slit-lamp ocular exmination; 
radiological skeletal surveying with special attention to the 
skull, optic foramina, and spine (and, in selected cases, 
internal auditory canals); cranial CT scanning with and without 
dye contrast, to include the orbits and optic chiasm; and 
measurement of 24-hour urinary excretion levels of epinephrine 
and novepinephrine. " 
At the outset of the present study no centre in the United 
Kingdom ran a specialist neurofibromatosis clinic. Discussions with 
colleagues in various disciplines suggested that some accepted the 
need to offer NF-1 sufferers regular follow-up although it was felt 
that screening investigations, such as those suggested by Riccardi, 
were unnecessary. 
(B) Genetic aspects - The first family in which NF-1 occurred in more 
than one generation was probably that reported by Virchow in 1847. 
Thomson undertook a systematic genetic survey in 1900, demonstrating 
that the disease was familial in 30 of 77 reported cases. Preiser & 
Davenport (1918) studied the frequency of NF-1 in children of 
19 
affected individuals in the literature; they found that 50/115 (44%) 
were affected, with no difference in the sex distribution and many 
instances of male to male transmission; it was concluded that 
inheritance was autosomal dominant. 
Subsequent authors accepted that at least in some families 
inheritance was autosomal dominant, but were confused by the high 
reported incidence of sporadic cases and failure to appreciate the 
significance of multiple CAL spots in relatives of affected 
individuals. Siemens (1926) suggested that inheritance was more 
often irregular dominant with frequent 'skipped' generations. 
Siemens concluded that the multiple CAL spots seen in relatives of 
index cases were an unrelated phenomenon; this was later to be proved 
wrong. In the same year, Fischer reviewed 466 previously reported 
cases and found that 81% of males and 64% of females were unmarried, 
that the age of marriage was high and fertility low. He suggested 
that mutation plays an important part in maintaining disease 
frequency and accounts for sporadic cases. Peyron et of (1937) 
thought the pattern of inheritance more complex and proposed 3 forms: 
monomeric dominant, monomeric recessive and a dimeric form in which 
there was one dominant gene and an additional modifying factor. 
The question of mode of inheritance was resolved by the studies 
of Borberg (1951) and Crowe et of (1956). Both concluded that 
inheritance was autosomal dominant with high penetrance and that 
sporadic cases represent new gene mutations. Crowe and colleagues 
were the first to estimate the frequency of the disease 
(1/2,500-1/3,300) and mutation rate (1 x 104 per gamete per 
generation - the highest known for a human disorder). The subsequent 
studies of Sergeyev (1975) and Samuelsson & Axelsson (1981) found the 
disease to be less prevalent and the mutation rate more in line with 
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other disorders. The three studies are summarised in Table 1.3. The 
study of Crowe et al (1956) is the only one in which the genetic 
fitness of NF-1 sufferers, which is synonymous with relative 
effective fertility, has been estimated. They found the fitness of 
NF-1 sufferers to be approximately half of that of the normal 
population (0.53); the reduction was more marked in males than 
females. 
In 1955 Penrose proposed that if mutations of disease genes are 
due to copy error at cell division, then as there are many more cell 
divisions in the male than female germ line, one would expect to see 
a paternal age effect - the fathers of new mutations being older than 
expected. This has been shown to be the case in several dominant 
diseases (e. g. achondroplasia, Apert syndrome; see Risch et a] 1987 
for most recent review). For NF-1, three studies have shown 
conflicting results. Samuelsson (1981) showed neither a birth order 
nor a parental age effect (with a paternal age effect one would 
expect sufferers to be born later than unaffected siblings). 
Sergeyev (1978) showed a birth order effect and a weak paternal age 
effect, the paternal age increase over population controls being 1.99 
years (p=0.03). However, Riccardi et al (1984) showed a highly 
significant paternal age increase (3.15 years, p<0.001). 
Another area of conflicting results has been in the investigation 
of maternal effect on disease severity. Miller & Hall (1978), 
studying 62 cases aged <18 years, found an increased severity in 
children born to affected fathers or new mutations. Two subsequent 
studies (Carey et al 1979; Riccardi & Wald 1987) failed to 
demonstrate this effect. 
For genetic counselling the two main pieces of information 
required, in addition to mode of inheritance, are an estimation of 
21 
Table 1-3 Summary of previons estimates of prevalence and mutation 
rate for NF-1 
Study (year) Method of Prevalence Mutation rate 
ascertainment (method) 
Crowe, Neel & Surveys of general 1/2500-3300 
Schull (1956) hospital admissions 
and state mental 
institutions 
Sergeyev (1975) Population sample 1/7800 
of 16 year old youths 










the likely disease severity in affected offspring and at what age the 
disease features appear. All previous large studies of NF-1 have 
found that complications occur at random, even within families, the 
only exception being in identical twins (reviewed in Section F(i)). 
However, only one previous study has stated actual figures for risk 
of complications to use in genetic counselling. Riccardi et al 
(1979), based on the results of a hospital-based survey, state that 
for an affected person in a family brought to medical attention there 
is a 25% chance of moderate or severe complications and following 
from this, a 12.5% chance of similar problems in their offspring. No 
study has looked specifically at the age of appearance of the major 
defining features to derive an age when relatives at-risk, not 
demonstrating these features, can be reassured that they do not carry 
the gene. 
(C) Pathological findings in NF-1 - Only the pathology of the major 
features of NF-1 and plexiform neurofibromas, a complication 
relatively specific to the disorder, are discussed here. For most of 
the complications, the underlying pathology is the same as when the 
lesion occurs in isolation; if this is not the case, the features 
specifically associated with NF-1 are discussed in Chapter 5, where 
the complications are individually reviewed. 
(i) CAL spots - CAL spots are not unique to NF-1 sufferers. Crowe 
and Schull (1953) reported that 684/6853 (10%) institutionalised 
patients, who had no other NF-1 features, had 1-3 CAL spots and Kopf 
et al (1985) observed this number of CAL spots in 13.8% of patients 
attending a private dermatology clinic. There are no clinical 
differences in the appearance of the CAL spots in NF-1 sufferers and 
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the general population; it is the number of CAL spots which 
distinguish NF-1 sufferers. 
Histologically there are two features which to some extent 
distinguish the CAL spots of NF-1 but neither is distinctive enough 
to act as a true diagnostic test. Johnson and Charneca (1970) 
reported that the CAL spots in NF-1 sufferers show an increase in 
DOPA-positive melanocytes, as did an axillary "freckle" from one of 
their cases. The control normal skin from NF-1 sufferers showed a 
less marked increase. In normal individuals with only one or two CAL 
spots, these authors found no alteration in number in the normal skin 
but a decrease in melanocytes in the CAL spots. They argued that 
these findings suggested that the axillary freckles in NF-1 are 
simply small CAL spots and conversely, that as normal freckles show 
decreased melanocytes (Breathnach 1957), the CAL spots in normal 
individuals are just large freckles. Their patient numbers, however, 
were small. 
In another study, Benedict et al (1968), studying only NF-1 
sufferers, found a similar significant increase in DOPA-positive 
melanocytes in both CAL spots and uninvolved skin (p=0.05). Their 
study highlighted an apparently more specific feature in that the 
melanocytes showed large numbers of giant pigmented granules (now 
termed melanin macroglobules) in CAL spots; they were also present, 
but less frequent, in normal skin. Melanin macroglobules (MMG), 
however, are not specific to NF-1, being an occasional finding in 
normals and being seen in other disorders, including Albright's 
syndrome, LEOPARD syndrome and Keroderma pigmentosum (Fitzpatrick and 
Martuza, 1986). 
To assess whether MMG could be used as a diagnostic marker for 
NF-1, Martuza et al (1985) studied their number per high-power field 
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on light microscopy in CAL spots in NF-1 sufferers and in normal 
individuals. The NF-1 CAL spots had a significantly greater number 
(p<0.0008). However, all the NF-1 patients were ; 16 years of age and 
at this age other NF-1 features are usually present. Riccardi and 
Eichner (1986) reported that CAL biopsy from two children with NF-1 
showed only occasional MMG, suggesting the number is age-related and 
that MMG would not be useful as a diagnostic marker in children. 
(ii) Neurofibromas - The neurofibromas in NF-1 can occur anywhere in 
the body, arising from sensory and autonomic nerves. It is the 
dermal neurofibromas that are regarded as a major defining feature. 
How frequently asymptomatic neurofibromas occur elsewhere in the body 
is an unknown factor; from the patient's viewpoint, however, it is 
only when they become symptomatic that problems arise, and for the 
purpose of the present study, symptomatic neurofibromas occurring 
"internally" have been regarded as complications of the disease (e. g. 
spinal and gastrointestinal neurofibromas). 
The neurofibromas in NF-1 are indistinguishable histologically 
from solitary neurofibromas occurring in otherwise normal individuals 
(Harkin and Reed 1969). Cutaneous neurofibromas are well 
circumscribed but not encapsulated, the nerve of origin is not 
usually obvious. Neurofibromas occurring elsewhere (e. g. on nerve 
roots, larger peripheral nerves) are more sharply demarcated and have 
an apparent capsule of perineural cells. The fibres of the nerve of 
origin pass through the tumour and are not stretched over its 
surface, as is the case in schwannomas (Harkin and Reed 1969). 
Microscopically the tumours consist of a disordered proliferation of 
schwann cell elements loosely arranged in a collagenous stroma. 
Other cellular elements identifiable in neurofibromas are 
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fibroblasts, perineurial, endoneurial and mast cells (Riccardi and 
Eichner 1986) 
Plexiform neurofibromas are distinct from other neurofibromas in 
that they are locally invasive (Harkin and Reed 1969; Harkin 1986), 
although they are composed of the same cells. The plexiform 
neurofibroma grows within and along the nerve, enlarging the nerve 
fascicles and elongating each fascicle; this growth causes the 
fascicles to twist on themselves, eventually creating a lesion 
resembling a tangle of worms. In the early stage of the lesion, 
hypercellular fascicles are found. As the lesion develops, there is 
an increase in the number of schwann cells and/or perineural cells. 
A few residual axons that have not been destroyed by the tumour can 
be found. As the lesion grows, the fascicle can either become 
hypocellular and myxomatous or even more cellular; the two 
pathologies can be found side by side in a single lesion. The skin 
overlying plexiform neurofibromas may be hypertrophied or 
hyperpigmented. 
(iii) Lisch nodules - LN are melanocytic hamartomas (Perry and Font 
1982) which on light microscopy are shown to be composed of a 
haphazard population of spindle-shaped cells with slender dendritic 
processes intermixed with round, plumper cells. On electron 
microscopy, these cells are shown to be melanocytes with many 
interwoven cytoplasmic processes and containing a mixture of immature 
and mature cells. 
(D) The different forms of neurofibromatosis - As mentioned in 
Section 2A, one of the problems in the past has been that patients 
with what are now recognised to be different types of 
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neurofibromatosis have been lumped together under the label of "von 
Recklinghausen's disease". Riccardi (1982) proposed a classification 
which includes 7 different types of neurofibromatosis and an eighth 
category for cases "not otherwise specified", the definition of the 
different forms depending on variation in the occurrence, number and 
distribution of the major defining features and associated 
complications, particularly tumours of the nervous system. 
Riccardi's classification is summarised in Table 1-4. 
This classification has not been widely accepted, because the 
type III 'mixed', type IV variant and type VII 'late onset' forms are 
not defined sufficiently to make their general use clinically 
applicable. The National Institutes of Health (NIH) Consensus 
Conference on neurofibromatosis addressed the issue of nomenclature 
and classification in July 1987. The consensus panel decided that at 
present there was clear evidence to distinguish NF-1 from bilateral 
acoustic NF (type 2, NF-2) but that there were insufficient grounds 
for further subclassification at the present time. The author feels 
that the different types which can be classified are as follows: 
(i) NF-1 - The clinical features of which are summarised in Table 
1-1 and compared with which all other forms are extremely rare. 
(ii) NF-2 - NF-2 is also inherited as an autosomal dominant; the 
major features are bilateral acoustic neuromas with or without other 
tumours (e. g. meningiomas, schwannomas, gliomas). The confusion with 
NF-1 arises because patients may also have CAL spots or peripheral 
neurofibromas. The largest series of patients has been reviewed by 
Kanter et al (1980) who found 42% had one or more CAL spots (but none 
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nodules are not seen in NF-2. In other words, more patients than 
expected had minor cutaneous manifestations, and it is this that has 
led authors in the past to classify patients or families with this 
condition as having "von Recklinghausen disease" (Crowe et al 1956; 
Rodriguez & Berthrong 1966; Lee & Abbott 1969). 
The recognition of NF-2 as a separate entity is important: its 
clinical and genetic implications are quite different from NF-1 
(Huson & Thrush 1985). The concept that acoustic neuromas occur with 
increased frequency in NF-1 may also be erroneous and due to lack of 
distinction between the two conditions. Crowe and colleagues (1956) 
found that 10 of their patients (approximately 5%) had clinical, 
radiological or pathological evidence for eighth nerve disease, but 
in retrospect there is good evidence for an acoustic neuroma in only 
4, none of whom would satisfy current criteria for the diagnosis of 
NF-1. Although the remaining 6 patients appear to have NF-1, none 
has convincing evidence for an acoustic neuroma. 
Whether NF-2 can be further subdivided into a group in which only 
acoustic neuromas occur and another in which there are multiple other 
CNS tumours in addition, as suggested by Riccardi's classification, 
is still to be established. 
(iii) Segmental neurofibromatosis - In the study of Crowe et a! 
(1956) 4 cases are reported where the CAL spots and neurofibromas 
were limited to one segment of the body. In a 1986 review, Carey et 
al describe 3 cases and cite a further 10 cases from the literature 
(Miller & Sparkes 1977; Zonana & Weleber 1984; Saul & Stevenson 
1984). The patient of Zonana & Weleber had facial involvement with 
Lisch nodules on the ipsilateral side. Crowe et al (1956) suggested 
these cases may represent somatic mutation of the NF-1 gene and 
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subsequent authors have agreed with this. 
(iv) CAL spots only - Two families have been reported by Riccardi 
(1982) in which the affected individuals have multiple CAL spots as 
their only defining feature. In one, both the affected mother and 
son are of low intelligence and have mild pectus excavation; the boy 
is described as having questionable unilateral axillary freckling. 
The importance of these families is that the diagnosis of NF-1 
can not be made in young children, with no affected relatives, and in 
whom the only feature is multiple CAL spots. 
(v) Other possible forms - In 1985 a series of papers in one issue 
of The American Journal of Human Genetics described a series of 
isolated cases with the features of both NF-1 and Noonans Syndrome 
(Allanson et al 1985a; Kaplan & Rosenblatt 1985; Mendez 1985; Opitz & 
Weaver 1985). It was proposed that these cases may represent a new 
syndrome which was referred to as the "Neurofibromatosis-Noonan 
Syndrome" (NFNS). Since that time two reports of apparent vertical 
transmission of NFNS have been published (Quattrin et al 1987; Abuelo 
& Meryash, 1988). 
On review of the presented cases, the present author finds it 
difficult to accept a new ', syndrome' with features of NF-1 and 
Noonans combined and no unique features. More plausible explanations 
are that the two genes may be closely linked or that individuals with 
NF-1 may occasionally have the Noonan phenotype, as has been 
suggested by Meinecke (1987). 
(E) Differential diagnosis - In the introduction to their classic 
monograph, Crowe et ai (1956) state: 
"There is much in the literature which suggests the diagnosis of 
Neurofibromatosis is frequently beclouded with uncertainty. Our 
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experience would indicate otherwise. " 
This seems to have been the experience in all major surveys, and 
although some have not clearly distinguished other forms of 
neurofibromatosis, distinction from unrelated diseases seems rarely 
to be a problem. 
The two other syndromes in which there is CAL pigmentation 
similar to that seen in NF-1 are: 
(i) McCune-Albright syndrome - in which the patients have areas of 
CAL pigmentation, but usually with more irregular borders than in 
NF-1, and occurring with polycystic fibrous dysplasia and sexual 
precocity (McCune 1936; Albright et al 1937). The reported cases 
have been sporadic and the aetiology is undetermined (Smith 1982). 
(ii) Watson syndrome - in which Watson (1967) has described the 
affected individuals as having multiple CAL spots alone, dull 
intelligence and pulmonary stenosis. Some individuals also had 
axillary freckling. Inheritance was autosomal dominant. These 
families may show overlap with those of Riccardi (1981b) with CAL 
spots alone and possibly with the NFNS, although despite the 
occurrence of pulmonary stenosis, none of the Watson syndrome 
patients had the Noonan phenotype (Watson 1986, personal 
communication). 
The Proteus Syndrome, first described by Cohen & Hayden in 1979, 
has also been confused with NF-1 in the past. The cardinal 
manifestations of the Proteus Syndrome are hemihypertrophy, 
macrodactyly, exostoses, scoliosis, cavernous hemangiomas, lipomas 
and linear sebaceous nevi (Clark et a! 1987). The hemihypertrophy, 
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with associated subcutaneous swelling, can resemble a large plexiform 
neurofibroma therefore causing confusion with NF-1, although the 
abnormalities in skin pigmentation in the two disorders are quite 
distinct. The famous Elephant Man, Joseph Merrick (Treves 1885), was 
believed to have NF-1 for many years, the diagnosis having been 
originally suggested by Parkes Weber in 1909; recently, however, 
Tibbles & Cohen (1986) have suggested, quite rightly in the author's 
opinion, that Merrick in fact had Proteus Syndrome 
(F) Pathogenesis 
(i) Principal theories - The pathogenesis of NF-1 is unknown, any 
theory has to allow for the numerous complications and the very 
varied gene expression. All of the previous large studies have found 
variable gene expression even within families; identical twins have 
been described which are both discordant for complications (facial 
plexiform neurofibromas, Diekman et al 1967; optic glioma, Vaughn et 
al 1981) and concordant (optic glioma, Crawford & Buckler 1983). 
There also appears to be a hormonal influence on the disease; the 
neurofibromas themselves do not usually appear until puberty and 
pregnancy has been reported to cause both an increase in size and 
number of neurofibromas (Ansari & Nagamani 1976; Swapp & Main 1973). 
The three main theories of pathogenesis proposed to date have 
been: 
(a) NF-1 as a neurocristopathy - Bolande (1974,1981) proposed that 
various dysgenetic hamartomatous and neoplastic conditions were 
pathogenetically united by their origin in neural crest development. 
The disease states resulting from abnormal migration, growth or 
cytodifferentiation of primitive neural crest cells at various stages 
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of human development. Bolande used the term neurocristopathies to 
describe the group of conditions, and divided them into two: 
1. Simple neurocristopathies - characterised by a singular 
pathological process e. g. Hirschsprung disease (dysgenetic) and 
phaeochromocytoma (neoplastic). 
2. Complex neurocristopathies - syndromes of multiple and 
variegated simple neurocristopathies, e. g. NF-1, Sipple syndrome, 
neurocutaneous melanosis. 
The major features of NF-1 (CAL spots, neurofibromas, Lisch 
nodules) all arise in tissues of neural crest origin, as do some of 
the complications (craniofacial abnormalities, endocrine tumours). 
More difficult to explain are the CNS abnormalities (neural tube 
origin) and those complications arising in tissue of mesodermal 
origin (skeletal and vascular abnormalities). The consideration of a 
primary neural crest problem with secondary changes in other tissues 
could explain this; to date there has been no laboratory evidence to 
prove that NF-1 is a neurocristopathy. 
(b) The NF-1 mutation involves a component of cell secretory 
membrane - This theory was put forward by Riccardi (1982) and 
proposes an actual site for the abnormality in neural crest cells in 
NF-1. In two earlier papers (Riccardi 1979,1981b) he had proposed 
that although neural crest derived cells are probably the site of the 
primary defect in NF-1, the mutation is only expressed when the 
intracellular defect of the mutant cells had not been masked by 
cross-feeding from adjacent non-mutant cells, thus explaining the 
variation of expression of the features of NF-1. 
Riccardi (1982) then proposed that the NF-1 mutation involves a 
hypothetical component of secretory and/or plasma membranes which he 
names the parareceptor component (pR); the function of the pR is in 
modulating the behaviour of cell receptors on the plasma membrane. 
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The pR may be synthesised purely for this purpose and incorporated 
directly into the plasma membrane, but Riccardi favours the idea that 
it is a component of the membrane of secretory vesicles and 
incorporated into the plasma membrane at the time of extrusion of 
vesicle contents through the plasma membrane. In cells with large 
amounts of secretory activity, such as neural crest cells, the 
influence of pR on receptor function may be a major one. If the NF-1 
gene involves a pR mutation then this would result in aberrant 
function of multiple receptor sites (e. g. for growth factors, 
melanocyte stimulating hormone). In addition, adjacent cells may 
dampen the pR effect by decreasing secretory activity of the neural 
crest-derived cell or increase it by enhancing this activity or 
stimulating proliferation of neural crest cells. 
Although this hypothesis would explain many of the phenotypic 
manifestations of NF-1, again there is to date no laboratory evidence 
to confirm or refute it. 
(c) Nerve Growth Factor (NGF) - NGF is a polypeptide necessary for 
the growth and maintenance of sympathetic and certain sensory 
neurons. Early studies in small numbers of patients (reviewed by 
Eldridge 1981) suggested that there may be increased NGF activity in 
the serum of patients with NF-1 and NF-2; in each form the activity 
was detected in different assay systems and it was proposed that the 
two forms may result from different abnormalities of NGF (Fabricant 
et al 1979). 
This theory has now been disproved in two ways. Riopelle et al 
(1984) investigated NGF activity in a much larger number of NF-1 
patients, with an improved assay system, and found no abnormalities. 
Darby et al (1985) used the ß-NGF DNA probe in linkage studies and 
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found multiple cross-overs, thereby excluding NGF as a 'candidate' 
gene for NF-1 (discussed in more detail in Chapter 2-2). 
(ii) Animal models - The occurrence of single or multiple 
neurofibromas has been reported in various birds (Bossart 1983) and 
mammals including cows, horses and dogs (Luginbuhl et al 1968; 
Goedegebuure 1975; Canfield 1978). No other features similar to NF-1 
however have been noted and none are apparently genetic in aetiology. 
The only animal known to have abnormalities of pigmentation and 
to develop neurofibromas is the bicolour damsel fish (Schmale et al 
1986). As these fish reach maturity they develop areas of thickened, 
hyperpigmented epithelium which is followed by the development of 
nerve cell tumours (neurofibromas, schwannomas and neurofibrosarcomas 
have all been documented). Epidemiological studies of these fish 
suggest an infectious rather than genetic aetiology. Schmale et al 
suggest a viral oncogene as a possible candidate. 
On this note, the recent finding of Hinrichs et al (1987) that 
transgenic mice arising from the incorporation of human 
T-lymphotropic virus type 1 develop neurofibromas is of interest. 
The authors speculate that at least some cases of apparent new 
mutations of the NF-1 gene may have an infective aetiology. 
(iii) The 'double-hit' hypothesis of Knudson - In 1971, using 
retinoblastoma as a model, Knudson proposed that tumours which occur 
both in isolated and familial forms arise from two mutational events. 
In the hereditary form one mutation is inherited via the germ cells 
and the second occurs in somatic cells. In the isolated tumours both 
mutations occur in somatic cells. The development of DNA markers 
meant this hypothesis could be directly tested at the molecular 
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level; the hypothesis was proved to be correct for retinoblastoma 
(Dryja et al 1984). 
The complex NF-1 phenotype and the fact that neurofibromas are 
multicellular in origin (Fialkow et al 1971) means that this model is 
unlikely to solely account for the pathogenesis of NF-1, although 
clearly second-step mutations may account for some of the 
complications (e. g. neurofibrosarcoma, phaeochromocytoma). In NF-2, 
however, the clinical picture would fit well for this mechanism. 
During the course of the present study (and including material from 
the one case of NF-2 identified by the study), Seizinger et al 
(1986a, 1987a) showed that this was the case. They looked for loss 
of heterozygosity in tumours from patients with both isolated 
acoustic neuroma and NF-2. They particularly focused on chromosome 
22 because of previous reports of loss of chromosome 22 in 
cytogenetic investigation of meningiomas. Loss of heterozygosity of 
chromosome 22 DNA markers was shown in the acoustic neuromas and in 
other tumours from NF-2 patients, but not for markers on 11 other 
chromosomes. That the locus for NF-2 was on chromosome 22, and not a 
secondary event, was subsequently confirmed by linkage studies 
(Rouleau et al 1987). 
(iv) "Reverse genetics" - The preceding account of the pathogenesis 
of NF-1 has highlighted our lack of knowledge of the underlying 
defect. The advent of recombinant DNA technology has given the 
methodology by which the gene for a particular disorder can be 
isolated with no prior knowledge of the underlying biochemical 
defect. This process has become known as 'reverse' genetics (Ruddle 
1984; Orkin 1986). NF-1 is an ideal candidate for this approach. 
The mapping of the NF-1 gene, the primary step in the reverse 
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genetics procedure, was one of the primary aims of the present study; 
the theoretical background and approaches used are presented in Part 
2 of this thesis. 
3. Aims of the present study 
The aims of the study described in subsequent chapters were to: 
(A) Define the prevalence of NF-1 in a UK population for the first 
time. 
(B) Perform a genetic analysis of the population defined with 
particular reference to mutation rate, genetic fitness, paternal age 
effect on mutation and parental effect on severity. 
(C) Assess the role of Lisch nodules as a diagnostic aid in NF-1 and 
to see if they occur in the normal population. 
(D) Study the age of appearance of the major defining features of 
the disease and the frequency of complications to derive guidelines 
for use in genetic counselling. 
(E) Assess the adequacy of the medical care received by NF-1 
sufferers in the study population. 
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CHAPTER 2 The South East Wales population study - ascertainment 
and assessment of cases 
1. The study area 
The study was carried out between October 1983 and February 1986 
in South Glamorgan and the west part of Gwent (the county districts 
of Newport, Islwyn and Blaenau Gwent). The area includes the Welsh 
capital, Cardiff, and two other main towns, Newport and Ebbw Vale. A 
map of the study area is shown in Figure 2-1. On the prevalence day 
(1st June 1985) the population of the study area, taken from the 
mid-year estimates of the Office of Population Censuses and Surveys, 
was 668,100. 
2. Patient ascertainment 
Index cases were ascertained by: 
(A) contacting general practitioners and selected consultants in 
the study area; 
(B) reviewing the case notes of patients identified by the 
in-patient activity analysis of hospitals serving the study 
area, available from 1969, using the codes for neurofibroma- 
tosis and its recognised complications except precocious/ 
delayed puberty, epilepsy and intellectual handicap; 
(C) reviewing the records of patients treated for scoliosis and 
pseudoarthrosis from 1954 at the Prince of Wales Orthopaedic 
Hospital, Rhydlafar, the main orthopaedic hospital in the study 
area. 
(D) reviewing the records of patients identified through the neuro- 
pathology register at the University Hospital of Wales (where 










tumour which could be associated with NF-1 or NF-2 removed 
since 1972; 
(E) reviewing the records of patients identified through the 
dermatology histology index at the University Hospital of Wales 
as having had a neurofibroma removed since 1972; 
(F) reviewing the records of the Department of Medical Genetics at 
the University Hospital of Wales also available from 1972; 
(G) after index cases identified by the above methods had been 
contacted, an article about the study was published in local 
newspapers requesting contact with sufferers who had not yet 
been identified. 
After obtaining permission from their General Practitioners, the 
index cases were contacted by letter and those who agreed to take 
part were assessed clinically on a domiciliary or out-patient basis 
by the author. If the diagnosis of NF-1 was confirmed, a family 
study was undertaken and all consenting first degree relatives living 
within the study area were examined. A minority of index cases had 
died prior to initiating the study; if their hospital records 
indicated a positive family history, relatives were contacted through 
the general practitioner. Details of the medical history of deceased 
first degree relatives were ascertained from the family, their 
medical records and/or death certificates. 
3. Patient assessment 
A full medical history was taken from the index cases and 
relevant family members using the questionnaire included in Appendix 
C. Affected individuals underwent a complete physical examination 
(where 'local' conditions allowed! ) and the findings recorded on the 
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examination record at the end of the questionnaire (Appendix C). For 
relatives who were found to be unaffected after cutaneous and/or slit 
lamp examination, the only other information recorded was height and 
head circumference. Height was measured using a portable stadiometer 
(Holtain Ltd. ). 
The criteria used for diagnosing NF-1 were that an affected 
individual had to have two or more of the following: 
A. 6 or more CAL spots measuring >1.5cm in diameter or >0.5 cm in 
diameter if the patient was 414 years; 
B. axillary freckling; 
C. 2 or more dermal neurofibromas; 
D. a plexiform neurofibroma; 
E. a first degree relative with NF-1 (based on criteria A-D). 
The diameters for counting CAL spots are those recommended by 
Crowe and Schull (1953) and Whitehouse (1966) for adults and children 
respectively; they enable accurate counts and reduce the risk of 
confusing CAL pigmentation with either lentigo or ephelis. Since 
accurate counting of dermal neurofibromas proved impossible, an 
approximate grading system was used: grade 1=0; grade 2= 1-10; 
grade 3= 11-100; grade 4= 101-500 and grade 5= >500. The 
presence/absence of Lisch nodules was examined for, using a Kowa 
portable slit lamp which was only available for part of the study. 
In assessing relatives of index cases who had <6 CAL spots and no 
other features, the diagnosis was considered equivocal in those aged 
<5 years with 1-5 CAL spots and those 25 years with 3-5 CAL spots, 
whereas individuals aged 25 years with one or two CAL spots were 
classified as normal. 
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Affected individuals were assigned to a severity grade for the 
disease. The grading system used was developed from the one 
described by Riccardi & Kleiner (1977), the patients being assigned 
to a given grade if they had any one of the disease features or 
complications listed for the grade: 
Grade 1 (minimal), - CAL spots only, or with unobtrusive cutaneous 
neurofibromas; 
Grade 2 (mild) - numerous cutaneous neurofibromas but without facial 
disfigurement; small plexiform neurofibromas with no associated 
problems; asymptomatic osseous lesions; learning difficulties 
with normal IQ; 
Grade 3 (moderate) - numerous cutaneous neurofibromas with facial 
disfigurement; plexiform neurofibromas with modest localised 
hypertrophy; visceral neurofibromas; mild retardation; scoliosis 
or pseudoarthrosis requiring surgery; controlled epilepsy; 
Grade 4 (severe) - disease complications leading to major health 
impairment, often requiring surgical intervention e. g. large 
plexiform neurofibromas with severe secondary problems, CNS 
tumours, malignancy, aqueduct stenosis, severe mental 
retardation, phaeochromocytoma and renal artery stenosis. 
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4. Analysis of results 
When the study questionnaire was originally designed all the 
recorded information was going to be stored on a computer file. As 
some of the questions proved to be unfruitful, a revised data input 
form was developed, which is included in Appendix C. The information 
was stored on a computer file specifically designed for the purpose 
by Mr G Wolak. For ease of comprehension the methods of analysis 
used are described with the relevant section in the subsequent 
chapters. 
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CHAPTER 3 Prevalence of NF-1 and genetic analysis of the 
South East Wales Population 
1. Outcome of clinical assessment of ascertained cases 
Using the methods described in Chapter 2,119 cases were 
ascertained who were reported to have NF-1. The outcome of follow-up 
of these cases is summarised in Figure 3-1. One had moved from the 
area prior to the study and one other could not be traced. 
Twenty-four ascertained cases were excluded after examination 
(Table 3-1), alternative diagnoses having been made in 17 (ONF 1,4, 
NNF 1-15)*. The distinction from NF-1 was clear-cut in all cases. 
The diagnostic criteria for NF-1 were not satisfied in the remaining 
7. One of these (NNF 16), aged 19 years and severely mentally 
retarded, had 3 large areas of atypical CAL pigmentation but no other 
features. One (ONF 3) had a plexiform neurofibroma of the left 
sciatic nerve only, and one (ONF 2) had 6 peripheral neurofibromas (2 
biopsy proven) but no other abnormalities. In the remaining 4 
patients (ENF 1-4), all of whom had no family history of NF-1, the 
only cutaneous feature was CAL spots. One of these (ENF 3) had had 
scoliosis surgery, but the number of CAL spots was thought to be 
within normal limits in this and 2 other cases. The fourth case (ENF 
4), who was ten months old when seen, had 4 CAL spots >1.5 cm in 
diameter and 10 which were >0.5 cm; her parents were normal on 
examination. -Although she may 
have NF-1, the diagnosis cannot be 
made until she develops 
* The reference numbers given in parentheses in this paragraph refer 
to Appendix A where the reader can find detailed clinical 
descriptions of these cases. 
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Table 3-1 Exclusions based on clinical features in 24/119 cases 
originally ascertained 
Excluded because of alternative diagnosis 
Diagnosis No. of cases Study Reference 
Number 
Multiple lipomas 11 NNF 1-11 
Multiple moles 1 NNF 13 
Steatocystoma multiplex 1 NNF 14 
LEOPARD syndrome 1 NNF 15 
Rheumatoid arthritis (nodular) 1 NNF 12 
Multiple spinal schwannomas 1 ONF 4 
Type 2 neurofibromatosis 1 ONF 1 
Excluded because of insufficient diagnostic criteria 
Clinical features 
Mental retardation, 3 large areas of atypical CAL 
pigmentation (age 19) NNF 16 
Plexiform neurofibroma of left sciatic nerve only 
(age 50) ONF 3 
6 peripheral neurofibromas, no other features (age 43) ONF 2 
14 CAL spots >0.5 cm diameter, no other features 
(age 10 months) ENF 4 
4 CAL spots, no other features (age 24) ENF 1 
2 CAL spots, corrected scoliosis, no other features 
(age 24) ENF 3 
1 CAL spot, no other features (age 30) ENF 2 
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other features. The clinical features of these 24 cases are reported 
in sections 2-4 of Appendix A. 
Ten of the originally ascertained cases had died prior to the 
study, but the diagnosis of NF-1 seemed definite on reviewing their 
hospital records. Of these, in 3/10 instances, one or more first 
degree relatives had been independently ascertained (families NF 13, 
18,29); 5/10 had no relatives living in the area, and the general 
practitioner indicated that there were no affected individuals in one 
other family. In the remaining family (NF 53) one previously 
unrecognised affected parent was identified. 
The diagnosis of NF-1 was accepted in the remaining 83 
ascertained cases either as a result of examination (77/83) or on 
good circumstantial evidence (6/83) using existing hospital records 
(cases 71,77,80,117,129) or details from the general practitioner 
(case 135). These 83 patients came from 68 families in which a 
further 115 at-risk relatives were identified: NF-1 was diagnosed in 
47/102 who were personally examined and 4/23 of the remainder who did 
not want formally to be assessed, either from their obvious facial 
cutaneous neurofibromas or hospital records. The remaining 64 
at-risk relatives were thought not to be affected either on the basis 
of examination (45/64) or details from the index case, who did not 
want their relative to be seen (15); findings were equivocal in 4/64, 
aged 1 month to 6 years (NF 7, IV-5; NF 28,111-2; NF 56, IV-4; NF 
61,111-4) 
In summary, 69 families with one or more affected members with 
NF-1 were living in the study area and were identified through 84/119 
of the originally ascertained cases. These 84 cases are hereafter 
referred to as index cases; in 13 families there were 2 or more index 
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cases. A total of 135 individuals (60 males and 75 females) with 
NF-1 were alive and resident in the study area on the prevelance day 
(83 index cases and 52 affected relatives). The age distribution at 
prevalence given as age range in years (no. of cases), was: 0-9(16), 
10-19(30), 20-29(26), 30-39(20), 40-49(12), 50-59(15), 60-69(10), 
70(6); the age range at time of clinical assessment was 11 months to 
83 years. 
The clinical summaries and pedigrees for these families are given 
in Section 1 of Appendix A (families NF 1-69). 
2. Outcome of analysis 
The results presented in this chapter are reported in the paper 
of Huson et al (1989a). The author was assisted with the statistical 
analyses by Dr P Clark, Section of Medical Statistics, Clinical 
Research Centre, Harrow. 
A. Pedigree analysis - The pedigrees confirm the autosomal dominant 
inheritance of NF-1. There are numerous examples of male to male 
transmission, and segregation analysis, in families where the index 
case is an adult and all their offspring examined, shows no departure 
from the expected 1: 1 ratio (23/47 children affected). There are 45 
instances of 3 generation and 1 of 4 generation transmission of the 
disease; in all cases the intervening parent had appropriate 
manifestations of the disease for their age. 
Forty-one index cases, 6 affected parents and 1 affected 
grandparent gave no history of NF-1 in their siblings or in 
preceeding generations. Examination of the parents and children of 
these cases was undertaken wherever possible. The patients were 
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often reluctant to involve their siblings in the study, being adamant 
that in all cases they were unaffected. A summary of the pedigree 
information for these 48 'sporadic' cases is given in Table 3-2; 
there was sufficient information for 41/48 to assume that they 
represent new mutations of the NF-1 gene. The case numbers of the 48 
cases are listed in the Introduction to Section 1 of Appendix A. 
Thirty-six of 41 new mutations were 120 years of age, 19 of whom 
had children, and in 14 of these cases, all the children were 
examined and classified unequivocally. Sixteen of 29 children were 
affected showing no significant departure from the 1: 1 ratio expected 
for a dominant gene (using the formula given by Roberts and Pembrey, 
1978; X2=0.14, p=0.71). 
B. Disease prevalence - On prevalence day (1st June 1985), the 
population of the study area, taken from the mid-year estimates of 
the Office of Population Censuses and Surveys, was 668,100, giving a 
minimum prevalence of 135/668,100, i. e. 1/4950, or 20.2/105 of 
population. 
The methods of ascertainment used could, however, have been 
expected to 'miss' mildly affected cases, particularly children who 
were new mutations and had no major disease complications. This 
possibility was examined by comparing the ratio of new mutations to 
familial cases with age; this showed marked disparity. Excluding 
the 7 cases in whom details of inheritance were uncertain, 5/45 (11%) 
of cases aged <20 years were new mutations (ratio 1: 8), compared with 
36/83 (43%) of cases aged >_20 years (ratio 1: 1.3). To bring these 
two ratios to equality would require 26 further cases aged <20 years. 
If it is assumed that these 26 cases were 'missed' by the study, the 
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corrected prevalence is 161/668,100, i. e. 1/4150, or 24.1/105 of 
population. 
C. Estimation of fitness in NF-1 - Tanaka (1974) has shown that 
Relative fitness, w= AP 
Ao 
where Ap = frequency of trait among parents of index cases and AO = 
frequency of trait among offspring of index cases. 
In the calculation of Ap, 4 index cases (cases 40,52,112,129) 
were excluded since parental disease status was uncertain, and in 
families with >1 index case, the parents of the oldest case were 
used. Twenty-nine of 130 parents had NF-1 (Ap = 0.223). 
For the estimation of Ao, adult index cases where all their 
children had been examined and the disease status certain, were used; 
18/38 were affected (Ao = 0.474), therefore: 
Relative fitness, w=0.223 = 0.470 
0.474 
Tanaka (1975) has further shown that the relative fitness in 
males (w') and females (w'') can be determined using the formulae: 
w' =AA' x x' +x" 
Aa' 2x' 
and w'' = Ap" x x' + x" 
A011 2x'' 
where Ap' and Ap '' are the frequencies of the disease in fathers and 
mothers of index cases respectively; Ao' and A011 are the 
frequencies of affected individuals among children of male 
and female index cases and x' and x1 the relative frequencies of 
affected males and females in the general population respectively. 
In the population studied, Ap' = 11/65 = 0.169; Ao' = 6/10 = 0.6; 
Ap'' = 18/65 = 0.277; Ao '' = 12/28 = 0.429; x' = 60/324,100 = 
0.000185 and x'' = 75/344000 = 0.000218. Therefore: 
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w' = 0.169 x 0.000403 = 0.307 
0.6 0.000370 
and w il = 0.277 x 0.000403 = 0.597 
0.429 0.000436 
demonstrating a large reduction in relative fitness of males compared 
with females. 
D. Mutation rate of the NF-1 gene 
(i) Direct method - Forty-one of 135 cases of NF-1 identified in the 
study population (668,100) represent probable new mutations of the 
disease gene. The mutation rate (u, ± 95% confidence interval; Emery 
1986, p. 33) is therefore equal to: 
u= 41 
1336200 
u= (3.07, ±0.94) x 10-5 
In order to correct for probable under-ascertainment of children 
who represent new mutations, two approaches have been used: 
(1) by analysing the study population aged >_20 years only, 36 new 
mutations were identified in a population of 438,900. 
36 = (3.72, ± 1.22) x 10-5 
967,800 
(2) by adding the 26 'missed' NF-1 cases, presumed to be new 
mutations, to the 41 actually identified: 
67 = (5.01, ± 1.20) x 10-5 
1336200 
(ii) Indirect method - This calculation (Emery 1986, p. 34) requires 
the incidence of the NF-1 gene at birth, and this is unknown. 
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However, given that the complications of NF-1 which cause death in 
childhood are rare, we have calculated the prevalence in those aged 
<20 years and assumed that this approximates to incidence. 
Forty-six cases were ascertained aged <20 years from a population 
of 184,200, giving a minimum prevalence in this age group of 
0.000250, or 1/4,000. 
Adding the 26 paediatric cases that we have shown were 'missed' 
by the study methods gives a maximum prevalence of 72/184,200, 
0.000391 or 1/2,558 of population. Therefore: 
(a) Using minimum prevalence at <20 years as = incidence 
11 =121 (1-f), where I=incidence and f=fitness of NF-1 
u=0.000125 (0.53) 
µ=6.62 x 10-5 
(b) Using maximum prevalence at <20 years as s incidence 
0.0001955 (0.53) 
u= 10.36 x 10-5 
Summary - The mutation rate of NF-1 therefore appears to be in the 
region of 3.1-10.4 x 10-5 
E. Analysis of parental age and mutation 
(a) Birth-order effect - Two of 41 of the cases (5,10) classified as 
new mutations were the parents' only child and for 6/41 inadequate 
information was available for analysis of birth-order 
(41,44,46,74,78,135). The birth order data for the remaining 33 
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cases are shown in Table 3-3. Using the method of Haldane and Smith 
(1947a) to analyse the data, no significant birth order effect is 
demonstrated (p=0.08). 
(b) Parental ages of mutations - The observed ages for parents of 
cases classified as being new mutations were compared with expected 
ages using the method described by Bundey et al (1975). Therefore 
the expected maternal age, adjusted for parity, was taken directly 
from the Registrar General's population data and the expected 
paternal age calculated by adding the expected mean difference in age 
between spouses. Accurate parental dates of birth were known for 
29/41 presumed new mutations, but maternal ages adjusted for parity 
are only available from 1938, therefore only 21/29 who were born 
after 1938 were used in analysis. The results are presented in Table 
3-4. No parental age effect was demonstrated, nor was the parental 
age difference significantly different from expected. A further 
analysis of parental age was performed on 15/21 new mutations in 
which both parents had been examined, and no significant parental 
effect was found (p=0.55). 
F. Parental effect on severity - 124/135 ascertained cases were 
included in this analysis; the remaining 11 cases were excluded 
either because of inadequate pedigree or clinical information. The 
severity grades for these patients were analysed using analysis of 
variance with parental disease status (affected father, affected 
mother, new mutation) and age (<18, ? 18 years) as factors. The 
results are shown in Table 3-5. There were no overall differences 
between the status categories (p=0.84) or between the age groups 
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Table 3-4 Mean parental ages of NF-1 cases classified as new mutations 
and born after 1938 (n=21) compared with parental ages in the 
general population 
n= 21 Mean paternal Mean maternal Mean paternal - 
age (years) age (years) maternal age 
difference (years) 
Observed 29.62 27.68 1.94 
Expected 29.91 27.62 2.29 
Mean observed- -0.29 0.06 -0.34 
expected 
difference 
Standard error 1.04 0.95 0.57 
of differences 
t -0.28 0.06 -0.60 
p 0.79 0.95 0.55 
* One sample t test of whether mean observed-expected difference 
was different from zero (df=20). 
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Table 3-5 Mean severity grade of 124 cases of NF-1 classified by 
disease status of parents and analysis of variance 
between groups 
Disease status of parents Age group 
<18 years 218 years All ages 
n 11 15 26 
Affected mean severity grade 1.73 2.53 2.19 
fathers 95% CI 1.18,2.28 2.06,3.00 1.83,2.55 
n 23 36 59 
Affected mean severity grade 2.00 2.25 2.15 
mothers 95% CI 1.62,2.38 1.95,2.55 1.91,2.39 
n 4 35 39 
New mean severity grade 3.25 2.23 2.33 
mutations 95% CI 2.34,4.16 1.92,2.54 2.04,2.62 
n 38 86 124 
All cases mean severity grade 2.05 2.29 2.22 
95% CI 1.75,2.35 2.09,2.49 2.06,2.38 
Analysis of variance 
Between parental disease status groups: F=0.179, df=2,118, p=0.84 
Between age groups: F=1.146, df=1,118, p=0.31 
Status x age interaction: F=4,574, df=2,118, p=0.012 
Mean square error = 0.8440, df=118. 
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(p=0.31). However there was a significant interaction between age 
and status (p=0.012), indicating that the young new mutations tended 
to be more severely affected than the older new mutations; there was 
no age difference effect for the other status groups. 
3. Discussion 
In the assessment of the originally ascertained cases, the 
diagnostic criteria for NF-1 were easily applied and other diseases 
distinguished without difficulty. The disorder most frequently 
confused with NF-1 was multiple lipomatosis. On examination, 
however, the lipomas were found to be quite different from 
neurofibromas. As lipomas are subcutaneous lesions, the only 
differential is from subcutaneous neurofibromas. Lipomas were found 
to have a softer consistency, less well-defined margins and were not 
painful on palpation. Subcutaneous neurofibromas usually develop on 
the trunks of major peripheral nerves and pain on palpation was found 
to be a characteristic feature. 
Seven of 119 originally ascertained cases (Table 3.1) had a 
feature of NF-1 on examination which was insufficient to meet the 
diagnostic criteria. It was felt that the 3 patients with 44 CAL 
spots (ENF 1-3) represent a variant of normal. Crowe and Schull 
(1953) found that 690/6853 (10.1%) institutionalised patients, who 
had no other cutaneous manifestations of NF-1, had up to 5 CAL spots; 
the majority (684/690) had 1-3 lesions, 4 had 4 and only 2 had 5. 
Burwell et al (1982) reported that 25.3% of 732 school children aged 
4-11 years had 1-3 lesions and Kopf et al (1985) observed this number 
of CAL spots in 13.8% patients attending a private dermatology 
59 
clinic. The case aged 10 months with 14 CAL spots (ENF 4) may well 
have NF-1 but was excluded as this was the only abnormality on 
examination and her parents were normal. In case NNF 16, who had 3 
areas of CAL pigmentation, all of which were >25cm in diameter, and 
was severely retarded, no diagnosis was made; a skin biopsy was 
performed to exclude chromosomal mosaicism and this was normal. The 
two other cases in this group may fall into the broad category of 
neurofibromatosis; the case with an isolated plexiform neurofibroma 
(ONF 3) may represent a variant of segmental neurofibromatosis and 
the patients with 6 peripheral neurofibromas (ONF 2) is similar to 
cases classified as NF VII, or late onset neurofibromatosis, by 
Riccardi (1982). This classification is reviewed in Chapter 1. 
Pedigree analysis of the 69 families with one or more affected 
individuals with NF-i confirms the autosomal dominant inheritance of 
NF-1. Segregation analysis of the children of adult index cases 
showed no significant departure from the expected 1: 1 ratio for a 
dominant disorder. In the pedigrees studied, there was no evidence 
of non-penetrance of the NF-1 gene; in 46 families there is at least 
3-generation transmission of the gene and all obligate heterozygotes 
satisfied the diagnostic criteria. 
In a recent paper Riccardi and Lewis (1988) cited a further 134 
examples of three generation transmission of NF-1 with no evidence of 
non-penetrance. In the medical literature we can find only 3 
examples of apparent non-penetrance of NF-1 (Spence et al 1983, 
1986). It must be concluded that penetrance of the NF-1 gene is 
virtually 100% by the age of 5 years, when affected individuals will 
have developed CAL spots (see also data presented in Chapter 4). 
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For 41/135 cases there was sufficient evidence to assume that 
they represent new mutations of the NF-1 gene. There was no history 
of the disease in preceding generations or their siblings and 
segregation analysis of their offspring showed no departure from the 
expected 1: 1 ratio. No families were identified where apparently 
normal parents had more than one affected child and no parents of 
apparently isolated cases with variant expression of the NF-1 
phenotype. There have been a few such occurrences reported in the 
literature. Riccardi and Lewis (1988) report two cases of affected 
siblings with normal parents and a further two families in which one 
parent appeared to have limited expression of the NF-1 gene. In one, 
a mother of two affected sons had bilateral Lisch nodules as her only 
disease manifestation and in the other the father of an affected son 
had a cervical schwannoma and two peripheral neurofibromas. In 
addition, Rubenstein et al (1983) reported two families where parents 
with limited disease expression had affected children. In one, a 
father and daughter both appear to have segmental neurofibromatosis 
and in the other the father of a boy with NF-1 had 6 neurofibromas 
and a CAL spot on his left flank. 
Germline mosaicism is the most obvious explanation for apparently 
normal parents having more than one affected child. The cases with 
limited expression in the parent may represent gonosomal mosaics; 
experimental work in the mouse and the available evidence in man 
suggests that the cells of the primitive ectoderm are multipotential 
(Gardiner 1983). A single mutation of the NF-1 gene at this stage of 
development could therefore result in limited disease manifestations 
and gonadal involvement. From the clinical viewpoint these cases 
emphasise the importance of examining both the skin and the irides of 
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parents and siblings of apparently isolated cases. In the light of 
the cases with limited features of NF-1 and affected children, it is 
also difficult to fully reassure individuals with apparent segmental 
neurofibromatosis that there is no risk of NF-1 occurring in their 
offspring, although with available information it is impossible to 
quantify this risk. 
The minimum prevalence of NF-1 in the general population based on 
this study is 1/4950 or 20/105. The true figure is almost certainly 
higher since children who represent new mutations of the HF-1 gene 
may have been under-ascertained. This figure compares with previous 
estimates of 1/2500-3300 in the USA (Crowe et al 1956), 1/7800 in the 
USSR (Sergeyev 1975) and 1/4600 in Sweden (Samuelsson and Axelsson 
1981); these studies are summarised in Table 1-3. The USSR study 
relied upon detection of CAL spots in a population sample of 16 year 
olds undergoing pre-military examination, those with a significant 
number of lesions being referred for the survey. Although this 
method should have screened all males in this age group, irrespective 
of state of health, the low prevalence suggests a significant 
under-estimation. The prevalence figure quoted by Samuelsson and 
Axelsson (1981) approximates to that obtained in the present study 
and was estimated from a population survey using similar methods. 
The figure of Crowe et al (1956) may be an over-estimate as it is 
based on a summary of three approaches, each with wide margins of 
error and none population-based. Nevertheless, the actual birth 
incidence of the NF-1 gene may be as high as the disease frequency 
estimated by Crowe et al (1956), the decreased prevalence in the 
general population being accounted for both by under-ascertainment 
and increased mortality. In Chapter 5 data are presented suggesting 
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an increased mortality in NF-1 and this was also demonstrated by 
Sorenson et al (1986) in the 39-year follow-up study of the cases 
originally identified by Borberg (1951). The true incidence of NF-1 
could only be estimated by following a large cohort of children from 
birth, but the prevalence data presented for those aged <20 years 
suggest it may be as frequent as 1/2558 or 39/105. 
This study has confirmed that the genetic fitness of NF-i 
sufferers is approximately half that of the general population 
(0.47), the effect being more marked in males (0.31) than females 
(0.60). Crowe et al (1956) found the overall fitness to be 0.53 with 
a similar relative reduction for the different sexes (males 0.41, 
females 0.75). This reduction of fitness cannot be explained solely 
by severe intellectual handicap or disease complications causing 
severe morbidity or mortality before adulthood, since these are 
infrequent complications. Crowe et al (1956) showed that a 
significant contribution to decreased fitness in NF-1 is failure of 
affected individuals to marry, although married individuals still 
showed a reduction (0.80). The reasons for this are not known but 
there is no evidence for pregnancy wastage, so that the explanation 
may be an overall reduction in fecundity. 
The mutation rate of the NF-1 gene in this study has been 
estimated to be between 3.1-10.4 x 10-5, confirming that the gene for 
NF-1 has one of the highest mutation rates yet identified in man. 
The estimates from previous studies range from 4.3 x 10-5 to 2.6 x 
10-4. The present study has not shown paternal age to be a 
significant factor in the aetiology of mutation. As reviewed in 
Chapter 1, three previous studies have shown conflicting results. 
The only study to show a highly significant paternal age effect was 
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that of Riccardi et al (1984). A possible explanation for the 
different results is ascertainment bias in the study of Riccardi et 
al. The cases analysed were drawn from a population referred to a 
special interest clinic and it may be that older patients of new 
mutations are more likely to seek specialist referral, resulting in a 
biased sample. Overall it must be concluded that if an increased 
parental age effect does exist for NF-1, it is small when compared 
with other disorders such as Achondroplasia or Apert syndrome (Risch 
et al 1987). 
A possible maternal effect on severity of NF-1 was first 
suggested by Miller and Hall in 1978. Studying 62 cases aged <18 
years, ascertained through the records of a children's orthopaedic 
and University hospital, they found an increased severity in children 
born to affected mothers compared with those having affected fathers 
or new mutations. Two subsequent reports (Carey et al 1979; Riccardi 
and Wald 1987) and the present study have not confirmed this effect 
in a combined total of 443 NF-1 sufferers. It must be concluded that 
there is no maternal effect on disease severity. In the present data 
(Table 3-5) the only group showing discordant severity were the new 
mutations aged <18 years, although the number in this group is small 
(n=4). This result is undoubtedly explained by under-ascertainment 
of new mutations with mild manifestations of the disease. 
In summary, the population study showed that NF-1 is one of the 
most frequent dominant disorders, with virtually 100% penetrance and 
a high mutation rate. The study did not confirm paternal age as a 
factor underlying disease mutation or a maternal effect on disease 
severity. 
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CHAPTER 4 The major and minor features of NF-1 
1. Introduction 
At the outset of the study it was known that the major features 
of NF-1 were CAL spots, peripheral neurofibromas and Lisch nodules. 
In formulating diagnostic criteria for the study however, Lisch 
nodules were excluded as their frequency had only been assessed in 
one previous large study of NF-1 sufferers (Lewis and Riccardi 1981), 
and whether or not they occur in the general population was unknown. 
One aim of the study was therefore to determine whether Lisch nodules 
occur in individuals without NF-1. No previous study had looked 
specifically at the age of appearance of the major features to 
determine the age at which at-risk individuals, not showing these 
features, could be reassured they had not inherited the disease. 
Therefore, in addition to looking at each of the features from a 
clinical viewpoint, the data have also been analysed to answer this 
specific question. 
Axillary freckling was first noted to be pathognomic of NF-1 by 
Crowe (1964), but that freckling occurs in other unusual sites 
(inguinal region, submammary region in females) has only recently 
been reported (Riccardi 1981a). The presence/absence of freckling in 
each of these areas was therefore noted on examination. 
Although macrocephaly and short stature are frequently mentioned 
in early case reports of NF-1 sufferers, head size and height have 
only recently been assessed in large series of patients. Carey et al 
(1979) and Riccardi (1981a) reported that 35% and 27% respectively of 
affected individuals in their series had head circumferences above 
the 97th centile. Riccardi also reported that 16% had heights at or 
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below the 3rd centile. As macrocephaly and short stature appeared to 
be relatively frequent but asymptomatic findings in NF-1, they were 
classified as minor features rather than complications in the present 
study; measurement of height and head circumference was included in 
the study protocol. 
The data presented in this chapter are based on the findings in 
all the examined affected members of NF 69, whether resident in or 
outside the study area, and families NF 70-73 ascertained via LINK 
for linkage studies. It was felt that the source of ascertainment 
would not bias the outcome of analysis for these disease features. 
Although 168 affected individuals were potentially available for 
assessing the major defining features, examination was either not 
performed or incomplete in 13 individuals. A portable slit lamp was 
available for only part of the study and the Lisch nodule data are 
therefore less complete. 
The data presented in Chapters 4,5 and 6 are reported in the 
papers of Huson et al (1988,1989b). 
2. The major defining features of NF-1 
A. CAL spots and freckling - CAL spots had been the first major 
feature to appear in all cases. Parents had noted CAL spots for the 
first time at 4 years or less in all affected children and within the 
first year of life in 82%. 
CAL spots were the only disease feature noted on examination of 
at-risk relatives subsequently classified as equivocal or unaffected. 
Four cases were classified as equivocal: 3 individuals aged 0.1,1.8 
and 3.5 years had 1,2 and 1 lesions respectively; one 6 year old had 
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5 extremely pale lesions 1 cm in diameter. Seven of 50 (14%) 
individuals aged 5 years were classified as normal despite having 1 
or 2 CAL spots. 
On examination CAL spots were found to vary in diameter from 0.5 
to 50 cm although the majority were under 10 cm; their contour was 
usually smooth but some, particularly larger ones, had irregular 
outlines. Their colour intensity varied with background skin 
pigmentation, often being very pale in young children when they were 
best assessed using a Woods lamp. The typical appearance of CAL 
spots in a young child is shown in Figure 4-1. 
The variation with age in number of CAL spots and percentage with 
6 or more is given in Figure 4-2 and Table 4-1. All but one of the 
cases aded S20 years had 6 CAL spots; one 17 year-old male had only 
5 spots. From the age of 20 years, however, an increasing number of 
cases had less than 6 spots. In some of the older cases, the CAL 
spots may have been disguised by the presence of large numbers of 
neurofibromas. However, several older patients, with fewer 
neurofibromas, reported "disappearance" of CAL spots with age. 
The age-related frequency of the different kinds of freckling 
unique to NF-1 is shown in Table 4-2. The overall frequencies were 
axillary (69%), inguinal (38%) and submammary (26% of females). 
Typical axillary freckling is shown in Figure 4-3. It is interesting 
to note that the frequency of freckling is also apparently 
age-related. It appears later than CAL spots, the youngest case with 
axillary freckling being 3 years; the age groups between 16-40 years 
showed the highest incidence of freckling but thereafter there was a 





FIGURE 4-1. Multiple CAL spots in a6 year old male wich NF-1 
(case 164); these were the only cutaneous features 


















FIGURE 4-2. Variation in number of CAL spots with age (n=153). 
A diameter of >0.5 cm being used for those aged 
<10 years and >1.5 cm for the remainder. 
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Table 4-2 Percentage of cases with each of the major defining 
features by age 
Major defining features 
Age 
CAL spots Cutaneous neurofibromas Lisch nodules 
0-5 100 0 66 
6-10 100 14 82 
11-15 100 33 71 
16-20 93 93 100 
21-30 93 100 90 
31-40 89 100 96 
41-50 62 100 88 
51-60 77 100 100 
61-70 62 100 88 












FIGURE 4-3. Axillary freckling (case 43). 
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B. Peripheral neurofibromas - Peripheral neurofibromas were 
classified as cutaneous or subcutaneous. 
(i) Cutaneous neurofibromas - The cutaneous lesions lay within the 
dermis and epidermis moving passively with the skin and were present 
in all cases with peripheral neurofibromas. The majority appeared as 
discrete nodules with a characteristic violaceous colour and were 
soft, almost gelatinous on palpation, varying from 0.1 to several cm 
in diameter. In older patients and in all those with very numerous 
lesions, some had become papillomatous and were larger in size; their 
typical appearance is shown in Figure 4-4. The cutaneous 
neurofibromas were found mainly on the trunk and were only present in 
large numbers on exposed areas of the body in more severe cases; in 
only 18% of cases were there obvious lesions on the head and neck. 
Figure 4-5 shows the variation in number of cutaneous neurofibromas 
with age. The youngest patient in whom they were seen was 7 years 
old. The number of neurofibromas is only roughly proportional to 
age, severely and mildly affected cases being seen in all age groups. 
Although not formally tested, the number of neurofibromas seemed to 
show no intrafamilial correlation. 
Cutaneous neurofibromas were the only one of the major disease 
features to cause symptoms or morbidity. These were only assessed in 
the 94 individuals within the population study area who had cutaneous 
neurofibromas. The only significant symptom was pruritis (20/94, 
21%); they were rarely painful. The majority of patients had come to 
terms with the appearance of these lesions but 19 individuals (15 
female, 4 male) were persistently distressed by their appearance. An 















The development of the cutaneous 
features with age. A is a 14 year old 
girl with CAL spots only (case 103); 
#B is her 42 year old father (case 97), 
in whom both CAL spots and neurofibromas 
:e seen, and C is her ii year old 
;, randmother (case 95), with multiple 






















10 20 30 40 50 60 70 80 90 
Age (years) 
FIGURE 4-5. The comparison of number of cutaneous 
neurofibromas with age (n=155). 
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pregnancy was commented on by 10/30 (33%) of parous women. One or 
more lesions had been removed surgically from 41/94 (44%), for 
cosmetic reasons (32), diagnosis (8) or because of rapid increase in 
size (1). 
(ii) Subcutaneous neurofibromas - These lesions were palpable as 
nodules along the trunks of peripheral nerves; they had a much firmer 
consistency and more defined margins than cutaneous neurofibromas. 
Unfortunately their presence/absence was not formally recorded; they 
were much less frequent than cutaneous neurofibromas and were 
probably present in no more than 5% of cases. When present they 
frequently gave rise to paraesthesiae on examination, and 4 
individuals in the population study had had subcutaneous 
neurofibromas removed because of local paraesthesiae; this had 
resulted in a posterior interosseus nerve palsy in one individual. 
C. Lisch nodules - Lisch nodules characteristically appeared as 
dome-shaped lesions found superficially around the iris on slit lamp 
examination, varying from being barely visible to up to 2 mm in 
diameter (Figure 4-6). Most appeared brown but a few, particularly 
in children, were very pale or almost white. Lisch nodules were 
easily seen in all patients except those with darker brown irides 
when they were difficult to distinguish. In a few patients, with 
very numerous nodules, they were visible on naked eye examination. 
They were easily distinguished from iris naevi, present in 
approximately 50% of normal adults (Michelson and Shields, 1977), by 
their smooth outline and shape. 












shown in Figure 4-7. They were present in 104/122 (85%) individuals 
overall and 71/76 (93%) of those >20 years. The youngest child in 
which they were seen was 3 years old, but the majority of children 
under 5 were unable to co-operate with examination. In 4 children 
Lisch nodules were only seen unilaterally. 
To confirm the portable slit lamp findings a subset of patients 
(n=53) attended the University Hospital of Wales for examination by 
Mrs L Beck and Mr D Jones in the Department of Ophthalmology. Lisch 
nodule status of each individual was confirmed in all cases by fixed 
slit lamp examination and the number of nodules was counted. The 
mean number was 25/eye (range 1 to 100); there was a highly 
significant correlation between age and number of Lisch nodules/eye 
(p=0.002 using Spearman rank correlation test). These findings were 
reported in the paper of Huson et al (1987). 
Mrs L Beck, in addition, examined the irides of 150 general 
ophthalmology outpatients to assess the frequency of Lisch nodules in 
the general population. No Lisch nodules were seen in 149 patients. 
One patient had several iris naevi and two lesions indistinguishable 
from Lisch nodules on the periphery of one iris. She was 27 years of 
age and had no family history of NF-1. Clinical examination of the 
patient showed no other NF-1 features; her parents had no features on 
either cutaneous or slit lamp examination. It was felt unlikely that 
this patient had 2 Lisch nodules as her sole manifestation of NF-1; 
the more likely explanation is that normal individuals may rarely 
have one or two Lisch nodules but that numbers greater than this are 











U __i - 
Age (years) 
FIGURE 4-7. The variation in presence/absence of Lisch 
nodules with age (n=122). 
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10 20 30 40 50 60 70 80 
D. The age of appearance of the major defining features - Two 
approaches have been used to look at this. Table 4-2 shows the 
percentage by age of affected individuals who had each diagnostic 
feature. In Figure 4-8 children of affected individuals, in families 
where the index case was an adult, have been analysed to see at what 
age, taking each feature in isolation, the expected 1: 1 segregation 
ratio for a dominant disorder is reached. CAL spots are the first 
disease feature to appear; the data presented indicate that affected 
and unaffected individuals can be distinguished on this criterion 
alone by 5 years. Lisch nodules are the next feature to appear and 
it would seem that if they are going to develop, they will have done 
so by the mid-teens. Cutaneous neurofibromas begin to appear from 
the early teens but the 1: 1 ratio of affected to unaffected was only 
reached by 20 years. 
E. Discussion - The findings presented suggest that all those who 
have inherited the gene satisfy the diagnostic criterion of Z6 CAL 
spots by the age of 5 years and that a large proportion do so by the 
age of 1 year. In the great majority of cases the distinction 
between normal and affected siblings was clear-cut from an early age. 
The only exceptions were the 4 children aged 56 years who had between 
1-5 CAL spots. In view of the previous general population studies 
reviewed in Chapter 3, which have shown that between 13.8 and 25.3% 
have 1-3 CAL spots, it is likely that 3 of these children (each with 
1-2 lesions) are normal. Only one case, the 6 year old with 5x1 cm 
diameter lesions and no other features, probably represented a truly 
"equivocal" diagnosis. 
During the course of the study two other centres reported on the 
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Age (years) 
FIGURE 4-8. Presence/absence of major defining features in the 
offspring of affected individuals analysed by age; 
families in which the only index case was a child have 
been excluded. 
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frequency of Lisch nodules in NF-1 sufferers (Flueller and 
Boltshauser 1986; Zehavi et al 1986) with similar findings. 
Combining their data with those of Lewis and Riccardi (1981) and the 
data presented here show an overall frequency of 267/313 (85%) and 
for those aged >_il years of 229/245 (93.5%). The data presented here 
also suggest that even 1 or 2 Lisch nodules are extremely rare 
findings in the general population and therefore the finding of 
multiple nodules is virtually pathognomic of NF-1. Lisch nodules 
were included as one of the diagnostic criteria for NF-1 decided at 
the NIH Consensus Conference on Neurofibromatosis (1988) and since 
they appear before cutaneous neurofibromas, their presence should 
help to resolve diagnostic difficulties presented, for example, by a 
child with multiple CAL spots only, and in the assessment of unusual 
cases, as Lisch nodules have not been reported in the other autosomal 
dominant forms of NF-1. 
The number of CAL spots and frequency of freckling have been 
found to decrease from middle age. Crowe et al (1956) also found 
this for CAL spots but did not look at the frequency of axillary 
freckling with age. Why the pigmentation, once developed, should 
"fade" with age is not apparent but the observation may provide 
insight into the underlying pathogenesis of the pigmentary 
abnormalities in NF-1. From a practical viewpoint, it means that 
cutaneous neurofibromas and Lisch nodules are more useful diagnostic 
criteria in the elderly. 
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3. Minor features of NF-1 
A. Macrocephaly - After excluding patients with CNS tumours, 
aqueduct stenosis and large plexiform neurofibromas, 63/123 (51%) 
affected individuals had a head circumference at or above the 97th 
centile compared with 8/50 (16%) unaffected siblings (p=0.001). No 
correlation was found between intellectual handicap and macrocephaly 
in those in whom this comparison could be made (n=108, i. e. those 
resident in the study area); 12/46 (26%) patients with macrocephaly 
had required remedial class or special school education compared with 
16/62 (26%) with normal head circumferences. This was also the case 
in the study of Carey et al (1979). The cause for the macrocephaly 
in NF-1 is unknown, although the study of Holt and Kuhns (1976) 
suggested that in some cases it was secondary to macroencephaly. 
They reviewed the skull X-rays of 52 patients of varying ages and 
found 44% of the patients had cranial capacities above the 95th 
percentile; four of these patients had normal pneumoencephalograms 
and cerebral angiograms. 
B. Short stature - Excluding those with skeletal complications of 
the disease and identified unrelated causes for short stature, 39/124 
(31.5%) individuals were at or below the 3rd centile for height. Dr 
S Herber of the Department of Paediatrics, University of Sheffield, 
kindly analysed the data further. The heights of affected 
individuals were converted to standard deviation scores, using the 
data of Tanner and Whitehouse (1976), by the formula 
SDS=x - 
SD 
where x is the patient's height, x the population mean for that age, 
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and SD the population standard deviation. The SDS for affected 
individuals was -1.20±1.07 and for normal siblings -0.12±1.02 (n=34). 
This is highly significant (p=0.001) by unpaired t testing. There 
was no significant difference between the sexes - SDS affected males 
= -1.21±1.27 (n=57), affected females = -1.18±0.88 (n=67). These 
results imply that affected males are 8 cm under expected height and 
females 7.62 cm purely on the basis of having NF-1. Two of the 
patients in the population study had been fully investigated 
endocrinologically for short stature and no abnormalities detected. 
This study therefore confirmed the findings of Riccardi (1981a) 
that a significant number of NF-1 sufferers have short stature. In a 
more recent review Riccardi and Eichner (1986) state that no 
underlying endocrinological abnormality has been demonstrated in 
their series. The aetiology of the short stature in NF-1 is 
therefore unknown. 
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CHAPTER 5 The complications of NF-1 
1. Introduction 
The morbidity and mortality caused by NF-1 are largely dictated 
by the occurrence of one or more of its complications. Accurate 
information regarding the incidence of complications and long term 
prognosis is essential for planning the management of NF-1 sufferers 
and genetic counselling. As reviewed in chapter 1 the difficulty is 
to distinguish true complications from chance associations. For the 
purpose of the present study, any condition was considered to be a 
complication of NF-1 if it had previously been associated with the 
disease in large population- or hospital-based surveys (Borberg 
1951; * Crowe et al 1956; * Brasfield & Das Gupta 1972; * Riccardi & 
Kleiner 1977; Bader & Miller 1978; McKeen et al 1978; Carey et al 
1979; * Samuellson & Axelsson 1981; * Riccardi & Eichner 1986*). The 
frequency of major complications in the surveys marked with an 
asterisk are given in Table 1-2. The studies of Bader & Miller 
(1978) and McKeen et al (1978) are not surveys of NF-1 sufferers. 
Both arose as follow-up studies to series of case reports to see if 
two types of malignancy (childhood leukaemia and rhabdomyosarcoma, 
respectively) were true disease complications. The respective 
authors reviewed large series of patients with each malignancy and 
found a significant association with NF-1. 
In this chapter the complications of NF-1 in the population based 
survey are presented. In addition, the other conditions which 
probably were coincidental findings are reviewed, and finally data 
are presented regarding disease mortality. 
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2. The complications of NF-1 
The frequency of complications of NF-1 in the 135 cases resident 
within the study area is shown in Table 5-1. As no individuals in the 
study area aged >_18 years had either a CNS tumour or malignancy with 
established disease associations, their frequency was estimated by 
looking at their occurrence in all affected family members 218 years 
on prevalence day (1.6.85) within and outside the study area and 
deceased affected relatives. In the introduction to Appendix A the 
case numbers of individuals with a given complication are listed so 
that the reader can obtain further clinical details from the appendix 
as necessary. 
The frequency of complications in those 218 years (Table 5-1) is 
probably the most accurate overall picture as it avoids bias due to 
variable age of presentation of the complications. Most 
complications occurred in index cases, not affected relatives. 
However, the frequency of those complications which would not 
necessarily have led to hospital referral or identified through a 
search of hospital records (scoliosis not requiring surgery, 
plexiform neurofibromas, delayed puberty, epilepsy and intellectual 
handicap) did not differ between groups. 
Complications occurred at random in most families although five 
showed apparent clustering of complications. In one (NF 17), the 
affected mother and a daughter had a gastrointestinal neurofibroma 
removed (but from different sites) and 2 further children (who lived 
outside the study area) had surgery for spinal neurofibromas. In two 
families there were 2 cases of scoliosis, although only 1 case in 
each had required surgery. In family NF 3, ascertained via a case 
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father and sister of the index case reported that they had mild 
curvature of the spine, unchanged from their teens. The father had a 
mild thoracic kyphoscoliosis and the sister a mild lumbar scoliosis. 
No old X-rays could be traced for further comparison. In Family NF 9 
the index case had had surgery for a thoracic scoliosis and her 
father had a very mild thoracic scoliosis unchanged from his teens. 
In a fourth family (NF 38) the 3 affected members (a mother and 
both her children) had each required special schooling (details of 
the father's schooling were not available). In the fifth family (NF 
1) 2 children required special schooling and one other had received 
remedial class education; their parents and 3 normal siblings had 
attended normal school but did not obtain any academic 
qualifications. In both families it was felt that social and 
environmental factors could have made a significant contribution to 
the children's school performance. 
A review of the complications of NF-1 in the study population is 
now given. Since some complications of NF-1 are rare, they may not 
occur in a population-based survey by chance. Those complications 
not identified in the study are briefly reviewed in the relevant 
section; it must be assumed their frequency in NF-1 sufferers is 51%. 
A. Plexiform neurofibromas - The appearance of these lesions was 
clinically quite distinct from cutaneous neurofibromas. They 
presented as large subcutaneous swellings with ill-defined margins 
varying from lesions a few cm in diameter to those involving a whole 
area of the body (Figure 5-1). The consistency was soft although 
occasionally hypertrophied nerve trunks could be palpated within the 
mass. The skin overlying the lesion was abnormal in 23/45 lesions (5 
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individuals had 2) due to a combination of hypertrophy, CAL 
pigmentation or hypertrichosis. The age at which the lesions 
appeared was also quite different from cutaneous neurofibromas. 
Sixteen of the 40 cases with plexiform neurofibromas were aged <14 
years; in 8 of these individuals the lesion had been noted within the 
first year of life and this was the case in all those with large 
facial lesions. 
Plexiform neurofibromas were most frequent on the trunk (20/45), 
followed by the limbs (17/45) and head and neck (8/45). They were 
rarely symptomatic but their cosmetic burden was considerable; in 
Table 5-1 the frequency of the more severe lesions is presented. 
Four patients (28,36,109,116*) had large plexiform neurofibromas of 
the face; involvement of the orbit had led to loss of vision in 2 
and in one overgrowth of the maxilla had resulted in problems with 
malocclusion. All 4 individuals had had a series of corrective 
plastic surgical procedures. A further group of 7 cases has been 
subdivided because of particularly large truncal lesions (70,115) 
associated with severe hypertrophy of the overlying skin and large 
lesions affecting the lower limb (26,49,57,76,132); in 4/5 of the 
latter group the lesions were around the ankle and overgrowth of the 
underlying bone had occurred. One case (57), whose lesion extended 
up the leg, had required epiphyseal plating at the knee to prevent 
further overgrowth of the long bones on the affected side. 
Eleven individuals had had operations to improve the appearance 
of these lesions but in no case had complete removal been achieved, 
surgery being relatively unsuccessful because of involvement of 
* Unless stated, numbers given in parentheses in this section are the 
case numbers of individuals with a given complication. 
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FIGURE 5-1. Plexiform neurofibromas. 
A. Facial plexiform neurofibroma in a4 year old 
girl (case 109) who had presented at 2 months of 
age. She had already had a number of surgical 
procedures. 
B. Plexiform neurofibroma overlying the lumbar 
spine of an 8 year old boy (case 31). The lesion 
was asymptomatic and had first been noted on 
routine examination at 3 years of age. 
C. Anterior and posterior views of large 
plexiform neurofibroma of left lower limb in 








major nerve trunks, excessive haemorrhage at operation, or poor 
delineation of the lesion from normal tissue. This is the experience 
in other large series (Riccardi & Eichner 1986). 
In the older NF-1 literature, the descriptive designation of 
"elephantiasis neuromatosa" or "fibroma pendulum" is used to describe 
very large plexiform neurofibromas (Borberg 1951; Crowe al 1956). 
The other point frequently raised in the literature (Breasfield & Das 
Gupta 1972; Riccardi & Eichner 1986) is that it is probably only 
plexiform neurofibromas that harbour the potential for malignant 
change. Although this was not seen in any of the 69 families in the 
population study, it had occurred in one of the originally 
ascertained cases who was a new mutation for NF-1 and died prior to 
the study. 
B. Intellectual handicap -A retrospective assessment of the 
education deemed appropriate for each affected individual was used to 
give an approximate measure of intellectual handicap attributed to 
the disease. The outcome is shown in Table 5-1. In only 2 affected 
individuals were there NF-1 complications which might have accounted 
for these problems. In case 76, who had attended a special school, 
hypsarrhythmia might have caused the intellectual handicap and in 
case 65, who had attended a remedial class, hydrocephalus secondary 
to aqueduct stenosis might have been responsible. 
Of the affected adults, only one was severely retarded, having an 
intellectual age of 2 years when seen at 33 years. Of the 11 other 
adults who had attended a special school, 2 were subjectively 
classified as moderately retarded, as they could barely read or write 
and, although living in the community, required considerable family 
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support; the remaining 9 individuals were classified as minimally 
retarded, since they were reasonably literate and leading independent 
lives. Those who required remedial class education were also 
classified as minimally retarded. Of the 34 children aged 25 to <18 
years) only one was attending a special school and was moderately 
retarded (aged 13 years at assessment); 8 were in remedial class 
education (classified as minimally retarded). Of the 7 individuals 
who reported specific learning difficulties, the main problem was or 
had been in reading, with normal performance in other areas. 
Combining the educational data on adults and children in terms of a 
subjective assessment of overall performance gives the following 
frequencies: severe retardation 1/124 (0.8%), moderate retardation 
3/124 (2.4%), minimal retardation 30/124 (24.2%) and specific 
learning difficulties 7/124 (5.6%). 
The educational placement of normal individuals with an affected 
parent was used for comparison. 43/45 (95%) of this group were 
attending or had been to a normal school and 2/45 (5%) were attending 
a remedial class. The educational achievements of the two groups also 
differed. Of the 95 affected individuals who had completed their 
education, 3 had achieved passes at GCE '0' level, 1 at 'A' level and 
1 higher school certificate, although none had gained university 
places. In the unaffected group, 22 had completed their education, 1 
had achieved '0' levels passes and 4 'A' level passes, of whom 3 had 
gained university places. 
As the risk of intellectual handicap is often a major factor 
influencing reproductive decisions for a particular disorder, it is 
appropriate to review the findings of previous series in detail. The 
frequency of intellectual handicap in NF-1 has been looked at in some 
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detail in 4 previous series. Borberg (1951), who ascertained cases 
through hospital records, found that the distribution of IQ was <70 
(7/71 - 10%); 70-80 (3/71 - 4%); 80-90 (45/71 - 63%) and >90 (16/71 - 
23%); Carey et al (1979), ascertaining cases through genetic clinic 
records, found 11.4% of index cases and 4.2% of affected relatives 
had an IQ of <70; 11.4% of the remainder had learning difficulties. 
Samuelsson (1981), in a population study with similar methodology to 
our own, found that 2/71 (2/8%) adult cases had required special 
school education, and 30/71 (42%) remedial class education. Riccardi 
& Eichner (1986), studying cases referred to a special interest 
clinic, found that 18/201 (9%) cases had an IQ of <70 and 30% of the 
whole population (n=238) had learning difficulties. The present 
study confirms the high frequency of learning difficulties (5.6%) and 
minimal intellectual handicap (24.2%) but found a slightly lower 
frequency of moderate/severe handicap (2.4% and 0.8% respectively) 
than most previous studies. A more exact understanding of the 
intellectual burden of NF-1 will only be reached when a large series 
of children are followed, with appropriate psychmetric examinations, 
from early childhood. 
Rosman & Pierce (1967) have demonstrated a possible cause for the 
intellectual handicap in NF-1. They reviewed the histology of the 
cerebral hemispheres from 10 patients with the disease who had come 
to autopsy. Five of these patients had been mentally retarded and in 
all, cerebral abnormalities were found. These included gross and 
microscopic disorders of cortical architecture, and neuronal 
heterotopias in the deep cerebral white matter. In the remaining 5 
cases, who were at least of average intelligence, similar but less 
severe changes were found. In view of these findings, the recent 
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report of Bognanno et a] (1988) is of interest. In a survey of 
Cranial Magnetic Resonance images (MRI) of 53 patients with NF-1 and 
NF-2, they found small focal areas of increased signal within the 
brain parenchyma on T2-weighted images in 23 patients; CT and TI- 
weighted MR images revealed few or no abnormalities in corresponding 
locations. The lesions were located primarily in the basal ganglia 
and internal capsule with other lesions seen in the midbrain, 
cerebellum and subcortical white matter. The authors postulate that 
they represent focal areas of heterotopic or possibly dysplastic 
tissue. Unfortunately, the authors do not categorise the cases by 
type of neurofibromatosis and insufficient information is given to 
allow correlation with clinical findings. Further evaluation of MRI 
in patients with well-defined NF-1 will be important to see if there 
is any correlation between these lesions and complications such as 
intellectual handicap and epilepsy; follow-up studies will also 
indicate whether the MRI abnormalities indicate sites which may 
harbour the potential for neoplastic change. 
C. Neurological complications 
(i) Epilepsy - The study confirmed the increased frequency of 
epilepsy in NF-1 sufferers. Six individuals suffered from epileptic 
fits for which no cause other than NF-1 had been demonstrated on 
investigation; of these, 3 individuals had grand mal seizures 
(36,61,77), one both grand mal and absenced attacks (21), one complex 
partial seizures (10) and one child petit mal attacks (20). All had 
achieved acceptable seizure control on anticonvulsant treatment. A 
further 2 cases had seizures which were attributed to a specific 
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disease complication - meningioangiomatosis (24) and aqueduct 
stenosis (65). In another patient (57) with complex partial seizures 
CT demonstrated an area of probable infarction in the right frontal 
region, the cause of which was unknown. 
Hypsarrhythmia also occurred more frequently in the study 
population than expected (2 cases) even though this is generally 
considered to be common in tuberous sclerosis but not NF-1. This 
association has previously been noted (Riccardi & Eichner 1986) so 
that hypsarrhythmia should probably be considered as having an 
increased frequency in NF-1. The two cases in the study presented at 
0.6 (89) and 0.7 years (76) and showed response to ACTH treatment. 
One (89) had no further seizures or residual neurological deficit, 
although did go on to develop an optic glioma. The other (76) had 
required special school education and developed grand mal seizures at 
the age of 17 years. 
(ii) Gliomas - Two of the individuals in the study population had 
optic gliomas. Case 48 had had a symptomatic chiasmal tumour treated 
with radiotherapy at 6 years. His vision improved after treatment 
and had then remained stable (assessed for the study at 12 years). 
Case 89 was diagnosed secondary to the study; he had been under 
review from the age of 3 years for unilateral optic atrophy with 
normal optic foramina on X-ray. The ophthalmologist was unaware of 
the family history of NF-1 and following assessment for the study 
(age 13 years) a CT scan was performed; it demonstrated changes 
consistent with an intra-orbital optic nerve glioma. 
Within the study area, the prevalence of optic nerve gliomas was 
therefore 1.5% (2/135). The benign course of the tumours in these 
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cases is in keeping with reviews of previous larger series (Wright et 
al 1980; Illgren et al 1985) that have shown that optic gliomas in 
NF-1 sufferers follow a much more benign course than when they occur 
in isolation. As CT and MRI scans are being performed on more NF-1 
sufferers, asymptomatic optic gliomas are being reported as 
relatively frequent findings. In the CT study of Lewis et al (1984) 
an overall frequency of 15% was reported but only 5.1% of lesions 
were symptomatic. In the MRI study of Bognanno et al (1988) 5/53 
(9.4%) had asymptomatic optic gliomas. 
Within the extended families of the population index cases, 3 
individuals were identified who had developed a glioma of the central 
nervous system, of whom 2 had NF-1 (Table 5-2). The status of the 
third case remained uncertain even after reviewing her medical 
records. To estimate the overall frequency of glioma, all index 
cases and affected relatives aged X18 years on 1.6.85 within (n=95) 
and outside the study area (n=18, of whom 12 were examined), and 
deceased affected relatives (n=25) were used as denominator. The 
frequency of glioma was 2/138 (1.5%) or 3/139 (2.2%) depending upon 
whether the case in whom the diagnosis of NF-1 was uncertain had the 
disease; the 2 index cases with optic glioma were excluded because 
of age. The overall frequency of gliomas was therefore lower than in 
most previous studies (Table 1-3). 
(iii) Spinal neurofibromas - Two individuals developed cord 
compression due to the presence of a spinal neurofibroma. Case 24 
had a neurofibroma removed at Cl and C2 on separate occasions and 
Case 48 a neurofibroma removed at T3. Neither patient had residual 
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that both had other CNS complications: case 24 (meningoangiomatosis) 
and case 48 (aqueduct stenosis). 
(iv) Acoustic neuromas and meningiomas - None of the patients in the 
study population or their extended families had had either of these 
tumours. As reviewed in Chapter 1, the previously reported 
association of acoustic neuromas with NF-1 may have been due to 
failure to distinguish NF-2 cases (Crowe et al 1956). This may also 
be the case for meningiomas as neither of these tumours have been 
reported in other recent large series (Samuelsson 1981; Riccardi & 
Eichner 1986). 
(v) Aqueduct stenosis - Two individuals had been successfully treated 
for hydrocephalus due to aqueduct stenosis; case 48 had presented 
with difficulty in walking at the age of 4 years and case 65 with 
grand mal seizures aged 16 years. The frequency of this complication 
(2%) is the same as that in the series of Riccardi & Eichner (1986). 
Both polypoid growths of ependymal granulation tissue (Russell 1949) 
and gliosis (Laurence 1962) have been demonstraed obstructing the 
aqueduct in autopsied cases with this complication. 
(vi) Meningioangiomatosis - Although one case (24) had this 
complication, it must be regarded as an extremely rare complication. 
Only 17 cases had been published prior to 1986 (Halper et a! ), 11 of 
these had NF-1. 
(vii) Co-ordination problems - Attention was drawn to the fact that 
individuals with NF-1 often experience co-ordination problems only 
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after completion of the clinical assessment of the cases was 
completed (Riccardi & Eichner 1986). Although no specific 
abnormalities were detected on limited neurological examination of 
the affected individuals in the present study, several parents 
specifically stated that their affected offspring were "clumsy" in 
comparison to their normal siblings. 
D. Skeletal complications 
(i) Scoliosis - This was the most frequent skeletal complication, for 
which 6 individuals had required surgery during their teens, 4 
(26,66,69,129) with thoracic and 2 (7,13) with thoracolumbar 
curvatures. In 3 cases, although surgery had stabilised the 
curvature, there was significant residual deformity (Figure 5-2). 
None had secondary neurological complications prior to or following 
surgery. In only one case (66) had dystrophic vertebral 
abnormalities been noted. A further seven individuals 
(5,6,9,25,108,120,133) had scoliosis which had not required surgery, 
in all but one of whom growth was complete when assessed for the 
study. Four out of 7 had only very discrete thoracic (120,133) and 
lumbar (5,9) curves. In the 2 cases (5,120) for whom X-ray reports 
were available, these curves involved 3 vertebrae only and were 
associated with abnormalities of the vertebral body. 
Scoliosis is therefore one of the more frequent complications of 
NF-1. In a large series of patients with scoliosis Winter et a! 
(1979) found 1% had NF-1. The majority of the NF-1 cases (80/102) in 
the series of Winter et a! (1979) had dystrophic changes of the 
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FIGURE 5-2. Scoliosis: variation in outcome 
A. Corrected scoliosis in a 26 
(case 69) who had no underlying 
abnormality. 
B. Kyphoscoliosis in a 19 year 
case); tue involved vertebrae wi 
he had had a spinal fusion (age 
severe residual deformity. 
4s 
of surgery. 
year old male 
vertebral 
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13 years) there is 
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dystrophic curves and cord compression was only seen in cases with 
dystrophic curves (11/102). The low frequency of, abnormal vertebrae 
in the present series may just reflect the fact that the information 
was recorded from case notes and the original films not reviewed. 
(ii) Pseudoarthrosis of tibia ± fibia - Four individuals had 
pseudoarthrosis of the tibia (17,28) or fibula (4) or both (111). 
The 3 cases with tibial involvement all presented within the first 
year of life, 2 with fractures and one with bowing which later 
fractured. Non-union had resulted in an eventual below-knee 
amputation in all 3 cases (at 11,12 and 39 years of age). Case 4, 
with fibular pseudoarthrosis, presented at 14 months and was 
successfully treated by bone grafting. One further case (34) had 
bowing of the tibia and fibula, first noticed at 8 months of age but 
no fracture had occurred by 11 years of age when he was assessed for 
the study. No cases were seen of pseudoarthrosis of the long bones 
of the forearm which has also been reported in association with NF-1 
(Gregg et al 1982). 
Twenty of the 40 cases of tibial pseudoarthrosis in the series of 
Morrissey et al (1981) had NF-1. The underlying pathogenesis is 
uncertain; there are a few histologically verified cases of 
intraosseus neurofibromas (Green & Rudo 1943; Berk & Mankin 1964) and 
schwannomas (Jacobs & Fox 1972; Gordon 1976) being found at the 
fracture site, but these seem to be exceptional. In the larger 
series of patients that have been studied using both light (Aegerter 
1950) and electron microscopy (Briner & Yunis 1973; Brown et al 
1977), no underlying tumours have been found and the authors have 



















(iii) Skull abnormalities - There- are two skull defects which are 
virtually unique to NF-1. These are congenital absence of the 
sphenoid wing (Holt & Wright 1947; Klatte et al 1976; Savino et al 
1977) and bony defect of the lambdoidal suture (Figure 5-3; Davidson 
1966; Klatte et al 1976). The former is frequently associated with 
an orbital plexiform neurofibroma but may occur in isolation, the 
patients then present with pulsatile enophthalmos. 
In the present study no cases of sphenoid wing dysplasia were 
identified. Case 119 had a lambdoidal suture defect which was picked 
up on a routine skull X-ray after an accident. However, the author 
only became aware of this manifestation of NF-1 towards the end of 
the study and the lambdoidal suture was not routinely palpated on 
examination. 
(iv) Vertebral scalloping and lateral thoracic meningogoele - These 
manifestations of NF-1 are usually asymptomatic (Heard & Payne 1962; 
Erkulvrawatr et al 1979) and as routine radiology was not undertaken 
their frequency cannot be estimated. Vertebral scalloping is a 
descriptive term used when the posterior wall of the vertebral body 
is markedly concave; it is unclear whether the primary defect is a 
bone dysplasia leading to erosion of the bone by normal pulsations of 
CSF pressure transmitted through the dura, or dural ectasia, with an 
expansion of the dural sac eroding the vertebral canal (Heard & Payne 
1962; Caselman & Mandell 1979). The majority of reported cases of 
lateral thoracic meningocoeles have been in patients with NF-1. They 
are usually detected as coincidental findings on chest X-ray and it 






FIGURE 5-4. Vertebral scalloping and durai ectasia. Plain lateral 
radiographs of lumbar spine (A, C) and myelograms (B, D) 
of case 5. A and B were taken age 20 years, C and D at 
44 years, and there has been some progression in the 
degree of vertebral abnormality. 
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vertebral scalloping (Erkulvrawatr et al 1979). The important 
differential is from spinal neurofibromas with a "dumbell" 
appearance. 
The only previous study in which routine radiology was undertaken 
was that of Riccardi & Eichner (1986); they comment on a frequency of 
10% for vertebral scalloping in the lumbar region but do not 
specifically comment on thoracic meningocoeles; it is therefore 
presumed none were identified. 
Case 5 in the present study was previously reported as case 4 in 
the study of Heard & Payne (1962); the vertebral scalloping in her 
lumbar spine is shown in Figure 5-4. 
E. Malignancy with established disease association - None of the 135 
cases in the study area had a malignancy known to be associated with 
the disease, but this complication had occurred in 3 deceased 
relatives and one who lived outside the study area (Table 5-2). The 
frequency of this complication was estimated using the same 
denominator as for gliomas. 
(i) Rhabdomyosarcoma - Two children had died from pelvic 
rhabdomyosarcomas (case 139 at 5 months, case 140 at 2 years) giving 
a frequency of 2/138 (1.5%). The site of these tumours is of 
particular interest, as in the previously reported series (Hope & 
Mulvihill 1981; Hartley et al 1988), in 9/16 children reported the 
tumours arose in the pelvis. 
(ii) Peripheral nerve malignancy - Two relatives (cases 141 and 142) 
had malignant tumours of peripheral nerves; one had died from a 
neurofibrosarcoma at 24 years and the other, who lived outside the 
study area and was not personally examined, had a low-grade malignant 
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neurilemmoma removed at 33 years, with no recurrence to the time of 
the study (4 years later). The frequency of peripheral nerve 
malignancy in this cohort is therefore 2/138 (1.5%), which is similar 
to that in most previous surveys (Table 1-3) except that of Brasfield 
& Das Gupta (1972). They reported a frequency of 29% which must be 
considered a significant over-estimate, resulting from ascertainment 
bias introduced when cases are identified solely through specialist 
hospital records. 
(iii) Other disease-related malignancies - No cases of 
neuroblastoma, Wilms tumour or childhood leukaemia were seen in the 
69 population study families. The association of childhood leukaemia 
(with an excess of non-lymphocytic cases) with NF-1 is now accepted, 
although a definite increase of neuroblastoma and Wilms tumour has 
not been definitely proven (Hope & Mulvihill 1981; Riccardi & Eichner 
1986). The finding of one case who died from Wilms tumour (NF 73, 
IV-2) in the families ascertained via LINK throws no further light on 
the matter. 
F. Endocrine complications 
(i) Endocrine tumours - The association of phaeochromocytoma and 
NF-1 is long established; 7/72 (9/7%) in one series of patients with 
phaeochromocytoma had NF-1 (Modlin et al 1979). In previous large 
series of NF-1 sufferers, the frequency of phaeochromocytoma has 
varied from 0/238 (Riccardi & Eichner 1986) to 3% (Samuelsson 1981). 
During the course of the present study two papers reported a possible 
association of duodenal carcinoid tumours with NF-1 and pointed out 
that these tumours often occurred in association with 
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phaeochromocytomas (Hough et al 1983; Griffiths et al 1983). In a 
more recent review, Griffiths et al (1987) presented a much larger 
series: 27/29 cases of carcinoid tumours in NF-1 were duodenal (at 
the ampulla vater) and phaeochromocytoma was present in 6/27. With 
regard to the pathology of the carcinoid tumours, the tumours are 
glandular, with frequent local infiltration and are frequently 
confused with adenocarcinomas. The tumours are also rich in 
somatostatin, although the majority of cases in the series of 
Griffiths et al (1987) presented with bile duct obstruction rather 
than symptoms of excess somatostatin secretion (diarrhoea, 
cholelithiasis, mild diabetes and dyspepsia). 
In the present study, case 61 had a phaeochromocytoma and at 
operation an asymptomatic duodenal carcinoid was found. Case 118 was 
said to have had a duodenal adenocarcinoma removed, following study 
assessment the histology was reviewed (by Professor E. D. Williams) 
and found to be a carcinoid tumour. At study assessment case 118 was 
normotensive and her urinary catecholamines were normal. Both of 
these cases are included in the report of Griffiths et al (1987). In 
reviewing previous large studies of NF-i sufferers, one patient is 
reported with both tumours in the 39 year follow-up of Borberg's 
cases (Sorenson et al 1986). It is likely that the association of 
duodenal carcinoid with NF-1 is significant and it is important to 
look for carcinoid tumours in patients presenting with 
phaeochromocytoma and vice versa. 
(ii) Premature/delayed sexual development - Two males in the study 
(82,85) had had endocrinological investigations for delayed puberty 
and no underlying abnormality demonstrated, both had subsequently 
developed normal secondary sexual characteristics. This frequency of 
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2% for delayed puberty is within the general population range (Tanner 
and Whitehouse 1976). Although sexual precocity as a complication of 
optic gliomas encroaching upon the hypothalamus is a well-recorded 
finding (Holt 1978), whether disturbances of sexual maturation 
without an underlying cause occur in NF-1 is uncertain. Riccardi & 
Eichner (1986) formally recorded the onset of puberty in 112 patients 
and found no variation from the normal population. 
G. Cardiovascular complications - The manifestations of 
cardiovascular problems in NF-1 can be either secondary to external 
compression by neurofibromas or due to a primary arterial dysplasia 
which most frequently mainfests as either renal artery stenosis 
(Halpen and Currarino 1965; Salyer & Salyer 1974; Zochodne 1984) or 
cerebrovascular disease (Taboada et al 1979; Levisohn et al 1978). 
In the present series two cases (67,94) had renal artery stenosis 
presumed secondary to arterial dysplasia; no cases of cerebrovascular 
disease related to NF-1 were identified. The occurrence of these two 
complications is not mentioned in most previous large studies of 
NF-1; Riccardi & Eichner (1986) report a 1% frequency of renal artery 
stenosis and although they mention cerebrovascular disease as being 
an important manifestation of NF-1, they do not state the frequency 
with which it occurred in their series. 
H. Symptomatic neurofibromas (other than peripheral and spinal) - 
Three individuals had developed symptoms from gastrointestinal 
neurofibromas. A mother (41) and daughter (42) had both presented 
with abdominal pain and altered bowel habit (aged 78 and 51 years 
respectively). In one the tumour was in the appendix and in the 
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other within the terminal small bowel; in both cases other small 
lesions were noted at operation either on the surface of the bowel or 
in the mesentery. Case 19 presented aged 7 years with anorexia and 
malaise and was found to have a large neurofibroma in the mesentery 
of the right colon. 
The only other case with symptomatic neurofibromas elsewhere was 
case 5, who had had 5 lesions in her gums for a number of years; 
these caused occasional pain but no other problems. 
I. Congenital glaucoma -A distinctive form of congenital glaucoma 
is associated with NF-1 (Grant & Walton 1968; Satran et at 1980) and 
is frequently associated with an orbital plexiform neurofibroma. 
However, cases of congenital glaucoma in isolation are also seen and 
the primary mechanism is uncertain, although dysplasia of the angle 
or invasion with neurofibromatous tissue are the most favourd 
hypotheses (Grant & Walton 1968). Case 71 in this study had 
unilateral congenital glaucoma described as 'characteristic of NF-1' 
by her ophthalmologist. In their series, Riccardi & Eichner (1986) 
report a frequency of 0.5%. 
J. overview of frequency of complications - Direct comparison of the 
present study with the previous large studies of the disease are 
difficult either because different forms of neurofibromatosis were 
not distinguished (Crowe et al, 1956; Samuelsson 1981) or 
ascertainment bias was introduced into the survey (Borberg 1951; 
Brasfield & Das Gupta 1971; Riccardi & Eichner 1986), or both (Carey 
et a! 1979). Although in this study an attempt was made to avoid 
bias by ascertaining all cases within a geographically defined 
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population, the frequency of complications may still be an 
overestimate because of failure to ascertain mildly affected cases in 
whom a medical opinion had not been sought. Analysing the frequency 
of complications is one way of correcting for this potential bias; 
however this group is not truly representative as survey methodology 
usually selects for cases with complications. In this study, no 
significant difference was found in the frequency of delayed puberty, 
epilepsy, intellectual handicap, minor scoliosis or plexiform 
neurofibromas between affected relatives or index cases, 
complications which either would not necessarily have led to hospital 
referral or have been identified through our search of hospital 
records. The true frequency of NF-1 complications however will only 
be established as large cohorts of disease sufferers are followed 
from childhood. 
3. Other diseases observed in the study population 
These are summarised in Table 5-3. The majority must be presumed 
to be entirely coincidental findings. However, both juvenile 
xanthogranuloma (Jenson et al 1971; Riccardi & Eichner 1986), 
cutaneous haemangiomas (Wertelecki et al 1982) and hypertrophic 
obstructive cardiomyopathy (Lin & Garver 1988) have been reported as 
occurring in excess in patients with NF-1, based on reports of single 
or small series of cases with both conditions. 
4. Disease mortality 
The contribution of NF-1 to mortality has been indirectly 
estimated first by looking at the variation in disease prevalence 
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Table 5-3 Other diseases observed in the study population 
Study No. Previous reported 
association with NF-1 
Juvenile xanthogranuloma 104 
Cutaneous haemangioma 122 
Hypertrophic obstructive 
cardiomyopathy 108 
Carcinoma of breast 52 (d) 
Carcinoma of penis 117 
Asthma 29,30 , 55,127,128 
Senile dementia 32,40 
Multiple sclerosis 42 
Gilbert's disease 105 
Congenital heart disease 












with age (Figure 5-5). Age-specific population figures are not 
available for the 9th decade and the low prevalence in those aged 
under 10 years is probably explained by under-ascertainment of 
sporadically affected children without complications. The decrease 
in prevalence from the second decade onwards cannot be accounted for 
solely by under-ascertainment. 
Mortality attributable to NF-1 can also be assessed from the 
cause of death in the 25 deceased relatives (Table 5-4); this was 
attributable to NF-1 in 6 (22%). A further 6 cases died of 
malignancies not known to be associated with NF-1. Twelve of the 
remaining 13 cases died from causes probably unrelated to NF-1; one 
died from subarachnoid haemorrhage in association with hypertension 
of unknown aetiology at the age of 48 years. 
The pattern of age-specific prevalence (Figure 5-5) and causes 
of death (Table 5-4) suggest an increased mortality in NF-1 although 
our study was not designed to assess this statistic. Mortality due 
to the disease has only been reported by Sorenson et al (1986), based 
on a 39-year follow-up of cases first identified by Borberg (1951). 
Survival rates to June 1983 of patients who were alive on January 1st 
1944 were lower than if their year-, age- and sex-specific death 
rates had been those of the general population. Mortality was 
increased among probands, especially females, compared with affected 
relatives; female relatives had a survival rate just below that of 
the general population. Borberg's probands were originally 
identified through hospital in-patient records and the authors 
concluded that patients requiring hospitalisation have a poor 
prognosis, whereas incidentally diagnosed relatives may have a 
considerably better outcome. This study also showed that NF-i 
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patients with one malignancy (including CNS tumours and 
phaeochromocytoma) appear to have an increased risk of developing a 
second malignancy; this occurred in 16/70 (23%) patients whereas a 
second cancer develops in only 4% of persons with malignancy in the 
general population (Storm et al 1985). As in the case of 
complication frequencies, a more exact picture of disease related 













FIGURE 5-5. Difference in the estimated prevalence of NF-1 
with age. 
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Table 5-4 Causes of death in 25 deceased affected relatives 
Case No. Sex Age Cause 
(years) 
Related to underlvina disease: 
137 F 32 
139 F 0.5 
140 M 2 
141 F 24 
143 F 51 





Obstructive hydrocephalus following 
removal of neurofibroma at C1-2 
Acute left ventricular failure and 
haemorrhage into undiagnosed 
phaeochromocytoma 
Possibly related to underlying disease: 
163 F 48 Subarachnoid haemorrhage, 
hypertension (aetiology unknown) 
Malionancv with no definite disease association: 
145 F 55 Ca cervix 
146 F 68 Ca stomach 
147 M 60 Ca stomach 
148 F 43 Ca breast 
149 F 49 Ca lung 
150 F 61 Leukaemia (type unknown) 
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Table 5-4 (continued) 
Remaining cases: 
151 M 66 Bronchopneumonia, fractured femur 
159 M 82 Bronchopneumonia, senile dementia 
153 M 57 Ischaemic heart disease 
155 F 71 Ischaemic heart disease 
154 M 45 Myocarditis 
162 M 68 Aortic valve disease 
152 M 52 Haematemesis ? cause, mentally 
subnormal secondary to untreated 
hydrocephalus 
157 M 63 Cerebrovascular disease 
158 F 70 Chronic bronchitis 
160 F 31 Pulmonary infarction following 
childbirth 
161 M 62 Pulmonary embolus secondary to 
deep venous thrombosis 
156 M 27 Suicide 
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CHAPTER 6 Patient care and genetic counselling in NF-1 
1. Introduction 
The last decade has seen increasing awareness of the problems 
encountered by NF-1 sufferers; prior to this, although the individual 
complications were frequently reviewed in the medical literature, no 
consideration was given to overall care of the patient or whether 
screening investigations were necessary. As discussed in Chapter 1, 
a significant factor in the increasing awareness of the medical 
profession has been the formation of Lay Societies for 
neurofibromatosis sufferers and their families. 
The British neurofibromatosis association, LINK (Let's Increase 
Neurofibromatosis Knowledge) was formed in 1981; the most frequent 
complaints of new members (C. Peperell, personal communication) is 
that they had been given inadequate information about the disease by 
their doctors and that no one person was prepared to coordinate their 
health care. 
The membership of Lay Societies present a biased group, with a 
majority of severely affected individuals. The study population, 
however, presented an unbiased group of NF-1 sufferers in which to 
assess the care and counselling of such patients. In this chapter 
the outcome of this analysis is presented, and arising from this, 
guidelines for the management and counselling of NF-1 sufferers are 
proposed. 
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2. Patient care in the South East Wales population 
Although a section on patients' attitudes to the disease was 
included in the study questionnaire (Appendix C), this was often not 
completed as it had already become obvious that the patient 
understood so little about NF-1 that the answers would have been 
uninterpretable. Many of the patients regarded NF-1 as "just a skin 
complaint", and those with complications often had no idea they were 
related to NF-1. Those who had sought to inform themselves often had 
an exaggerated impression of their risk of malignancy or fear of 
becoming an "Elephant Man". However, the data obtained were 
sufficient to look at by whom, and at what age the diagnosis of NF-1 
had been made, the medical care received by the patients and the 
number who had received formal genetic counselling. 
A. The diagnosis of NF-1 - The results presented in Chapter 4 show 
that CAL spots are present in NF-1 sufferers by the age of 5 years. 
If 6 CAL spots are found on routine examination in childhood, NF-1 
is by far the most likely cause. The 'awareness' of the medical 
profession to the diagnosis of NF-1 has been indirectly assessed by 
looking at by whom and at what age the diagnosis of NF-1 had been 
made in the 135 individuals in the study population. The outcome is 
presented in Table 6-1. Twenty of the 135 cases were diagnosed for 
the first time when assessed for the study. A further 10 
individuals, all members of family NF 49, were aware of having the 
disease through discussion within the family but, regarding it as 
'just a skin complaint', had never sought medical advice. 
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Table 6-1 The 135 affected individuals in the study population 
divided according to who had made the diagnosis of NF-1 
Diagnosed by No of No. for whom age Mean age at 
cases at diagnosis known diagnosis in yrs 
(range) 
Paediatrician 26 23 3.7 (0.3-15) 
Dermatologist 21 18 23.0 (0.5-41) 
Study** 20 20 22.1 (1-83) 
General Practitioner 16 10 37.6 (4-67) 
Neurologist 12 8 26.8 (12-46) 
Family ** 10 - - 
Orthopaedic Surgeon 9 9 12.8 (1-31) 
General Physician 7 5 30.8 (18-54) 
Plastic Surgeon 7 7 12.4 (1-24) 
Ophthalmologist 3 3 4,7,35 
Neurosurgeon 2 2 4,33 
Clinical Geneticist 1 1 4 
General Surgeon 1 0 - 
* For numbers <5, age at diagnosis individually listed 
z* See text for explanation 
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Table 6-2 The 41 affected individuals aged <18 years in the study 
population divided according to who had made the diagnosis 
Diagnosed by No. of cases Mean age at diagnosis 
in years (range) 
Paediatrician 20 2.7 (0.3-10) 
Study 11 8.3 (1-15) 
Family 4 - 
Clinical Geneticist 1 4 
Plastic Surgeon 1 1 
Ophthalmologist 1 4 
Orthopaedic Surgeon 1 11 
Dermatologist 2 0.5,15 
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The mean age of diagnosis in the remaining 105 cases was 17.7 
years. The majority of cases had not been diagnosed until early 
adulthood when the appearance of neurofibromas had caused them to 
seek medical attention. In view of the improved child health 
surveillance in recent years, the data have been analysed separately 
for those aged <18 years (n=41) and is presented in Table 6-2. It can 
be seen that the findings are similar to those for the whole study 
population. Fifteeen out of 41 children had not been diagnosed prior 
to the study and in 6/27 of the remainder a major disease 
complication had been the mode of presentation. In a further 4 cases 
the diagnosis was only made during a hospital consultation for 
unrelated medical problems. On a purely subjective level, many 
parents said that they had pointed out the CAL spots to various 
doctors only to be told they were 'just birth marks'. ' 
B. Patient care and genetic counselling - 94/135 (70%) cases in the 
study population had had at least one hospital consultation for NF-1 
prior to their assessment for the study. Yet only 30/135 were being 
regularly followed in a hospital clinic, and in half of these it was 
to monitor a specific disease complication (Table 6-3). None of the 
remaining 105 individuals were under regular review with their 
general practitioner for NF-1. The medical histories of many of the 
cases (Appendix A) demonstrate that regular follow-up with more 
information about the disease would have avoided delay in diagnosis 
of complications and distress caused by uncertainty. The cases with 
hypertension secondary to renal artery stenosis (67,94) or 
phaeochromocytoma (61) illustrate clearly the value of regular 
follow-up. In all three of these cases, the raised blood pressure 
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Table 6-3 Reason for hospital follow-up in 30/135 
individuals in study area 
Reason Number 
General overview of disease 15 
- Adults 5 
- Children (<18 years) 10 
Because of disease complication 15 
- Neurological complications 5 
- Facial plexiform neurofibromas 3 
- Ophthalmological complications* 3 
- Orthopaedic complications 2 
- Endocrine complications 1 
- Follow-up after GI surgery 1 
* Including optic gliomas as both individuals with this complication 
followed only by an ophthalmologist. 
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was a coincidental finding on examination when they had presented 
with another problem. 
Only 9 individuals from 7 families had received formal genetic 
counselling, and in 4 cases this was after they had completed their 
families. Although others had been informed of the mode of 
inheritance, the variation of disease severity and risk of 
complications had not been explained. 
3. Guidelines for the management and counselling of NF-1 sufferers 
The data presented in Section 6-2 shows that there is a need for 
improved patient care in NF-1. Although many complications are 
individually rare, their combined burden is significant and it is 
likely that sufferers are not being diagnosed sufficiently early, nor 
receiving appropriate follow-up and counselling. Based on the 
findings of the study, guidelines for genetic counselling and patient 
management in NF-1 are now presented. 
A. Genetic counselling - The information needed in genetic 
counselling of NF-1 sufferers can be divided into three main areas: 
(i) Recurrence risks for parents of an isolated case - The reports 
of cases with limited expression of the NF-1 gene having affected 
children (reviewed by Riccardi & Lewis 1988) means that detailed 
cutaneous and slit lamp examination of the parents of an apparently 
isolated case is essential before counselling is given. In the 
absence of any abnormalities, there is no significant increased risk 
of a further affected child. The author is aware of only 2 cases of 
recurrence with apparently normal parents (Riccardi & Lewis 1988). 
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(ii) Assessment of at-risk children - The data presented in Chapter 
4 show that, in assessing children of an affected patient, those who 
have inherited the gene can be distinguished from their normal 
siblings on the basis of whether or not CAL spots are present by the 
age of 5 years. 
(iii) Risk figures for prospective parents - The 50% risk of 
autosomal dominant inheritance is straightforward; what is more 
difficult is explaining the risk of complications. Informing 
sufferers and their families about the varied complications of NF-1 
is a difficult counselling task, and there is a fine balance between 
providing adequate information and causing unnecessary alarm. Rather 
than presenting patients with a long list of complications, it is 
probably more useful to group the complications according to the 
effect they will have on an individual's life as shown in Table 6-4. 
The risks to offspring of an affected parent are therefore: 
intellectual handicap, 16.5% (moderate/severe retardation, 1.5%, 
minimal retardation/learning difficulties 15%); complications 
developing in childhood and causing lifelong morbidity, 4.5%; 
'treatable' complications which can develop at any age, 8%; and 
malignant or CNS tumours, 2-3%. The risk for a given complication 
group has been halved and rounded to the nearest 0.5%. 
B. Patient management - Based on the experience of this study, it is 
recommended that patients with NF-1 have regular clinical 
assessments, although none of the complications occur often enough to 
warrant biochemical or radiological screening. As many of the 
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Table 6-4 Frequency of complications for counselling purposes 
Complication Group Frequency 
1. Intellectual handicap: 
moderate-severe retardation 
minimal retardation or learning difficulties 
2. Developing in childhood and causing lifelong morbidity: 
severe plexiform neurofibromas of head & neck 
scoliosis, requiring surgery 
severe pseudoarthrosis 






renal artery stenosis 
4. CNS and malignant tumours: 
optic gliomas 
other CNS tumours 
rhabdomyosarcoma 





















complications develop early in life, children with the disease should 
have biannual review, particular attention being paid to intellectual 
development so that the child can be channelled into appropriate 
schooling. In adults, unless a particular complication indicates 
more frequent review, annual clinical examination only is 
recommended. 
In Figure 6-1 the age ranges for presentation of the majority of 
NF-1 complications are given. It is intended that this can be used 
when seeing patients to assess what complications an individual of a 
given age is still at risk of developing. This can be used both for 
reassurance, for example a young adult with no problems to date can 
be reassured they have no risk of certain complications, and in 
monitoring for complications which may yet occur. The age range 
during which a given feature may present has been derived as follows, 
from review of previously published series: aqueduct stenosis 
(Horwich et of 1983), endocrine tumours (Modlin et al 1979; Griffiths 
et of 1987), CNS tumours (Illgren et of 1985, Lewis et of 1984), 
pseudoarthrosis (Morrissy et of 1981), rhabdomyosarcoma (Hartley et 
of 1988; Hope & Mulvihill 1981) and scoliosis (Chaglassian et al 
1976; Winter et of 1979); from the age of presentation in this study 
and that of Riccardi & Eichner (1986): plexiform neurofibromas; for 
intellectual handicap it was assumed that severe development delay 
would have been identified by the age of 5 years and milder problems 
by the end of primary school education; for the remaining 
complications given as having a 'lifelong' risk of presentation, 
examples of each occurring from childhood throughout life were found 
either in this series or in the literature. Insufficient data are 








Severe Head and Neck PNFS 1.2%* 
L_ 
I 
Severe Pseudoarthrosis 2.1 % 
Severe Retardation 0.8% 
F-- I 
Learning Difficulties 5.6% 
F- 71 
Min. Retardation 24.2% 
Mod. Retardation 2.4% 
Scoliosis 5.2% 
PNFs(except *1 25.5% 
Optic Glioma 0.7/0+ 
Stenosis 2.1 % 
osarcoma 1.5% 





CNS Tumours, other than + 0.7-1.5% 
Renal Artery Stenosis 2.1% 
Spinal NFS 2.1 % 
Gastrointestinal NFS 2.1 % 
Endocrine Tumours 3.1 % 
Epilepsy 4.2% 
05 10 15 20 25 30 'Lifelong' 
Age (years) 
Risk 
FIGURE 6-1. Age range of presentation and frequency of major 
NF-1 complications. The following abbreviations 
have been used: PNFS for plexiform neurofibromas 
and NFS for neurofibromas. 
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Which specialty should take on the responsibility of follow-up of 
NF-1 sufferers is open to debate. The paediatric clinic is clearly 
appropriate for children, but in adults the general practitioner or 
any one of a number of specialists (e. g. clinical geneticist, 
neurologist or dermatologist) are equally appropriate. There may be 
a case for a few centres in the UK establishing specialist 
neurofibromatosis clinics, so that particular expertise can be 
developed in treating some of the more difficult or unusual 
complications, and in the assessment of atypical cases. In Figure 
6-2, an outline of how such clinics would interact with 'local' 
clinics is illustrated. Although one person would have overall 
charge for the specialist clinic, they would need to identify 
colleagues in a number of specialties to assist in the management of 
different complications. The clinic would also be an ideal setting 
for evaluation of new diagnostic techniques and treatments and for 
the coordination of long term follow-up studies of NF-1 sufferers. 
Through such studies, clinical features which predispose to the 
development of certain complications (e. g. malignancy) may emerge, 







































































































































GENETIC LINKAGE STUDIES OF VON RECKLINGHAUSEN NEUROFIBROMATOSIS 
CHAPTER 7 Introduction to human gene mapping and review of 
literature pertinent to the possible localisation 
of the NF-1 gene 
1. Introduction 
Since 1970 a series of discoveries in the field of molecular 
biology have led to a complete reorientation and renewed interest in 
research into human genetic disease. Through these discoveries we 
are now able to look at genetic disease not just on a cellular and 
biochemical level but on a molecular level. For a disease like NF-1 
it has made it possible to consider localising and eventually 
isolating the gene without knowing the gene product. This chapter 
briefly outlines the DNA techniques used in gene mapping, then 
reviews the principal methods used to map genes and finally the 
possible 'clues' to the localisation of the NF-1 gene at the outset 
of this work are reviewed. 
2. Recombinant DNA technology and the study of human genetic disease 
The fundamental principle on which most methods of DNA analysis 
of human genetic disease are based is the ability of small amounts of 
pure labelled DNA to hybridise to a much larger amount of genomic 
DNA. The labelled DNA is used as a 'probe' to study its 
complementary sequence in the genomic DNA of the individual under 
study. The DNA probe may be all or part of a gene known to cause a 
particular disease and used to study the rearrangements of that gene 
in affected patients. Alternatively random unique sequence DNA 
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probes which identify variation within the normal population can be 
used in linkage studies. The actual methods by which DNA probes are 
used in hybridisation experiments are described in detail in Chapter 
8. The developments which made this approach possible are briefly 
reviewed here. For more detailed reviews, see Watson et al 1983; Old 
& Primrose 1985; Weatherall 1985. 
(A) Restriction endonucleases - These are a group of bacterial 
enzymes which cut double stranded DNA where they recognise particular 
base sequences, usually 4-6 in length. In bacteria their action is 
to break down foreign DNA. The first of these was described in 1970 
(Smith and Willcox; Kelly and Smith) and since that time over 400 
have been isolated. Their importance is that they have given 
molecular biologists a way of cleaving genomic DNA into small 
fragments of known size suitable for cloning and hybridisation 
experiments. Furthermore, the finding of variation between 
individuals in the presence/absence of sites where these enzymes cut 
the DNA has given rise to a new class of genetic markers, restriction 
fragment length polymorphisms, which are described in section D. 
(B) Cloning of DNA fragments - The development of these techniques 
was fundamental to recombinant DNA technology . The principle is to 
insert foreign DNA into a suitable vector molecule which serves to 
propagate that DNA segment in a bacterium such as E. coli. The 
vectors used are plasmids, phages and cosmids. The choice of vector 
depends upon the size of the DNA to be cloned. A detailed account of 
DNA cloning is given by old and Primrose (1985). 
4 
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Cloning vectors usually have two or more single sites for 
different restriction endonucleases. Generation of a recombinant 
molecule involves cleaving donor and vector DNA using the same 
restriction enzyme; they are then mixed in the presence of a DNA 
ligase which promotes the rejoining of the cut strands of DNA. Some 
vectors reanneal to reconstruct their original form but others form 
recombinants by incorporating the foreign DNA into their structure. 
The vectors containing recombinant DNA molecules are then introduced 
into a bacterial host, usually E. coli; the bacteria are then 
cultured, resulting in large amounts of the recombinant vectors being 
produced. The recombinant DNA can then be retrieved from the 
bacteria, the final product being large amounts of the original 
'foreign' DNA for use in hybridisation experiments (Maniatis et al 
1982). 
(C) Gene libraries - Using the techniques of DNA cloning it has 
become possible to construct gene "libraries" which are the usual 
source of single copy DNA sequences for use as probes. Gene libraries 
may be of 3 main types: 
(i) Complementary DNA (cDNA) - cDNA libraries can be made from 
particular tissue or cell types, cDNA copies of the cells' RNA being 
cloned and the clones therefore representing all the active genes of 
that particular specimen (Williams 1981). 
(ii) Genomic libraries -A genomic library consists of total cellular 
DNA digested with a restriction endonuclease and recombinants 
prepared between the fragments thus created and plasmid or phage 
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treated with the same enzyme. A total human DNA library consists, 
therefore, of hundreds of thousands of clones, each representing a 
different piece of the genome (Lawn et al 1978). 
(iii) Chromosome specific libraries - These are of particular use 
when the chromosomal localisation of the disease under study is 
known. The chromosome of interest can be separated by flow-sorting 
and used to prepare recombinants or somatic cell hybrids, containing 
all or part of the human chromsome of interest, can be used. By this 
method the number of clones to be screened is greatly reduced. 
Gene libraries thus created can be used in a variety of ways. If 
the nucleic acid sequence of a given protein is known, then a 
synthetic DNA probe can be constructed from the appropriate 
nucleotides and used to screen DNA libraries for clones containing 
all or part of the actual gene encoding the protein of interest. 
Alternatively, libraries can be used as sources of random unique 
sequence DNA, and these in turn used to detect restriction fragment 
length polymorphisms for use in genetic linkage studies, as explained 
in the subsequent section. The earliest example of the success of 
this approach is the X-library of Davies et a! (1981) which provided 
the first DNA probe which identified a random genomic DNA 
polymorphism linked to a disease locus (Duchenne muscular dystrophy, 
Murray et al 1982). 
(D) Application of DNA technology to localisation and isolation of genes 
The genetic diseases to which DNA technology was first applied 
successfully were those where the gene product is known, the 
haemoglobin disorders being a classical example (Weatherall, 1985). 
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As the RNA in human reticulocytes is almost entirely globin messenger 
RNA (mRNA), it was possible to make purified mRNA for single globin 
chains and thus make cDNA probes. With these it was possible to 
isolate the globin genes from libraries of human DNA, characterise 
their fine structure and then compare normal structure with that of 
DNA from patients with haemoglobin disorders. 
These studies have shown that the haemoglobin disorders and 
structural haemoglobin variants have arisen from a number of DNA 
arrangements of varying complexity. From the findings of these and 
related studies, it seems likely that the majority of human genetic 
diseases will turn out to have resulted from not just one but a 
variety of DNA rearrangements. The importance of these discoveries 
clinically has been that families with haemoglobin disorders can be 
offered DNA diagnosis with a chorionic villous biopsy at eight to 
twelve weeks of pregnancy, rather than foetal blood sampling in the 
second trimester. 
One of the main ways in which normal genes are compared with 
abnormal genes is the technique of 'restriction mapping'. The cloned 
gene is labelled with radioactive phosphorus and used as a DNA 
'probe'. Its hybridisation with fractionated human DNA which has 
been digested with a series of restriction endonucleases is studied 
and a restriction 'map' of the gene built up. This in turn can be 
compared with the findings when the probe is used with the DNA from 
patients with a disorder of that particular gene. If the 
rearrangement underlying the abnormal gene causes the loss of or 
creation of a restriction site, the DNA probe will detect this by 
'lighting up' segments of different length from normal. In more 
extreme cases the disease may have been caused by the deletion of the 
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whole of a region of DNA and this will be detected by the DNA probe 
failing to hybridise (and therefore 'light up') with a complementary 
sequence. 
It is however relatively uncommon for the actual gene 
rearrangement itself to affect a restriction enzyme site. 
Fortunately, as genes were cloned and their restriction maps studied, 
it became apparent that some restriction sites were polymorphic with 
no phenotypic effect due to presumed 'neutral' mutation, i. e. they 
showed variation within the normal population. Therefore, a DNA 
probe for a given site is able to detect variation therein, as on 
hybridisation it will pair with differing lengths of DNA i. e. there 
is polymorphism of restriction fragment length (RFLP). The first 
human RFLP to be discovered was a Hpal site about 5 kbs from the 3' 
end of the beta-globin gene (Kan and Dozy, 1978). Further studies 
of RFLPs showed that they were inherited in a Mendelian co-dominant 
manner and it was anticipated that they would be fairly evenly 
distributed throughout the genome and that more variation could be 
expected in regions between structural genes (Jeffreys 1979). 
In 1980, Botstein and his colleagues pointed out the potential 
usefulness of RFLPs as genetic markers for chromosome mapping. They 
emphasised that the RFLP need not be within a gene, but could occur 
in any random unique sequence DNA for which a complementary DNA probe 
was available. They estimated that if approximately 200 probes that 
identified RFLPs were available and evenly spread throughout the 
genome, then all genetic diseases could be mapped. The first RFLP 
identified by a random unique sequence probe was described by Wyman 
and White in 1980. The "detection" of an RFLP by a DNA probe is 
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FIGURE 7-1. Diagrammatic representation of detection of a RFLP 
by a DNA probe and corresponding genotypes on an 
autoradiograph. 
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DNA probes can be used in linkage studies in two ways: 
(i) probes for 'candidate' 
can be used to identify 
studied in families, and 
excluded as the cause of t 
(ii) random probes which 
genes (e. g. Nerve Growth Factor for NF-1) 
RFLPs, the segregation of which can be 
if cross-overs are found, the gene is 
he disease; 
identify RFLPs can be used as genetic 
markers to look for linkage. 
Once the gene has been mapped to a given chromosome using these 
methods, then recombinant DNA technology provides the means by which, 
in conjunction with somatic cell hybrids and cytogenetic techniques, 
'fine' mapping and eventual isolation of the gene itself are possible 
(Orkin 1986). 
3. Methods of human gene mapping 
(A) Family linkage studies - 
(i) Historical background - Two genes are said to be linked when they 
are located on the same chromosome within measurable distance of each 
other. Genes on the same chromosome that do not show linkage are said 
to be syntenic (Renwick 1969). In family linkage studies the 
segregation of "marker" genes, the chromosomal localisation of which 
is known, is followed through pedigrees in which the disease under 
study is segregating: if the two loci are closely linked then one 
allele of the marker gene will nearly always segretate with the 
disease, thus localising the disease to the same chromosome. 
The term linkage was first used by Morgan in 1910 following on 
from the work of Bateson and his colleagues (1908). In 1865 Mendel 
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had concluded that the segregation of two different pairs of alleles 
is independent but soon after the rediscovery of his work in the 
first decade of this century, Bateson et al (1908) found an exception 
to this rule in the sweet pea. They observed certain combinations of 
alleles more frequently than expected. The alleles of the parental 
combination seemed either to attract one another or to repel one 
another. Bateson et al coined the terms "coupling" for the former 
phase and "repulsion" for the latter phase. Morgan (1910) recognised 
that coupling and repulsion represent two aspects of the same 
phenomenon, location of two genes on the same or on homologous 
chromosomes. He coined the term "linkage". Morgan explained the 
finding by exchange of chromosome pieces between homologous 
chromosomes during meiosis (recombination) and recognised that the 
frequency of crossing over depends upon the distance between the two 
loci. 
In the first two decades of this century, using recombination as 
an analytical tool, Morgan and his co-workers were able to draw up 
detailed genetic maps of the four chromosomes of drosophila. In man, 
however, directed breeding is not possible and therefore statistical 
methods had to be developed to study human pedigree data. The 
technique of lod scores, most extensively used today, is described in 
the second part of this section. Another problem in man is that the 
occurrence of two genetic traits in the same family is a rare event 
and so for many years the application of linkage techniques to human 
gene mapping was very limited. The demonstration of genetic linkage 
by human pedigree studies was first reported on the X-chromosome by 
Bell and Haldane (1937) who demonstrated linkage between haemophilia 
and colour blindness on the X-chromosome. 
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With the identification of the blood groups and polymorphisms of 
proteins and enzymes, it was possible to apply their variation within 
the normal population and to use them as "marker" genes. A useful 
marker gene shows frequent polymorphism within the general 
population. Linkage between the markers themselves can be searched 
for by studying their segregation in human pedigrees, or the 
segregation of marker genes studied in families with a given 
Mendelian disorder to try to identify a linked marker. The first 
autosomal linkage in man was reported by Mohr (1951) between the 
Lutheran and Secretor loci. 
Prior to the advent of recombinant DNA technology the limited 
number of polymorphic genetic markers meant that there was no 
systematic method for mapping human genetic disease. Many linkage 
studies were performed on the more serious autosomal diseases using 
classical markers but few were fruitful. Since 1980, however, there 
has been a renewed interest in family linkage studies following the 
discovery of RFLPs. The clinical usefulness of the approach 
proposed by Botstein et al (1980) was dramatically demonstrated by 
the mapping of Huntington Is Chorea in 1983 (Gusella et al) and adult 
polycystic kidney disease in 1985 (Reeders et al). Not only does the 
localisation of the gene by linkage mean that it should be possible 
to 'move in' onto the actual gene of interest from the linked RFLP 
but also, where appropriate, closely linked RFLPs can be used in 
genetic counselling (Meredith et al 1986). 
(ii) Methodology of linkage analysis: The aim of any linkage study 
is to establish whether or not the loci under observations lie within 
measurable distance of each other. The distance between genes is 
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measured in centiMorgans (cM), where one cM represents 1% 
recombination between two loci and in physical terms is thought to be 
equivalent to one million base pairs. Thus if 5% of the progeny from 
matings informative at two loci are of the recombinant type, these 
loci are said to have a recombination fraction (8) of 0.05. Over 
short distances the recombination fraction is equivalent to the 
distance in cM between two genes. This relationship does not hold 
for larger distances because of the probability of double 
cross-overs. The maximum recombination fraction between two genes is 
therefore 0.5, equivalent to random assortment. 
Early human linkage analysis was done by the methods of Bernstein 
(1931) or Penrose (1935) who compared the traits of interest in sib 
pairs. Nowadays, however, both these methods have been replaced by 
the method of "lod scores" as developed by Haldane and Smith (1947b) 
and Morton (1955,1956,1957 and 1962). Using this method the 
probability that the observed family data conform to the behaviour of 
two loci under full recombination is first calculated, then the 
probability of the data based on a range of 8 from 0.00 to 0.50. The 
ratio (Pr) of these two probabilities is the likelihood ratio and 
expresses the odds for and against linkage. 
Pr = 
P(family, given 0= 0-0.5) 
P(family, given 0=0.5) 
For convenience, Pr is usually expressed as its logarithm, the 
log,,, of the relative probability is called the "log of the odds" or 
the lod score. 
In a family linkage study the lod score is calculated for each 
family and these are then added. The maximum likelihood estimate of 
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8 may be obtained by plotting the sum of the lod scores against the 
various values. of 8 and is the value corresponding to the peak of the 
curve. Because of the known sex difference in frequency of 
recombination, it being increased in females, the lod scores are also 
calculated for male and female meioses separately. Autosomal linkage 
can be considered highly probable when in a collection of families 
the sum of the lod scores at any value of 8 reaches +3 (i. e. odds 
1000: 1 in favour of linkage); if it reaches -2 (i. e. odds 100: 1 
against linkage) then linkage is considerably unlikely. 
The calculation of lod scores for the non-mathematician was much 
simplified first by the introduction of tables of lod scores for 
given pedigree situations (Maynard Smith et al 1961) and more 
recently the development of computer programs. The programs most 
widely used today are LIPED developed by Ott (1974) and LINKAGE 
(Lathrop et al 1985). Both these programs make maximal use of human 
pedigree information which was difficult when using extensive 
pedigrees and the lod score tables. 
(B) Somatic cell hybrids The techniques involved in the creation of 
somatic cell hybrids are based on the observation that somatic cells 
of the same or of two different species will fuse under certain 
conditions (see Francke 1983 for more detailed discussion). For the 
purpose of human gene mapping rodent-human cell lines are generally 
used. This is because when an established rodent cell line is fused 
to human fibroblasts or lymphocytes, the human chromosomes will be 
preferentially eliminated. The initial chromosome loss from fused 
cells during mitosis is marked but after a short period of time the 
hybrid cells become stable and retain one or more human chromosomes. 
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Over longer periods, additional human material may occasionally be 
lost but regular characterisation of the cell line will monitor this. 
When creating hybrid cells, it is also possible to select for the 
retention of certain human chromosomes. The means used include 
culture media in which a certain cell type cannot grow or grows 
preferentially, or selective killing of one cell type with toxins, 
antibodies or viruses to which other cells are resistant. There are 
now selection systems for about half the human chromosomes (Francke 
1983). 
Fortunately, it is not necessary to have 23 hybrids each with one 
human chromosome for mapping, but a smaller panel of hybrids each 
with a unique combination of several human chromosomes can be used. 
Thus a characteristic distribution pattern for each chromosome can be 
created. Further refinements of these techniques have led to the use 
of panels of hybrids created from human lines with chromosomal 
rearrangements, usually translocations. This enables regional 
mapping of a gene on a given chromosome (see Brook et al 1984, for 
chromosome 19 as an example). Initially only genes expressed in 
culture could be mapped using hybrids but this problem has been 
overcome with the developments in DNA technology. The initial 
assignments using hybridisation panels were of enzymes which could be 
studied electrophoretically and surface antigens identified 
immunologically. Using DNA techniques, however, the DNA of the 
different hybrids of a panel can be fractionated using the 
appropriate restriction endonuclease, separated on an electrophoresis 
gel and then hybridised with the DNA probe of interest. This might 
be a gene or a random piece of DNA which identifies an RFLP and 
therefore its chromosomal localisation is important. Using a hybrid 
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panel the localisation of the 'probe' can be deduced. 
(C) Cytogenetics and gene mapping - Although cytogenetic techniques 
play an integral part in mapping using somatic cell hybrids, 
karyotype analysis per se can result in or play a part in the mapping 
of a gene in several other ways: - 
(i) Marker chromosomes - Typical markers consist of heterochromatic 
variants, fragile regions or structurally abnormal chromosomes. The 
first autosomal assignment in man was that of the Duffy locus which 
was found to segregate with a large variant of the centric 
heterochromatin in chromosome 1 (Donohue et al 1968). The most 
important example of fragile site association is that on the long arm 
of the X-chromosome which segregates with the most common form of 
X-linked mental retardation (Howard-Peebles and Stoddard 1979). With 
regard to structural variants, an important assignment was of the HLA 
locus to chromosome 6 by means of a pericentric inversion segregating 
in a family (Lamm et a! 1974). 
(ii) Gene dosage effects in cases with chromosome deletion/ 
duplication - Cases with isolated chromosomal deletions can be 
compared with their parents for variation in polymorphic markers. 
The first example of this was the mapping of red cell acid 
phosphatase to chromosome 2. The patient had lost a maternal allele 
for this enzyme and also had a level of 45% less than expected 
(Ferguson-Smith et al 1973). Assay of enzyme levels is thus the 
second way these cases can be studied and in cases with chromosome 
duplication the enzyme levels will be raised. 
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(iii) Chromosomal deletions/translocations giving clues to 
localisation - Perhaps the best example of this has come from 
the study of the karyotype of females who have a clinical picture 
indistinguishable from X-linked recessive Duchenne Muscular 
Dystrophy. Several of these cases have been reported and in each an 
X-autosomal translocation is present, with the X-chromosome 
breakpoint in band Xp21 (see Jacobs et al 1981 for case report and 
review). In these cases the normal X-chromosome is inactivated which 
means that recessive genes on the translocated X are expressed. 
However if this were the only explanation, the breakpoint should be 
random rather than always in Xp21 and it was therefore suggested that 
the DMD locus was at Xp21. DNA techniques have since shown this 
localisation to be correct (Murray et al 1982; Monaco et al 1985; Ray 
et al 1985). 
(iv) In situ hybridisation - This technqiue has developed with the 
advancement of DNA techniques. In this method, metaphase spreads are 
banded and photographed and then the radiolabelled DNA clone of 
interest is annealed to the spread, which is then rephotographed. 
The chromosomes are then re-examined to locate the grains of 
radioactivity. The first human single genes were localised with this 
technique in 1981. These were the alpha-globin genes assigned to 
chromosome 16 (Gerhard et al 1981) and beta-globin genes to the short 
arm of chromsome 11 (Malcolm et al 1981). 
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4. Review of previous reports pertaining to the localisation of NF-1 
gene 
At the outset of this work in October 1983, there were no clues 
to the possible gene localisation from patients with chromosome 
abnormalities-and there were only two published reports of linkage 
analysis. The first of these was the study of Lepage et al (1981) 
which excluded close linkage with the HLA locus. The second was the 
linkage study of 28 classical markers undertaken by Spence and her 
colleagues (1983). For 16 of the studied markers the lod scores 
provided statisticlly significant evidence against linkage for at 
least some values of 8. Of the other 12 markers, none gave a lod 
score >1 which might have encouraged 'a further look' at the 
particular locus. The only interesting finding was that the GC locus 
gave a lod score of +2.2 in the first five informative families 
tested, but the sixth family gave a negative score; the combined lod 
score was 0.89. These results were tested for linkage heterogeneity, 
and the results were not statistically significant. 
Despite the paucity of published linkage studies of NF-1, there 
had been two families reported where NF-1 and myotonic dystrophy (DM) 
appeared to segregate together, suggesting that the two diseases may 
be closely linked. The first of these families is shown in Figure 
7-1 and was reported by Ichikawa and his colleagues (1981); it can be 
seen that there are 7 individuals in generations II and III with both 
NF-1 and DM. In generation I the origin of NF-1 is clear (i. e. I-1) 
but that of DM uncertain. If one assumes that I-1 had both NF-1 and 
DM, then the lod score from his counted descendants in generations II 
and III is 2.4. This would be highly suggestive of linkage between 
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NF-1 and DM. If however, 1-2 had DM then the segregation in this 
family is strongly against linkage. 111-9, age 19 yrs, and all 
members of generation IV were excluded from analysis because of the 
delayed age of onset of DM. Studies of the segregation of secretor 
(Se) (Ichikawa et al 1981) and the third component of complement (C3) 
(Pericack-Vance et al 1984) polymorphisms in this family supported 
the clinical observation that the DM in this family was the same 
locus as in other families. 
The second family was presented in poster form at the 7th 
International Workshop on human gene mapping by Rivas and Di Liberti 
(1984). In this family there were seven individuals with both 
disorders in 4 generations, all doubly-affected offspring having a 
doubly-affected parent. One adult, a 23 year-old female with NF-1 
only, appeared to be a possible recombinant. If one assumes she will 
not develop DM, then the lod score is 0.75 at a recombination 
frequency of 0.20, BUT if she does develop DM then the lod score 
would be 3.01 with no recombination. 
In neither of these families were any clinical 'peculiarities' 
reported that might have made one speculate about a new disease in 
which the features of NF-1 and DM were combined. Therefore, if the 
clinical assumptions in these families were correct, they provided 
strong evidence of close linkage between NF-1 and DM which merited 
further investigation. A study of the segregation of chromosome 19 
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CHAPTER 8 Genetic linkage studies of NF-1 and chromosome 19 
markers linked to DM 
1. Introduction 
DM was the first serious autosomal dominant disease for which a 
linked marker was identified. In 1954 Mohr reported a suggestion of 
linkage between DM, the Lutheran blood group (Lu) and the secretion 
of ABH blood group substances (Se). This linkage was confirmed by 
the later studies of Renwick et al (1971) and Harper et al (1972). 
Further linkage studies added peptidase D (PEPD, Cook et al 1972) 
and C3 (Eiberg et al 1982). The whole linkage group was assigned to 
chromosome 19 with the assignment of C3 to that chromosome by 
Whitehead et al in 1982. In that year apolipoprotein E (APOE) was 
also shown to be linked to C3 (Olaisen et a1 1982). The linkage 
relationships of APOE to DM however were only studied after 
completion of this study (Laberge et al 1985). 
At the outset of the study, therefore, the polymorphic markers 
known to be within a measurable distance of DM were Lu, Se, PEPD and 
C3, of which PEPD was the closest (Davies et a] 1983; O'Brien et al 
1983), but which is rarely polymorphic. Fortunately, during the 
period of family identification and collection of specimens, the 
apolipoprotein CII (APOC2) gene was localised to chromosome 19 and 
shown to be closely linked to APOE, the cDNA probe being found to 
detect a frequent RFLP (Myklebost 1984). Linkage analysis of APOC2 
in DM families subsequently showed close linkage (Shaw et al 1985). 
The possibility of NF-1: DM linkage was therefore explored by studying 
the segregation of PEPD, APOC2, Lu, Se and C3 in NF-1 families. 
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2. Methods 
A. Family ascertainment - The linkage family panel for the 
chromosome 19 studies was assembled prior to the population study. 
The families were ascertained through the records of the Section of 
Medical Genetics, University Hospital of Wales (familes NF3,7,9, 
12,49,71) and the British Neurofibromatosis Patients' Association 
(LINK, families NF70,72,73). The clinical asssessment and 
diagnostic criteria applied were as described for the population 
study, apart from the classification of the "equivocal" status; for 
the linkage studies any child (<10 years) with 1-5 CAL spots and no 
other features was considered equivocal. From relevant family 
members a sample of venous blood (10-30 ml) was taken into tubes 
containing the anticoagulant EDTA for DNA, Lu and PEPD typing, and 
specimens of saliva were collected into sterile universal containers 
for Se typing. 
B. Typing of C3 and APOC2 RFLPs - The methods used in this section 
(unless stated) are taken from Maniatis et al (1982). A diagrammatic 
summary of DNA analysis is shown in Figure 8-1. 
(i) DNA extraction - The specimens of whole blood were stored at 
-20°C until DNA extraction could be performed; this was done using a 
modification of the method described by Kunkel et al (1977) as 
follows: 
(a) The sample was thawed and mixed with sucrose lysis buffer (0.32M 






























--- seen as bands 
on developed 
x-ray film 
FIGURE 8-1. Diagrammatic representation of the procedures 
involved in RFLP analysis. 
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180 ml of buffer was used for 10 and 20 ml of blood respectively. 
The specimen was then centrifuged at 10 rpm for 20 minutes. 
(b) The resulting nuclear pellet was then resuspended in 4.5m1 of DNA 
extraction buffer (0.075M NaCl, 0.024M EDTA pH 8.0). 25011 of 10% 
sodium dodecyl sulphate (SDS) and 100pl of 10mg/ml proteinase K were 
then added. The mixture was then incubated at 55°C for 3 hours. 
(c) 5m1 of phenol (saturated with 20mM Tris-HC1 pH 8.0) were added 
and the tube gently mixed, then spun at 10,000 rpm for 15 minutes. 
(d) The upper aqueous layer was re-extracted with 2.5m1 of 
chloroform-isoamyl alcohol mixture (24: 1) and 2.5m1 of phenol then 
centrifuged at 10,000 rpm for 5 minutes. 
(e) The upper aqueous layer was re-extracted with 5m1 of CHC13 and 
centrifuged at 10,000 rpm for 5 minutes. 
(f) The DNA was precipitated from the aqueous phase by adding 2.5m1 
of 7.5M NaOAc and 10ml of 100% ethanol. 
(g) The DNA pellet was placed in an eppendorf tube and dissolved in 
TE buffer (10mM Tris, 1mM EDTA pH 7.5). 
(h) The DNA and protein concentrations were estimated by a 
spectrophotometric method (Schleif & Wensink 1981). DNA absorbs 
ultraviolet light so efficiently that optical absorbance at 260 nm 
gives an accurate and rapid measure of concentration. Absorbance at 
280 nm gives the concentration of protein. A sample with a 260: 280 
ratio greater than 1.8 was accepted as being sufficiently pure to 
enable its digestion with restriction enzymes. 
(ii) Preparation of APOC2 and C3 probes - The cDNA probe for the 
APOC2 gene was provided by Dr 0 Myklebost, who had previously 
reported that it identified a frequent Taq 1 polymorphism (Myklebost 
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et al 1984). The clone was prepared for use as a probe by Dr D Shaw 
who, after a standard plasmid preparation, had separated the coding 
sequences from the vector by restriction enzyme digestion to enhance 
the efficiency of radioactive labelling (Feinberg and Vogelstein 
1984). 
The human genomic C3 DNA probe was provided by Dr G Fey. This 
probe identifies a relatively frequent Sstl polymorphism (Davies et 
al 1983). Dr L Meredith prepared the plasmid DNA for use by standard 
methods, satisfactory labelling was achieved without separation of 
the coding sequences from the vector. 
(iii) Restriction enzyme digestion - The enzymes used were Taq 1 
(APOC2) and Sstl (C3) which require the same conditions to work. To 
each probe the 33 'key' individuals were first typed and then, for 
those informative (i. e. heterozygous), the relevant remaining family 
members were studied. 
5 jig DNA digests were made up for each individual containing 2 p1 
core buffer, 2 pl bovine serum albumin (BSA), 1 pl 0.1M spermidine, 
10 units of the appropriate restriction enzyme (i. e. 2 units/pg DNA) 
and the volume made up to 20 pl with distilled water. The digest was 
then incubated for 2 hours at 37°C. Any sample showing incomplete 
digestion on an electrophoresis checking gel was redigested with 
additional amounts of enzyme. 
(iv) Electrophoresis - Following complete digestion of DNA samples 
by restriction enzymes, the DNA fragments were separated according to 
molecular weight by agarose gel electrophoresis. 
Electrophoresis gels were made with 0.8% agarose dissolved in 
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electrophoresis buffer (4 mM Tris-acetate, 0.1 mM EDTA) with 0.5 
pg/ml of ethidium bromide. The latter dye intercalates between DNA 
bases and allows visualisation of DNA on gels under ultra-violet 
light (Sharp et al 1973). After heating to dissolve the agarose, the 
cooled solution was poured onto a glass plate gel mould. Wells in 
the gel were formed using a comb with 20 teeth of 2mm width. 
When set, the gel was placed in an electrophoresis tank 
containing electrophoresis buffer. DNA digest samples were mixed 
with ficoll-orange G to act as loading buffer and tracking dye, and 
introduced into individual slots in the gel. Electrophoresis was 
carried out overnight at 30v (70 MA). Visualisation of the gel under 
ultra-violet light confirmed that digestion and electrophoresis were 
complete. 
(v) Southern blotting - In order to localise particular restriction 
fragments it is necessary to transfer the DNA from the gel onto a 
nitrocellulose or nylon filter before hybridisation to the DNA probe. 
This procedure was first described by Southern (1975) and preserves 
the relative position of the DNA fragments during transfer. Prior to 
blotting the double strands of DNA in the gel are denatured by alkali 
treatment to render them single stranded and therefore ready for 
subsequent hybridisation to the probe. 
The gel was denatured in alkaline solution (0.5M NaOH, 1.5M NaCl) 
on an agitator for 90 minutes, and then neutralised in acidic 
solution (1.5M NaCl, 1M This pH 7.5) for 90 minutes, the solution 
being changed after the first hour. The DNA was then transferred to 
"Zetaprobe" nylon membrane (Amersham) by Southern blotting (Figure 
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FIGURE 8-2. Southern blotting procedure. Shown in cross-section 
are: (1) tray containing lOxSSC, a glass plate (on 
supports) covered with Whatman 3MM paper presoaked in 
lOxSSC; (2) cling film cover around gel edge; (3) agarose 
gel; (4) membrane; (5) 2 sheets of Whatman 3MM paper 
presoaked in lOxSSC; (6) paper towels; (7) glass plate 
and (8) weight. 
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glass support and dipping into a 10 x SSC reservoir (prepared from 
stock solution of 20 x SSC, 3M NaCl and 0.3M NaCit). The gel was 
placed on top of this, and the edges sealed to the edge of the 
container using cling-film. The gel was then covered with a piece of 
Zetaprobe presoaked in 10 x SSC. Two pieces of 3MM Whatman paper 
also soaked in 10 x SSC were placed on top and covered with a stack 
of absorbent paper towels. A glass plate and weight were placed on 
top of the towels. This was then left overnight. Transfer occurs 
because as liquid flows from the reservoir upwards, the DNA is eluted 
from the gel and deposited onto the membrane. The procedure is shown 
in Figure E-2. 
After transfer, the membrane was washed in 2x SSC and baked for 
3 hours at 80°C. 
(vi) Nick translation of probe DNA - The DNA probes were 
radioactively labelled using the nick translation process (Balmain & 
Birnie 1979). This is catalysed by E. coli DNA polymerase I which 
adds nucleotide residues to the 3'-hydroxyl terminus that is created 
when one strand of a double-stranded DNA molecule is nicked by the 
action of DNase I. In addition, the enzyme, by virtue of its 5' to 
3' exonucleolytic activity, can remove nucleotides from the 5' side 
of the nick. Nucleotides are therefore added to the 3'-hydroxyl side 
of the nick and removed from the 5' side, the nick is thus 
'translated' along the DNA. By replacing existing nucleotides with 
radioactive ones the DNA becomes labelled. 
The DNA probes were radiolabelled using a nick translation kit 
(Amersham). 5 ug probe DNA was mixed with 10 pl nucleotide buffer, 5 
pl of enzyme solution (DNase 1 and polymerase 1), 2.5 ul of 
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deoxycytidine triphosphate labelled with radioactive phosphorus 
(a-32P dCTP) and distilled water to a total volume of 50 p1. The 
mixture was incubated at 16°C for 2 hours. Labelled DNA was then 
separated by passage of the mixture through a Sephadex G-50 column 
suspended in elution buffer (150 mM NaCl, 10 mM EDTA, 0.1% SDS, 50mM 
Tris HC1 pH 7.5). 100pl aliquots were collected into 20 Eppendorfs 
by adding elution buffer to the top of the column, and monitored for 
radioactivity by scintillation ß counting. The peak fractions 
containing labelled DNA were pooled; specific activity of the probe 
DNA of 1x107 cpm/O. lug or greater was considered sufficient for 
hybridisation experiments. The labelled DNA was boiled for 5 minutes 
and then cooled in ice to dissociate the DNA molecules into single 
strands. 
(vii) Hybridisation - By this process the single strand probe DNA 
joins with homologous sequences on the membrane. The membrane was 
prepared for hybridisation by soaking initially in 0.1 x SSC and 0.5% 
SDS for 1 hour at 65°C and then in a solution of 5x SSC, 10 x 
Denhardt's solution (2% Ficoll, 2% BSA, 2% polyvinyl pyrrolidane), 
0.5 mg/ml herring sperm DNA and 50mM phosphate (pH 6.5) for 3 hours 
at 65°C. 
The membrane was then hybridised with the probe overnight at 65°C 
in a solution of 5x SSC, 2x Denhardt's solution, 100 pg/ml herring 
sperm DNA and 10% dextran sulphate. After hybridisation the membrane 
was then washed in 4x SSC and 0.1% SDS 3 times for 15 minute periods 
at 65°C. If high background activity was still detected with a 
hand-held ß counter, the filters were washed in solutions of 
increasing stringency at 65°C for 15 minutes, initially 1x SSC and 
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0.1% SDS was used and then, if necessary, 0.5 SSC and 0.1% SDS. 
(viii) Autoradiogra by - The fragments of sample DNA to which the 
probe had hybridised were then visualised by autoradiography. The 
filters were then wrapped in cling film and autoradiographed in 
cassettes with intensifying screens at -70°C. The film was developed 
after 24 hours; if the band intensity was insufficient to allow 
interpretation, the filters were exposed to new X-ray film for longer 
periods (2-7 days). 
C. Secretor typing - 
(i) Background - The A, B and H blood group antigens are not confined 
to the red cells but are widely distributed throughout the body. 
Yamakami (1926) noted that the antigens were present in saliva, and 
in 1930 Lehrs and Putkonen realised independently that some 
individuals secreted the antigens in saliva and others did not. The 
ability to secrete the A, B or H antigen in the saliva was shown by 
Schiff and Sasaki to be a Mendelian dominant in 1932. Secretor 
status is independent of ABO blood group and the locus was shown to 
be linked to the Lu blood group by Mohr in 1954. Although the 
ability to secrete the antigens is independent of the blood groups, 
in secretors the antigens present in saliva reflect the blood group 
as shown in table 8-1 below. 
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Table 8-1 Expected ABH antigens in saliva 
ANTIGEN IN SALIVA 
ABO group secretors ABH 
A Much None Less 
B None Much Less 
0 None None Much 
AB Much Much Less 
Non-secretors None None None 
(regardless of blood group) 
(ii) Method - The method of secretor typing used was taken from Race 
and Sanger (1975). 
(a) On the day of collection the saliva was boiled for 10 minutes to 
destroy enzyme activity and break down muco-proteins. The specimen 
was then centrifuged (bench centrifuge, maximum speed, 5 minutes) and 
the clear supernatant fluid removed and stored at -20°C until tested. 
(b) The antisera for the A, B and H antigens were obtained from 
Biotest Folex Ltd.. They were titrated against appropriate red cells 
(doubling dilutions for anti-A and B, serial dilutions for anti-H). 
The dilutions used for the subsequent test were the last but one to 
give good agglutination: 1/16 for anti-A and anti-B and 1/6 for 
anti-H. 
(c) The test saliva was diluted 1: 2 with normal saline. To one 
159 
I 
volume of dilute saliva in 3 separate tubes one volume of anti-A, 
anti-B and anti-H was added. After 20 minutes, a volume of 2% A2, B 
and 0 cells were added to the appropriate tubes (A2 cells are a more 
sensitive test of inhibition than A, ); the cells had been washed with 
saline 4 times to wash off A, B, H substances in the plasma and 
diluted to an approximately 2% suspension by eye. 
(d) After one hour the results were read based on the 
presence/absence of agglutination as shown in Table 8-2 below. 
Table 8-2 Agglutination results for secretors of blood group 
0, A, B and AB, and non-secretors 
Antigen present 
Anti-A Anti-B Anti-H 
Non-secretor +* + + 
0-secretor + + 0 
A-secretor 0* + 0 
B-secretor + 0 0 
AB-secretor 0 0 0 
*+ indicates agglutination present; 0: no agglutination. 
D. Lu and PEPD typing - The Lu blood group and PEPD typing was done 
in the laboratories of Dr P Tippett and Professor EB Robson, 
respectively . 
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E. Linkage analysis - The linkage analysis was performed using the 
programme LIPED 3 (Ott 1974) with the assistance of Dr M Sarfarazi. 
In the case of unaffected relatives, only those over the age of 5 
years were included because of the uncertainty about the age by which 
affected subjects will have manifested CAL spots. Penetrance for the 
NF-1 gene was taken to be 100%. The gene frequencies for secretor 
status were taken from Race & Sanger (1975, secretors 0.77, 
non-secretors 0.23). 
3. Results 
Fifty-seven affected subjects and 41 normal relatives from the 9 
families were studied. Three children were excluded because of 
equivocal clinical findings (NF7, IV-11; NF72, IV-2; NF73, IV-7); 
patient IV-5 in family NF7 was also equivocal but he and his two 
unaffected siblings (IV-2,3) were also excluded on the grounds of 
possible non-paternity. 
The Taq 1 polymorphism detected by the APOC2 probe is a2 allele 
system with alleles of lengths 3.8 kb (allele 1) and 3.2 kb (allele 
2). The allele frequencies in the population studied were 0.56 
(allele 1) and 0.44 (allele 2). This polymorphism is illustrated in 
Figure 8-3a. 
The Sst 1 polymorphism detected by the C3 probe is shown in 
Figure 8-3b. It consists of 2 alleles, a single 12.0 kb band (allele 
1) or 2 bands (9.0 and 3.0 kb, allele 2). The frequencies in the 
population studied were 0.53 and 0.47 respectively. 
None of the families were informative for Lu or PEPD. 
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Taq 1 Polymorphism (APOC2) 
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The results of linkage analysis are shown in Table 8-3 and the 
typing results shown on the pedigrees in Appendix B. The three 
informative markers all showed significant evidence against linkage 
(lod .4 -2.0) for at least some values of 8. There was no evidence of 
linkage when male and female meioses were analysed separately. No 
family showed a positive result which might have suggested 
non-allelic heterogeneity. 
These results were published in the paper of Huson et al (1986). 
4. Conclusions 
The physical map and genetic relationships of the markers studied 
are shown in Figure 8-4. The information used is taken from Shaw et 
al (1986) and Naylor et al (1985). APOC2 is the closest marker to DM 
with a maximum lod score of 23.9 at 8=0.04; C3 and Se flank the DM 
locus but are much less closely linked. This study showed clear 
evidence against linkage with all 3 informative markers and therefore 
excluded the possibility of linkage of NF-1 to DM and the NF-1 locus 
from a considerable region of chromosome 19. 
In view of the negative findings, an explanation had to be found 
for the apparent co-segregation of NF-1 and DM in the families 
reported by Ichikawa et al (1981) and Rivas and Di Liberti (1984). 
One explanation would be that there is more than one NF-1 locus; 
another that the affected individuals in these families actually have 
a disease in which the features of NF-1 and DM are combined. It was 
felt that both these possibilities were unlikely and that the 
explanation is that the clinical assumptions that have to be made to 
show linkage in these families were incorrect. 
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The family reported by Ichikawa et al (1981) is the only one for 
which full clinical details have been published. In this family, the 
origin of NF-1 in generation I is clearly from the mother but that of 
DM is uncertain. If her husband had DM then there is no evidence of 
linkage in this family. This would be supported by the fact that in 
generation IV (not included in the linkage analysis) there is an 
individual who has congenital DM and no stigmata of NF-1 at the age 
of 2 years. As shown in the clinical studies in this thesis, this 
would be very unusual if he had inherited the NF-1 gene. 
This work was later confirmed and extended by Pericak-Vance et al 
(1987) who, in addition to finding no evidence of linkage with APOC2 
and C3, also found no linkage with locus D19S6 on the long arm of 
chromsome 19. NF-1 was therefore virtually excluded from this 
chromosome. 
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FIGURE 8-4. Physical and genetic map of chromosome 19. 
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CHAPTER 9 An exclusion map for NF-1 
1. Introduction 
With the exclusion of linkage of NF-1 to the DM region of 
chromosome 19, one of the principal 'clues' to the localisation of 
the NF-1 gene had been disproved. It therefore seemed likely that a 
'search' of the genome was going to be necessary to map the gene. 
The author's main emphasis at this time was on the population study 
in South East Wales; linkage analysis of other markers using the 
family panel described in Chapter 8 was continued in Cardiff and 
samples from the family panel were made available to collaborators in 
other centres with a view to expediating the mapping of the gene. As 
families with a suitable structure for linkage analysis (and who were 
agreeable to giving samples) were identified through the population 
study, blood samples for DNA analysis were collected (NF-1,17,20, 
41 and 42). 
In this chapter the results of linkage analysis of other markers 
in the family panel are presented. By mid-1986, with further 
negative data from markers on other chromosomes, the author compiled 
the available linkage data for an exclusion map of NF-1; this is 
presented in the final section. 
2. Outcome of linkage analysis of other genetic markers and NF-1 
The results of the analysis of the markers described in sections 
(A) and (B) are presented in Table 9-1. 
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(A) Protein polymorphisms - In addition to typing the families for 
PEPD, the MRC Human Biochemical Genetics Unit (courtesy of Professor 
EB Robson and Dr S Povey) also typed 4 protein polymorphisms: 
Group-specific component (Gc), immunoglobulin gamma 1 polypeptide 
(Gm), alpha-1-antitrypsin (Pi) and the sixth component of complement 
(C6). The results all showed significantly negative lod scores. The 
Gc results showed no evidence of heterogeneity as had been suggested 
by the earlier results of Spence et al (1983). 
(B) Studies of other DNA polymorphisms - The typing of further DNA 
polymorphisms in Cardiff was done by Dr M Upadhyaya. The strategy 
chosen was to systematically exclude the gene from given chromosomes 
using highly polymorphic DNA probes available in the laboratory and 
from various colleagues. The only specific 'clue' followed arose 
from the probable assignment of NF-2 to chromosome 22 by the work of 
Seizinger and colleagues in 1986 (Seizinger et al 1986a). They 
demonstrated loss of chromosome 22 markers in both isolated acoustic 
neuromas and those from patients with NF-2. No evidence of linkage 
was found with the IGLV probe, and this, taken with the previously 
published negative results for the locus SIS (Seizinger et al 1986b) 
showed that NF-1 and NF-2 were genotypically as well as 
phenotypically distinct. 
The negative results with 3 chromosome 20 markers, two on 20p and 
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(C) Collaboration with other Centres 
(i) Studies of ß Nerve Growth Factor (ß-NGF) - The early reports of 
abnormalities of NGF levels in NF-1 patients are reviewed in Chapter 
1. The cloning of the gene for ß-NGF (Ullrich et al 1983) meant that 
since it was found to detect RFLPs (Breakefield et al 1983; Darby et 
a] 1985) it could be directly tested as a candidate gene by studying 
the segregation of these RFLPs in NF-1 families. In an initial 
report in 1985, Darby and his colleagues reported several 
recombinants with a lod score of -3.77 at 8=0.05 in 4 families with 
NF-1. Although this made it unlikely that ß-NGF was the candidate 
gene it was felt more families should be tested to exclude 
heterogeneity. DNA samples from our original 9 families were 
therefore sent to Dr Darby. Again, multiple recombinants were found 
with a combined total lod score of -17.2 at e=0.01 (Darby et al 
1986). No family gave a positive result suggesting heterogeneity. 
(ii) Other candidate genes - The laboratory of Dr J Gusella was 
testing other possible candidate genes (oncogenes, growth factors and 
their receptors) for NF-1 by the linkage approach. Specimens from 
the 5 largest families (NF-7,12,49,72,73) were therefore sent to 
Dr Gusella so that lymphoblastoid cell lines could be established and 
the families used in their work. The results were all negative and 
were published in the paper of Seizinger et al (1987b). 
(iii) Hypervariable minisatellite probes - Hypervariable 
minisatellite regions, consisting of tandem repeats of a short 
sequence and showing multiallelic variation in repeat copy number, 
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exist in human DNA and provide highly informative genetic markers. 
In 1985 Jeffreys et a! (1985a & b) reported the development of two 
probes consisting of tandem repeats of the "core" sequence of one 
subset of human minisatellites. The two probes each detect a 
different pattern of variable DNA fragments to produce distinct DNA 
'fingerprints' that are individual-specific and show somatic and 
germ-line stability. 
The probes can be used in linkage analysis if particularly large 
sibships are available and up to 34 hypervariable loci analysed 
simultaneously (Jeffreys et al 1986). If a locus is identified that 
apparently segregates with the disease, it can be isolated and 
locus-specific probes developed for further analysis. 
Dr Jeffreys kindly agreed to analyse family NF-49 with probes 
33.6 and 33.15 and no locus of potential interest was identified. 
3. An exclusion map for NF-1 
(A) Background - By 1986 the possible clues to the localisation of 
NF-1 had all been excluded; it was therefore apparent that a 
systematic search with RFLPs was going to be necessary to map the 
gene. As a prerequisite to this, it was necessary to gather all the 
available data in an 'exclusion' map, which would avoid unnecessary 
duplication of negative results and highlight those areas of the 
genome not yet studied. The author therefore tabulated the published 
linkage data with those from the Cardiff laboratory, and Dr M 
Sarfarazi used the program 'EXCLUDE' (kindly made available by 
Professor JH Edwards) to produce an exclusion map for NF-1. 
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(B) Description of the 'EXCLUDE' program - The program is designed to 
calculate the likelihood distribution of an unplaced locus around a 
series of previously mapped loci (Edwards 1987), following the 
general principle of Cook et al (1980) who first used the term 
'exclusion mapping'. It is written in Pascal (Turbo version). The 
likelihood distribution at various recombination fractions or map 
distances gives the relative chance that the locus is in that 
position. When direct counts of recombinants and non-recombinants 
are available, the peak and position of the likelihood distribution 
are uniquely defined by them. As data are more usually presented as 
lod scores, the EXCLUDE program converts the data into equivalent 
observations, by defining the numbers of recombinants and 
non-recombinants which would give the same height and position of the 
likelihood distribution. For a given value of 6 and the 
corresponding value of lod score (z), the equivalent number of 
informative meioses (s) is defined as : 
s= z/[0. log(20+1-0). log2(1-0)] 
and the equivalent number of recombinants (r) = 8. s. The likelihood 
for each position is then computed directly from these equivalents. 
The input to the program consists of the locus name and position 
expressed as a percentage from pter-qter. When the localisation of a 
marker is expanded over a chromosomal region, the localisation is 
taken to be in the middle of that region. This is followed by the 
data, either in lod scores (in which case the program calculates the 
value of r and s) or recombinants and non-recombinants. For data 
which are uniformly negative, the lod score at 8=1.10 is usually 
used, with positive scores the maximum lod score and recombination at 
which it occurred are used. The program then accesses an internal 
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FIGURE 9-1. Example of the likelihood distributions produced by 
the programme 'EXCLUDE' when a marker locus at 50 cM 
on a chromosome 100 cM length is studied with varying 
results. Reproduced from Edwards (1987) with permission. 
173 
Likelihood dtstrihutioa for r:  of 0: 10. 
Chrnmosomc length 100 cM. Marker locus al , 
SO cM. 
Likclihond dislrihu: ion for r: n of5: 3. Chromosome 
Irngrh /00 cM. Marker hwue at 50 cM. 
Likelihood distribution for rn of 2: 18. 
Chromosome length 100 cM. Marker locus at 30 cM. 
file (HUMAN. CHR) which contains the approximate length of each of the 
human chromosomes in centimorgans. The program then calculates the 
positional likelihood of the disease locus on each chromosome, and 
also the percentage probability of any locus being on any of the 22 
autosomes. The program presents a graphical display of the 
likelihoods of the locus being on a given chromosome. Examples are 
shown in Figure 9-1 to demonstrate this; these are taken from the 
paper of Edwards (1987, with permission of Professor Edwards and the 
publisher). 
(C) Origin of linkage data - The data used for the exclusion map, in 
addition to those presented in Tables 8-3 and 9-1, are those 
published or presented before the middle of 1986 and are from the 
papers of Darby et al (1986), Dietz et al (1985), Dunn et a] (1985), 
Lepage et al (1981), Seizinger et al (1986b) and Spence et al (1983, 
1986). The data are presented in Table 9-2. 
(D) The exclusion map for NF-1 - The exclusion map is presented in 
Figure 9-2a. It can be seen that no markers had been tested on 8 
chromosomes but NF-1 had effectively been excluded from chromosomes 
16,19,20 and 22, and in addition, from the majority of chromosomes 
1,4 and 9. This map was subsequently presented at the American 
Society of Human Genetics meeting in October 1986 (Upadhyaya et al), 
when other groups expressed an interest in pooling their linkage data 
to further extend the map. All groups involved in linkage analysis 
of NF-1 were subsequently invited to attend the first European 
Symposium on Neurofibromatosis (sponsored by LINK) in February 1987; 
the author was one of the principal organisers of this meeting. As a 
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Table 9-2 Combined linkage data for NF-1 used for exclusion ma 
shown in Figure 9-2 
Marker HGM8 localisation LOD score Source(s) of 
0=0.10 data* 
RH 1p36.2-34 -10.4 3,8 
DNF15S1 1p36 -1.1 1 
PGM1 1p22.1 -2.9 3,8 
NGFß 1p22.1 -4.8 1 
FY 1p21-q23 -11.0 3,8 
ACP1 2p25 or 2p23 -5.1 3,8 
DNF15S2 3p21 -0.71 3 
Gc 4g12-13 -11.4 2,3,8,9 
MNSs 4g28-q31 -11.1 2,3,8 
HLA 6p21.3 -6.7 4,7 
GLO1 6p21.31-p21.1 -3.5 3,7 
METD 7q22-32 -0.6 9 
ABO 9q34 -7.1 3,7 
ESD 13g14.1 -3.3 3,7 
Pi 14q32.1 -3.1 9 
Gm 14q32.3 -0.3 9 
PGP 16pter-p11 -2.8 3,7 
HBA 16pter-p12 -0.7 9 
HP 16q22.1 -2.7 3,7 
C3 19p13.3-13.2 -1.9 3,9 
APOC2 19CEN-g13.2 -7.4 9 
SE 19q -2.3 3,9 
D20S5 20p12 -1.2 9 
D20S6 20p -1.9 9 
D20S4 20g13.2 -3.0 9 
IGLV 22pter-qll -4.1 9 
SIS 22g12-13 -0.6 6 
* The references numbered refer to: Darley et al 1986(1), Dietz et al 
1985(2), Dunn et al 1985(3), Lepage et al 1981(4), Seizinger et a! 
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FIGURE 9-2. Exclusion map for NF-1. (A) using limited data set; 
(B) final exclusion map using pooled data of NF-1 
linkage consortium. 
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result of this, the International Consortium on NF-1 Linkage was 
formed; its first task was to produce an updated exclusion map. The 
data were compiled by Dr M Sarfarazi and subsequently published 
(Sarfarazi et al 1987) in conjunction with a series of papers from 
the individual groups who had pooled data (Journal of Medical 
Genetics, 24,522-538,1987). 114 markers had been tested, for 90 of 
which the localisation was known and could therefore be used in 
EXCLUDE. The resulting map is shown in Figure 9-2b, and showed that 
the gene was most likely to be on chromosome 5,10,17 or 18. A 
small positive result for a marker on chromosome 17 (Barker et al 
1987a) taken with the exclusion data, meant that this was the most 
likely localisation, with a likelihood seven times greater than for 
any other chromosome. 
(E) Mapping of the gene for NF-1 - The final exclusion map was made 
available to Consortium members in March 1987 and within a few weeks 
the NF-1 gene was localised to chromosome 17. Barker et al (1987b) 
showed linkage to two pericentromeric probes, D17S71 and D17Z1, and 
Seizinger and colleagues (1987c) to the nerve growth factor receptor 
(NGFR) in a study which included 5 of the Welsh families. NGFR was 
excluded as a possible candidate gene by the finding of recombinants, 
the maximum lod score being 4.41 at 0=0.14. 
The formation of the International Consortium was an important 
step in 'speeding up' the mapping of the NF-1 gene. The exclusion 
map highlighted the areas of the genome on which efforts should be 
concentrated, thereby avoiding repetition of negative results using 
markers already studied. The spirit of collaboration established 
continued after the chromosomal localisation had been established. 
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The rapid pooling of data and materials by Consortium members 
resulted in the rapid progress towards the cloning of the NF-1 gene 
described in the final chapter. 
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CHAPTER 10 Sub-chromosomal localisation of the NF-1 gene 
1. Introduction 
The mapping of NF-1 to chromosome 17 by linkage studies in May 
1987 represented the first crucial step in applying the reverse 
genetics approach to the isolation and characterisation of the gene 
itself. The next steps in this approach are the exclusion of 
non-allelic heterogeneity by testing large numbers of families with 
the linked probes, and the accurate sub-chromosomal localisation of 
the gene using a number of approaches, which include identifying 
closely linked, flanking markers and physical mapping studies. The 
work involved in these strategies is enormous and can rarely be 
achieved by a single research group working in isolation. Following 
the mapping of the gene, the members of the International Consortium 
for NF-1 linkage continued to collaborate with regular pooling of data 
and resources, such as new probes and cell lines. This was made 
possible by the sponsorship of a series of workshops by the National 
Neurofibromatosis Foundation and enhanced by the rapid publication of 
the data presented at these meetings (Genomics 1: 337-383,1987; 
American Journal of Human Genetics 44: 1-72,1989). This degree of 
collaboration has resulted in extremely rapid progress towards the 
isolation of the gene itself. 
In this chapter the progress made by January 1989 is described. 
The author's direct involvement in the work was as clinical 
co-ordinator for the laboratory based work in Cardiff. 
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2. Linkage analysis of chromosome 17 markers 
A. Studies in the Cardiff family panel - The family panel for the 
chromosome 17 linkage studies comprised 22 families, 14 identified by 
the author through the South Wales population study and LINK 
(described in chapters 8 and 9), and a further 7 families ascertained 
through genetic counselling clinics in other parts of Wales (specimens 
collected by the author and Dr Alan Fryer) and one large family seen 
for counselling at the Kennedy Galton Centre, Harrow, by the author. 
This expanded family panel comprised 148 potentially informative 
meioses, 64 of which were phase known. 
From the initial reports of Barker et al (1987b) and Seizinger et 
al (1987c), NF-1 appeared to be in the pericentromeric region of 
chromosome 17. The RFLPs identified by 16 DNA probes spanning from 
the proximal short to distal long arm of chromosome 17 were chosen for 
study in order to further define the sub-chromosomal localisation of 
the NF-1 gene. The laboratory analysis was performed by Dr M 
Upadhyaya and Ms W Broadhead; the statistical analyses were performed 
by Dr M Sarfarazi. The markers studied, their known physical 
localisation (at the outset of the studies) and the results of two 
point linkage analysis are shown in Table 10-1; the researchers who 
kindly made the probes available for these studies are also shown. 
The results showed that eight pericentromeric markers (HHH2O2, 
EW206, CRI-L946, CRI-L581, EW203, EW301, p17H8 and FG2) were closely 
linked (840.10) to NF-1. Loose linkage (8>0.10) was observed with a 
further three markers (EW207, pA10.41, pe5l) and four markers (EW205, 
heAl, EW204 and BS3) were not sufficiently informative within the 
families. No significant linkage was observed with hGH. Data on the 
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Table 10-1 outcome of linkage analysis of 16 chromosome 17 DNA markers 
and the Cardiff NF-1 family panel 
The probes were kindly donated by: (a) Dr Y Nakamura; (b) Dr D 
Barker; (c) Dr K Stephens; (d) Dr H Willard; (e) Dr B Sykes; (f) 
Dr M Chao; (g) Dr G Moore; (h) Dr F Ruddle; (i) Dr P Seeburg. 
Probe (source) Locus Physical z6 Confidence interval 
localisation 
HHH202(a) D17S33 17q 9.68 0.02 0-0.10 
EW206(b) D17S57 17q 4.16 0.04 0-0.18 
CRI-L946(c) D17S36 17 9.46 0.06 0.02-0.15 
CRI-L581(c) D17S37 17 6.06 0.06 0.02-0.17 
EW203(b) D17S54 17q 2.56 0.06 0.00-0.28 
EW301(b) D17S58 17p 11.79 0.08 0.03-0.16 
p17H8(d) D17Z1 17cen 4.53 0.08 0.00-0.22 
FG2(e) COLIAI 17g21.3-q22 3.38 0.10 0.03-0.26 
EW207(b) D17S73 17q 6.39 0.13 0.06-0.24 
pA10-41(b) D17S71 17p11 3.58 0.16 0.07-0.29 
pE51(f) NGFR 17q22 2.21 0.24 0.14-0.39 
EW205(b) D17S56 17q 0.27 0 0.00-0.11 
hE A1(g) ERBA1 17g11-q21 2.16 0.12 0.00-0.34 
EW204(b) D17S55 17q 0.16 0.17 0.08-0.35 
B53(h) HOX2 17g21-22 0.19 0.33 -- 
hGH(i) GH 17q22-24 NO LINKAGE 
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analysis of recombination frequency in males and females suggested a 
slight increase in recombination in females, but the numbers of 
meioses for each sex was too limited to draw statistically significant 
conclusions. Of the probes used, 5 identified a known gene locus; as 
NGFR had already been excluded as a candidate gene (Seizinger et al 
1987c), only ERBA1 remained as a possible candidate for the NF-1 
locus; the finding of 2/9 phase unknown recombinants excluded this 
possibility. 
The data were analysed for heterogeneity using the progam HOMOG 
(Ott, 1983), which assumes that there are two family types, one linked 
and the other unlinked. No evidence of heterogeneity was found. 
The data were further analysed to see if the position of the NF-1 
locus with respect to the centromere could be established. Several 
families contained multiply informative meioses from which the order 
of the probes could be inferred. The most informative was NF-17, 
which is shown with the genotypes of 5 of the closest linked markers 
in Figure 10-1. The pedigree provided information on the order of the 
NF-1 gene in relation to EW301, p17H8, HHH2O2 and EW206 (EW207 is 
uninformative). Individual IV-1 is a recombinant for EW301, pl7H8 and 
HHH2O2 but not EW206. On the basis of this family, the likely order 
is pter-EW301-cen-HHH2O2-NF1-EW206-qter or pter-EW301-cen-HHH2O2-EW 
206-NF1-qter. As shown in Table 10-1, NF-1 is linked to HHH2O2 at a 
distance of 2cM and to marker EW206 at 4cM. Linkage data for the 
marker loci showed HHH2O2 to be linked to EW206 at 6=0.19, z=8.07. If 
NF-1 were assigned to a location distal to EW206, the expected genetic 
distance between NF-1 and HHH2O2 would be >19cM, which is not 
compatible with the data. Therefore, based on this family, the likely 
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study of the other multiply informative meioses. 
The programmes LINK and LINKMAP (Lathrop et al 1985) were used for 
multipoint analysis which placed NF-1 between HHH2O2 and EW206, with 
the likelihood of 83: 1. The most likely order of the most closely 
linked probes on the basis of multiply informative meioses and 
multipoint mapping was pter-pA10.41-EW301-cen-HHH202-NF1-EW206-EW 
207-qter. This work therefore identified flanking markers for the 
NF-1 gene and placed the locus on the proximal long arm of chromosome 
17. This work is presented in the paper of Upadhyaya and colleagues 
(1989). 
B. The combined NF-1 linkage consortium data set - The purpose of 
linkage studies of markers around a disease locus is to establish the 
order of the markers and to establish accurate recombination 
fractions. This is essential for strategies towards cloning the gene 
itself and for clinical application. For these purposes, the more 
data available for analysis the more accurate the information 
obtained. Therefore, in June 1988 the NF-1 linkage Consortium agreed 
that the pooling of available data on the closely linked markers would 
be of great benefit. The outcome of this analysis is presented in the 
paper of Goldgar et al (1989) and is briefly reviewed below. 
The combined data set included 142 families studied by eight 
groups and no suggestion of non-allelic heterogeneity was found. The 
data were analysed using the program CRI-MAP (Barker et of 1987c). 
The closest markers were HHH202 (z=29.1,8=0.01, upper 99% confidence 
limit 4%) and EW206 (z=19.2,6=0.03, upper 99% confidence limit 9%). 
The best order of the markers studied is shown, alongside the physical 
map of chromosome 17, in Figure 10-2; the distances given are 
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sex-averaged. Ten of the 13 loci were uniquely ordered with odds of 
21000: 1. The 3 loci which could not be uniquely ordered at odds 
21000: 1 (HHH2O2, EW204, HOX2) are placed in their most likely 
position; for mapping and clinical application, the most important of 
these is HHH2O2 which was placed with odds of 275: 1. 
For clinical application it is also important to know whether 
there is a significant difference in recombination between the sexes. 
Although overall this was the case, the total genetic distance from 
pA10.41 to NGFR being 26cM in males and 56cM in females, the closely 
linked flanking markers are still close enough to give a prediction 
with >95% accuracy in females as well as males (HHH2O2,8m=0.00, 
8F=0.01; EW206 8M=0.02,8F=0.04). 
In summary therefore, linkage studies have shown no evidence of 
locus heterogeneity for NF-1 and identified closely linked flanking 
markers suitable for clinical application in prenatal/pre-symptomatic 
testing. 
3. Physical mapping studies of the NF-1 region on chromosome 17 
A. Cytogenetic studies in NF-1 patients - Prior to the mapping of the 
gene to chromosome 17 by linkage studies, routine cytogenetic 
investigations of NF-1 patients had not revealed any consistent 
abnormalities (Riccardi & Eichner 1986). Once the chromosomal 
localisation of the gene was known, cytogenetic analysis of patients 
with NF-1 could now focus on chromosome 17 in detail to see if 
patients, particularly new mutations or those with severe retardation, 
malignancy, or who were dysmorphic, had a visible cytogenetic 
rearrangement of the pericentromeric region. 
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FIGURE 10-2. Physical and genetic map of chromosome 17 based on 
data available up to January 1989. 
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Nine of the patients in the population study have had normal 
cytogenetic investigation to date (28,53,68,79,82,108-111) and in a 
further 15 unrelated patients seen either for counselling at the 
Kennedy Galton Centre (by the author) or for assessment for a study of 
intellectual handicap in NF-1 (by Dr R Ferner) also had no visible 
cytogenetic abnormality. 
Two cases have however been reported in the literature with 
balanced reciprocal translocations in NF-1 patients, which had a 
common breakpoint at 17g11.2. In the first case (Schmidt et al 1987), 
a mother (a probable new mutation for NF-1) and her two children with 
NF-1 were shown to have a t(1; 17) (p34.3; g11.2) translocation. The 
chromosome analysis was initially undertaken in the mother because of 
a history of recurrent miscarriages in her sibship. In the second 
case (Ledbetter et al 1989), a new mutation for NF-1 was ascertained 
when her child, who had multiple congenital abnormalities and died at 
10 months of age, was found to have an apparently balanced 
translocation involving chromosomes 17 and 22. The child is not 
reported to have had any NF-1 features prior to death. Detailed 
analysis of the mother's karyotype showed the breakpoints to be 
t(17; 22)(g11.2; q11.2). Ledbetter et al (1989) have constructed a 
hybrid cell line from this mother which contains only the derivative 
chromosome 22, and mapping studies reported in the same publication 
and by Fountain et a1 (1989) showed that the markers that were shown 
to flank the NF-1 gene by linkage studies also flank the translocation 
breakpoint. It therefore seems likely that the translocation events 
in these two patients have disrupted the NF-1 gene and have identified 
its precise localisation. 
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B. Physical mapping studies using hybrid cell lines and Pulse Field 
Gel Electrophoresis (PFGE) - In Figure 10-2 the physical 
localisation of the probes used for the linkage studies in Section 1 
are shown; these are based on the reports of Shaw et al 1987, Fain et 
al 1987, VanTuinen et al 1987 and Fountain et al 1989. The oncogene 
ERBB2 is included as it was another possible candidate gene; an RFLP 
at the ERBB2 locus has so far not been identified (Upadhyaya et a1 
1987) and therefore it could not be excluded as a candidate gene by 
linkage analysis. However, the physical mapping studies of Fountain 
et al (1989) have shown ERBB2 to be distal to the probable NF-1 locus 
and their PFGE analysis of NF-1 patient DNAs has failed to show 
rearrangements involving ERBB2. None of the markers studied so far 
has identified rearrangements in NF-i patients on PFGE or identified 
the breakpoints in the two translocation cases (Fountain et al 1989). 
C. Analysis of tumour DNA from NF-1 patients - With the mapping of 
the gene another immediate question which could begin to be addressed 
was the mechanism of tumour formation in NF-1. If the mechanism was 
analogous to that in NF-2 (see Chapter 1, Section 2F) then loss of 
heterozygosity would be seen in closely linked probes in tumour DNA 
when compared with lymphocyte DNA. Tumour material from patients seen 
by the author during the course of her work had been sent to Dr B 
Ponder to add to his extensive collection of NF-1 tumour material. Dr 
Ponder's initial work (personal communication, January 1989) has shown 
no loss of heterozygosity in simple neurofibromas; this is the 
experience of other centres (Dr B Seizinger, personal communication, 
January 1989). Dr Seizinger has however shown deletions on the short 
arm of 17 in 4 NF-1 neurofibrosarcomas, i. e. not involving the NF-1 
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gene, and therefore the trigger for tumour formation may involve other 
loci. In Dr Ponder's material 2 NF-1 phaeochromocytomas have shown 
loss of alleles with probes HHH2O2 and EW204, i. e. in the region of 
the NF-1 locus. 
In summary, therefore, the mechanism of tumour formation in NF-1 
is more complicated than can be explained by the hypothesis that the 
NF-1 gene is a tumour suppressor gene; of the findings to date only 
those from the phaeochromocytomas studied by Dr Ponder would fit this 
mechanism. 
4. Conclusions 
In summary, therefore, by January 1989, major locus heterogeneity 
for NF-1 had been excluded; the findings of physical and linkage 
studies had complemented each other in identifying closely linked 
flanking markers and the accurate sub-chromosomal localisation of the 
NF-1 gene had been identified. The cloning of the breakpoints in the 
two translocation cases, and therefore by implication the NF-1 gene, 
should be achieved in the near future. 
The immediate clinical implications of the data presented in this 
chapter is that very accurate prenatal/pre symptomatic diagnosis using 
closely linked flanking markers is now possible in families with a 
suitable structure. To this end, the guidelines for genetic 
counselling developed from the population study of NF-1 in South East 
Wales will be helpful in discussing these options with NF-1 families. 
However, as prenatal tests using linked probes will not predict 
disease severity and will not be applicable for the significant 
proportion of affected individuals who are new mutations, the uptake 
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by couples of these tests will probably be limited. The real hope for 
future care of NF-1 sufferers lies in the cloning of the gene, the 
identification of its product, eventual understanding of disease 
pathogenesis and development of possible treatments. 
".... the reverse genetics trail that is currently being blazed 
for NF-1 shows a greater promise of providing an understanding of 
the true basis of this major genetic disease than has any previous 
endeavour in the more than a century since the original 
description of the disease. " 
Collins et al (1989) 
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Clinical Summaries of families seen. 
Appendix A is divided into three sections: 
Section 1- in which the clinical details of families with NF-1 are 
presented; the family number is prefixed with NF. 
Section 2- in which the clinical details of index cases who had CAL 
spots as their only feature are presented; the family number is 
prefixed with DNF. 
Section 3- in which the clinical details of index cases and their 
families who had other forms of neurofibromatosis or diseases closely 
related are presented; the family number is prefixed with ONF. 
Section 4- the clinical details of index cases with a diagnosis 
other than NF-1 are presented; their number is prefixed with NNF. 
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Section 1 
The families have been grouped according to the place of 
residence of the index case(s) as follows: 
(a) NF 1-40 resident in South Glamorgan; 
(b) NF 41-69 resident in West Gwent; 
(c) NF 70-73 index cases resident outside study area and 
ascertained for linkage studies. 
For each family the index case(s) is described first, followed by 
details of relevant family members, beginning with generation I. For 
each affected individual the following details are listed: 
(a) date of birth 
(b) age when assessed for study 
(c) occupation* 
(d) social class* 
(e) details of education* 
(f) academic qualifications* 
(g) numbers of CAL spots >1.5 cm in diameter and <0.5 cm if 514 
years old 
(h) areas of freckling 
(i) number of cutaneous neurofibromas (CNF) graded: none=l, 
few (<10)=2, scanty (10-99)=3, moderate (100-500)=4, 
extensive (>500)=5 
(j) facial appearance: normal=no, abnormal=yes, i. e. whether the 
diagnosis of NF-1 was obvious from the face, e. g. face: no 
means there were no obvious facial features of the disease. 
(k) Lisch nodules (LN): average no. /eye, e. g. LN: 14. 
(1) grade of severity of NF-1 on a scale 1-4 (described 
in Chapter 2), e. g. GNF 1* 
(m) height in cm (centile for age), e. g. height: 90(>97) means 
the individual was 90 cm tall which was >97th centile. 
(n) head circumference in cm (centile for age), e. g. HC: 40 (50) 
means the head circumference was 40 cm and on the 50th 
centile. 
*Denotes items of information listed only if individual resident in 
study area. 
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A brief clinical summary is then given if appropriate, with 
particular reference to NF-1 complications. The pedigrees of 
families NF1-73 follow the text of Section 1. For relatives found to 
be unaffected, the findings on cutaneous and slit lamp examination 
are given and other information (e. g. education, height) if this has 
been used in analysis. For all individuals, if a given piece of 
information is not stated, it was not available or examination was 
inadequate for the purpose. 
In Tables A-1 and A-2 the study numbers of affected individuals 
used in the main text are cross-referenced with the pedigree numbers. 
In the case of affected individuals resident in South East Wales, the 
mode of inheritance and complications are also listed. 
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Table A-1 Study numbers of all affected individuals resident in 
South East Wales cross-referenced with pedigree numbers, 
mode of inheritance and complications 
Study No. Pedigree No. Mode of Complication 
inheritance 
1 1,11-3 NM - 
2 1,111-3 M 1,2 
3 1,111-4 M 2 
4 1,111-5 M 2,9 
5 2,11-1 NM 8 
6 3,11-2 NM 8 
7 3,111-1 F 8 
8 3,111-2 F - 
9 3,111-3 F 8 
10 4,11-1 NM 3 
11 5,11-9 NM 1 
12 6,111-2 NM 1,2 
13 7,111-3 M 8 
14 7,111-6 M - 
15 7,111-7 M - 
16 7,111-8 M - 
17 7,111-9 M 9 
18 7, IV-1 F - 
19 7, IV-4 F 1,2,13 
20 7, IV-6 F 1,2,3 
21 7, IV-7 F 3 
22 7, IV-8 M 1 
23 7, IV-10 M - 
24 8,111-3 F 3,5,7 
25 9, II-1 NM 1,2,8 
26 9,111-1 F 1,8 
27 10, II-1 NM - 
28 11, II-1 NM 1,9 
29 12,111-8 M 2 
30 12, IV-7 F - 
31 12, IV-8 F 1,2 
32 13,11-1 U - 
33 13,111-2 M - 
34 14,111-1 M 2,9 
35 14,111-2 M 2 
36 15,11-1 M 1,2,3 
37 15,11-2 M 1,2 
38 15,11-4 M - 
39 15,111-1 F - 
40 16,11-4 U - 
41 17,11-1 NM 13 
42 17,11-2 M 13 
43 18, III-1 F - 
44 19,11-3 NM 2 
45 19,111-3 M - 
46 20,11-1 NM 
47 20,111-1 M - 
48 20, IV-1 M 2,4 
49 20, IV-2 M 1 
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50 21, IV-2 M 1 
51 21, IV-3 M - 
52 22,11-1 U - 
53 23,11-2 NM 1,2 
54 24,111-5 M 2 
55 25,11-8 NM - 
56 25,111-2 M - 
57 26,11-1 NM 1,3 
58 27,11-1 NM - 
59 28,11-2 NM 
60 28,111-1 M 1 
61 29,11-1 U 1,2,3,11 
62 29, IV-2 M 1,2 
63 29, IV-3 M 2 
64 30,111-1 F - 
65 30, IV-1 M 3,6 
66 30, IV-3 M 1,8 
67 31,11-4 NM 12 
68 32,11-2 NM 1,2 
69 33, IV-4 M 8 
70 34,11-3 NM 1 
71 34,111-3 F 15 
72 35,11-3 NM - 
73 36,111-1 F - 
74 37,11-16 NM 2 
75 38,11-2 M 2 
76 38,111-1 M 1,2,3 
77 38,111-2 M 2,3 
78 39,11-4 NM - 
79 39,111-2 F 1,2 
80 40,11-3 F - 
81 41,111-1 M 1 
82 41, IV-1 M 2,14 
83 42,11-6 NM 1 
84 42,111-3 M 1 
85 42,111-4 M 2,14 
86 42,111-6 M - 
87 43,11-7 NM 
88 44, III-1 M - 
89 44, IV-1 M 1,3,4 
90 45,11-3 NM - 
91 46,11-5 NM - 
92 46,111-3 M - 
93 47,11-9 M - 
94 48,11-5 NM 1,2,5,6,12 
95 49,1-1 U - 
96 49,11-1 M 2 
97 49,11-2 M 2 
98 49,11-3 M - 
99 49,11-7 M - 
100 49,111-1 M 2 
101 49,111-2 M 2 
102 49,111-3 M - 
103 49,111-4 F - 
104 49,111-5 F - 
105 49,111-7 M 2 
106 49,111-8 M - 
107 49,111-9 M - 
108 50,11-1 NM 1,2,8 
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109 51,11-2 NM 
110 52,11-2 NM 
111 53,111-2 F 9 
112 54, N. P. * U 1,2 
113 55,11-3 NM 1 
114 56,11-1 M - 
115 56,111-3 M 1 
116 56, IV-3 M 1 
117 57, II-1 F - 
118 58, II-5 NM 2,11 
119 59,11-2 NM 2,10 
120 60,11-1 NM 8 
121 60,111-2 M - 
122 61, II-2 NM 1 
123 62,111-3 F 1,2 
124 63,11-2 NM - 
125 63,111-5 F - 
126 64,11-4 NM 
127 64,111-1 M - 
128 64,111-2 M 1 
129 65, N. P. NM 8 
130 66,11-2 NM 2 
131 67,11-1 NM 1,2 
132 67,111-1 F 1 
133 68,111-1 F 8 
134 68, IV-2 M - 
135 69, N. P. F - 
Key to Table A-1: 
(1) N. P. * = no pedigree 
(2) For mode of inheritance -M= mother affected; F= father affected; 
NM = new mutation; U= uncertain. 
(3) The complications of NF-1 are coded as follows: 
1= plexiform neurofibromas; 2= intellectual handicap; 3= epilepsy; 
4= glioma; 5= spinal neurofibroma; 6= aqueduct stenosis; 
7= meningioangiomatosis; 8= scoliosis; 9= pseudoarthrosis; 
10 = lambdoidal suture defect; 11 = endocrine tumours; 12 = renal 
artery stenosis; 13 = visceral neurofibromas; 14 = delayed puberty 
and 15 = congenital glaucoma. 
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Table A-2 Study numbers, cross-referenced with pedigree numbers, for 
other affected family members specifically mentioned in 
main text of thesis. 
Study Number Pedigree Number 
Deceased affected relatives 
137 12,11-6 
138 24,11-4 
139 7, IV-9 





















162 36, II-4 
163 24,11-1 
Affected relatives with CNS tumours or malignancy 
136 47,111-1 
142 36,111-2 
Other affected relatives specifically mentioned 
164 24, IV-1 
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NF 1 
11-3 was ascertained both by referral from her general practitioner 
(GP) and medical records. 
I1-3 - 15.1.28,57.3 years. 
Housewife; SC: V; attended secondary modern school, no 
qualifications. 
8 CAL; freckling: axillae and submammary region; CNF: 4; face: no; 
LN: 20; GNF: 2; Ht: 150(<3); HC: 57.5(>97). 
11-3 had had 2 cutaneous neurofibromas removed in 1969 and thought 
NF-1 'was just a skin problem'. She did not understand the genetic 
implications of NF-1 until seen for the study. On examination the 
only other problem was long-standing weakness of the evertors and 
dorsiflexors of the right ankle; this was the result of diphtheria at 
the age of 9 years. 
I-1 - born 1885, died aged 57 years, 1942. 
11-3 reported multiple 'lumps' like her own in her father but knew of 
no details of his parents or siblings. He also had rheumatoid 
arthritis and died from ischaemic heart disease (case no. 153 in 
cause of death analysis). 
II-1 - born 1924. Lived outside study area, reported normal. 
11-2 - born 1926. Lived outside study area, reported normal. 
III-1 - 9.5.47,38 years. 
Housewife, SC: V; attended comprehensive school, no qualifications. 
Examination of skin normal. Height 162.5 (50). Both children 
reported normal. 
111-2 - 28.1.49,36.3 years. 
Distribution assistant (Gas Board), SC: IV; attended secondary modern 
school, no qualifications. Examination of skin normal. Ht: 170 (25). 
Daughter reported normal. 
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111-3 - 28.5.51,33.9 years; coalman (unemployed); SC: V; remedial 
class education; no qualifications. 
10 CAL; freckling: axillae; CNF: 3; face: no; LN: 50; GNF: 3; Ht 168 
(10); HC: 60 (>97). 
111-3 was entirely asymptomatic and was unaware that he had NF-1. He 
had a small plexiform neurofibroma on his left lower back with 
overlying skin hypertrophy and hypertrichosis. 
111-4 - 21.6.56,28.9 years; coalman (unemployed). SC: V; special 
school education, literate. 
7 CAl; freckling: axillae and groins; CNF: 3; face: no; LN: not 
examined; GNF: 3; Ht: 173 (50); HC: 57 (90). 
Entirely asymptomatic, unaware of diagnosis and had never had a 
hospital assessment. 
111-5 - 6.9.57,27.7 years; coalman; SC: V; special school education, 
literate. 
12 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: not 
examined; GNF: 3; Ht: not appropriate; HC: 57.5 (97). 
111-5 had been noted to have an abnormal left foot when he started 
walking (at 14 months). Orthopaedic referral showed a valgus 
deformity secondary to pseudoarthrosis of the fibula. Radiology 
showed irregularity of the distal tibial epiphysis, with retonation 
of growth on the left side and complete absence of a2 cm segment of 
the fibula just proximal to the epiphyseal line. He had 3 corrective 
orthopaedic operations during childhood (1960,1968 and 1969). 
Resulted in fusion of fibula with good mobility, although ankle still 
abnormally shaped on examination. No mention of NF-1 features in his 
orthopaedic notes, nor of his mother being affected. He had had no 
other problems. 
111-6 - 21.7.63,21.8 years. Housewife; SC: V; attended 
comprehensive school, no qualifications. Examination of skin normal. 
Ht: 153 (10). Both children reported normal. 
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NF 2 
II-1 was referred by both her GP and neurologist. 
II-1 - 3.7.40,44.6 years. Secretary (personal assistant); SC: II; 
educated at private high school, attained GCE '0' levels. 
6 CAL; freckling: none; CNF: 4; face: no; LN: 10; GNF: 2; Ht: not 
appropriate; HC: 56.5 (>97). 
II-1 was diagnosed at 20 years when she presented with a peptic 
ulcer. During treatment (with bed rest) she complained of backpain, 
also slight frequency and urgency of micturition. Examination of the 
lumbar spine showed a scoliosis at L1-3. Plain radiographs showed 
marked scalloping of the lumbar vertebrae but myelography showed only 
dural ectasia and no other lesion. No active treatment was 
undertaken. 
Apart from intermittent slight back pain, she was then well until 
1984 when she developed pain in the distribution of L1 which was 
aggravated by coughing. Examination showed no focal neurological 
signs. Repeat myelography (Figure 5-4) and CT of the spine showed 
increase in the degree of scalloping and scoliosis; the nerve roots 
were displaced by the dural sac. The pain was presumed to be related 
to the dural ectasia but as the myelogram had excluded a space 
occupying lesion, no active treatment was advised. 
Her only other NF-1 problem was a neurofibroma in the gum of the 
upper jaw. She was under periodic review for this. She was unaware 
of the genetic implications of NF-1 when seen for study. 
Classified as new mutation. 
I-1 - 30.8.05, died 1973. 
His wife was sure that I-1 had no NF-1 skin lesions. Died of an 
abdominal reticulosarcoma. Autopsy report reviewed: skin normal. 
I-2 - 1.11.05,80.2 years 
1 CAL on examination, slit lamp examination normal, i. e. no evidence 
of NF-1. 
III-1 - 10.3.65,20 years. Waitress; SC: IV; attended comprehensive 
school, attained GCE 'A' level passes. 
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2 CAL on examination; slit lamp examination normal. 
111-2 - 7.1.67,18.1 years. Bank clerk; SC: III(N); attended 
comprehensive school, attained GCE '0' level passes. Examination of 
skin and iris normal. 
NF 3 
Ascertained via III-1, who was referred to the study by a consultant 
clinical geneticist and her GP independently; her records were also 
ascertained via the Prince of Wales Orthopaedic Hospital. 
III-1 - 31.10.55,28.9 years. Housewife; SC: IVM; attended 
comprehensive school, no qualifications. 
4 CAL; freckling: no; CNF: 3; face: no; LN: 3; GNF: 3; Ht: not 
appropriate; HC: 55.5 (90). 
Developed left thoracolumbar scoliosis at 9 years and referred for 
orthopaedic assessment. Curve involved T10-L2,33°, vertebrae 
normal. Progression of curve over one year to 68°, posterior final 
fusion performed in January 1967. Successful correction to 25° but 
relapsed in 1968 to 95°, further fusion undertaken in 1969, final 
correction to 70°. Left with marked residual kyphoscoliosis but no 
pain and therefore no further operations were undertaken until she 
presented with severe pain over her curve in 1985. Re-exploration 
showed a stable fusion with 2 nerve roots trapped. These were 
released with resolution of symptoms. 
III-1 had no other medical problems but she was unaware her spinal 
condition was related to NF-1. 
I-1 - 15.11.1880, died 77 years. 
I-1 died as a result of a stroke. 
I-2 - 2.10.1898, died 73 years. 
Died from left ventricular failure secondary to a myocardial 
infarction. 11-2 was sure both his parents had no stigmata of the 
disease. 
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II-1 - 4.5.21. II-1 and offspring reported normal. 
11-2 - 10.1.25,59.7 years. Clerical officer; SC: IIIN, attended 
elementary school, no qualifications. 
0 CAL; freckling: axillae; CNF: 4; face: no; LN: 2; GNF: 2; Ht: not 
appropriate; HC: 56 (75). 
Slight curvature of the spine noted on naval entrance at 22 years. 
Asymptomatic, no progression, minimal left thoracic kyphoscoliosis on 
examination. Diagnosed as having NF-1 when his daughter developed 
severe scoliosis. Classified as new mutation. 
11-3 - 27.10.26. He and one child reported normal. 
II-4 - 12.11.30, reported normal. 
11-5 - 28.12.31,53.9 years. Fitters mate; SC: IV; attended 
elementary school, no qualifications. 
Reviewed as family had noted CAL spot on chin of 111-4. Cutaneous 
examination of 11-5 normal. 111-4 had a1 cm diameter CAL mark on 
her chin but nothing else. Both her and her father classified as 
normal. 
11-6 - 3.5.34, reported normal. First child had died in infancy, 
cause uncertain, remaining children said to have no problems. k 
111-2 - 23.5.58,26.3 years. Painter and decorator (unemployed); SC: 
IIIM; attended comprehensive school, no qualificatins. 
5 CAL; freckling: no; CNF: 3; face: no; LN: 6; GNF: 1; Ht: 170 (25); 
HC: 57.5 (97). 
111-3 - 16.3.60,24.5 years. Factory inspector; SC: IVM; attended 
comprehensive school, no qualifications. 
6 CAL; freckling: axillae; CNF: 3, face: no; LN: 20; GNF: 2; Ht: not 
appropriate; HC: 55.5 (90). 
Had been reviewed by an orthopaedic surgeon in late teens for slight 
lumbar scoliosis. Notes untraceable. On examination, asymptomatic 
slight left lumber scoliosis, no investigations undertaken. 
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NF 4 
II-1 was referred to the study by his GP and also ascertained via 
medical records. 
II-1 - 26.6.32,52.1 years. Received invalidity benefit, had 
formerly worked as clerical officer until made redundant in 1979 when 
could find no further employment; SC: IIIN; attended grammar school, 
no qualifications. 
4 CAL; freckling: axillae; CNF: 5; face: yes; LN: 6; GNF: 3; Ht: 174 
(50); HC: 58 (97). 
Developed epilepsy in his late teens; his fits took the form of 
complex partial seizures when he experienced depersonalisation, 
mumbled incoherently and clenched his right fist. NF-1 was diagnosed 
by a Consultant Neurologist in 1957 and he had been intermittently 
reviewed by the Department of Neurology since that time. He seems at 
first to have been reasonably controlled on a 
phenytoin/phenobarbitone mixture but in 1979 the frequency of attacks 
increased and he also developed a gait disturbance; a spinal 
neurofibroma was queried. EEG showed generalised abnormality and 
suggestion of left temporal focus; myelogram was normal. The 
frequency of his fits decreased spontaneously with no change in 
medication. 
At the time of review for study, he shc-.; ed mild inco-ordination 
of the limbs with gait ataxia, reduced knee and absent ankle jerks, 
his left plantar was extensor. Similar findings had been noted in 
1977. Full neurological review was undertaken (by Dr Compston) and 
CT scan showed the left lateral ventricle was enlarged compared with 
the right and a degree of cerebral atrophy. It was felt that his 
cerebellar disturbance and peripheral neuropathy were complications 
of long-standing phenytoin treatment and an underlying cause of his 
seizures was not identified. As he was extremely anxious regarding 
his attacks and his disease generally, it was felt that at least some 
of his attacks may be due to panic. 
Classified as a new mutation. He and his wife had tried to have 
children for a number of years, but with no success. No formal 
investigations for infertility had been undertaken. 
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I-i - born 1895, died 68 years from carcinoma of the lung. 
I-2 - born 1900, died 76 years from carcinoma of the pancreas. 
II-1 was sure both his parents were unaffected. There was no history 
of NF-1 in their extended families. 
NF 5 
11-9 was referred by her GP and also ascertained by the 
dermatology/histology index. 
11-9 - 25.7.06,78 years. Retired former housemaid, SC: IV; attended 
normal school, no qualifications. 
2 CAL; freckling: none; CNF: 5; face: yes; LN: 12; GNF: 3; Ht: 156 
(10); HC: 54 (50). 
11-9 was aware of being different from her siblings from the time-she 
began to develop cutaneous neurofibromas. Her only medical 
treatment in relation to NF-1 through the years had been to have the 
largest of her cutaneous neurofibromas removed. Her only other 
problem was bilateral deafness, from the age of 27 years, the cause 
of which was uncertain; she coped well with the use of a hearing aid. 
Her mother, II-1 and 11-5, had had similar hearing problems. 
On examination she had bilateral conductive deafness and no other 
neurological signs. She had a small plexiform neurofibroma on her 
left arm with overlying skin hypertrophy and pigmentation. 
11-9 felt NF-1 had "ruined her life" and she had never been swimming 
or gone out without her arms covered. Why she had not had children 
was not discussed because it was felt she was already distressed by 
the interview. 
Classified as a new mutation. 
I-1 - born 1862. Died 81 years from uraemia secondary to 
complications of a prostatectomy operation. 
I-2 - year of birth uncertain. Died 76 years, cause uncertain. 
The propositus was adamant she was the only affected family member. 
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Details regarding her siblings were vague other than this fact. Six 
of her siblings were deceased and the details were as follows: 
II-1 - died 78 years from Parkinson's disease; 
11-2 - died 86 years from carcinoma of the oesophagus; 
11-3 - died 64 years, cause unknown; 
11-4 - age and cause of death unknown; 
11-6 - died 80 years from cancer, site unknown; 
II-10 - died 76 years as a result of a stroke; 
The remainder of her siblings were healthy. 
NF 6 
111-2 was referred both by a consultant dermatologist and her GP. 
111-2 - 23.2.65,19.5 years. Packer in shoe factory; SC: IVM; 
remedial class education, obtained some CSE passes with relatively 
low grades (4 and 5). 
14 CAL; freckling: axillae; CNF: 4; face: no; LN: 51; GNF: 3; Ht: 
162.5 (50): HC: 57 (>97) 
NF-1 had been diagnosed at 10 years when her parents became concerned 
about her appearance. No details regarding the nature of her disease 
had been discussed. She had had one cutaneous neurofibroma removed 
prior to being seen because of pressure from a strap. 
Although her motor milestones had been normal, her speech 
development had been delayed. She had required remedial class 
education and still experienced difficulty with reading. 
Psychometric examination was undertaken after she had been seen for 
the study (by Dr Vingoe, Principal Psychologist, UHW), this showed 
verbal IQ 90, performance IQ 101 and full-scale IQ 94. She was 
therefore of average intelligence but it was noted that her attention 
span was particularly poor; it was felt her performance was marred to 
some extent by very low self-esteem. 
On examination, she had severe NF-1 manifestations for her age 
and a 10x10 cm plexiform neurofibroma over the right iliac crest. 
Classified as a new mutation. 
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I-2 - 14.8.10,74 years. 
The parents of 111-2 had asked her to attend when the family were 
assessed because she had one CAL spot and numerous freckles. The CAL 
spot was confirmed on examination but the freckles were only in 
exposed areas of the body. There was no history of NF-1 in her or 
her husband's extended families. 
II-1 - 22.12.41,42.6 years. Detective Sergeant of police. SC: 
IIIN; no abnormality of skin or iris on examination. Ht: 183 (90). 
No history of NF-1 in either of his parent's extended families. 
11-2 - 14.1.41,43.6 years. State Enrolled Nurse; SC: II. No 
abnormality of skin or iris on examination; Ht: 165.5 (75). 
III-1 - 2.3.64. Reported normal. 
111-3 - 29.1.67 Reported normal 
111-4 - 25.3.71,13.4 years. 
On examination, 1 CAL spot; normal irides. 
NF 7 
Three affected individuals in this large family were independently 
ascertained: 111-3 (via his GP, orthopaedic and genetic records), 
111-9 (referred by her GP) and IV-4 (general hospital records and 
GP). 
111-3 - 18.11.41,42.5 years. Sewerman; SC: IV; secondary modern 
school education, no qualifications. 
4 CAL; freckling: axillae; CNF: 4; face: yes; LN: 0; GNF: 3; Ht: not 
appropriate; HC: 54 (25) 
Presented with right thoracolumbar scoliosis age 9 years (1958); 90° 
curve from T10-L3, vertebrae normal. Posterior spinal fusion 
performed September 1959, curve improved to 70°. In 1969, pain over 
the residual kyphoscoliosis led to re-exploration, no problem 
detected. Left with relatively severe residual deformity and still 
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experienced intermittent pain at time of study assessment. 
He had been aware of the diagnosis of NF-1 since childhood. 
Apart from not swimming because of his appearance, he had no other 
related problems. On examination on two occasions for the study his 
blood pressure was marginally elevated to 150/100 erect and supine; 
24 hour urinary VMA was normal on one occasion and he declined 
further investigations. 
111-9 - 4.1.54,30.5 years. Housewife; SC: IIIM; secondary modern 
school education, no qualifications. 
10 CAL; freckling: axillae and over whole trunk; CNF: 3; face: no; 
LN: 23; GNF: 3; Ht: not appropriate; HC: 53 (10) 
Her mother had noted bowing of the right tibia on the third day of 
life; orthopaedic referral showed severe bowing of the right tibia in 
association with multiple CAL spots and the diagnosis of NF-1 was 
made. Wore a caliper until 9 years, but shortly after its removal, 
111-9 fractured her tibia and non-union resulted. Had various 
orthopaedic procedures with no success, below knee amputation 
performed in 1968. 
Although the orthopaedic notes clearly state the diagnosis of 
NF-1,111-9 thought her leg problem was secondary to osteomyelitis. 
She had no other problems until just prior to her assessment when she 
had developed intermittent severe thoracic pain and was referred for 
neurological assessment. There were no localising signs but a 
myelogram was performed to exclude an intraspinal lesion, this was 
normal. Following this a subcutaneous neurofibroma in the region of 
the pain was removed with partial resolution of symptoms. 
IV-4 - 21.12.75,8.6 years. Schoolgirl; SC: IIIM; remedial class 
education. 
8 CAL >1.5 cm, 0>0.5 cm; freckling: axillae; CNF: 1; face: no; LN: 2; 
GNF: 3; Ht: 117 (3); HC: 50 (25). 
IV-4 had presented at the age of 6.5 years with anorexia and general 
malaise. Examination had shown multiple CAL spots and a mass in the 
right ileac fossa. At laparotomy a single large benign neurofibroma 
was found in the mesentery of the right colon; hemicolectomy and 
terminal ileectomy was performed with resolution of the symptoms. 
She attended a remedial class and a psychological assessment in 
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February 1982 showed (on Wechscler Intelligence Scale) verbal IQ 71, 
performance IQ 82, full-scale IQ 75. Assessed as being below average 
ability with marked learning difficulties. 
On examination for the study, found to have 2 plexiform 
neurofibromas: an indiscrete mass above her left nipple with 
overlying skin hypertrophy and hypertrichosis and a similar lesion on 
the left thigh. 
II-1 - 19.6.11, died 68 years. 
The diagnosis of NF-1 had been made in 1955 when she presented with 
unrelated gynaecological problems. At that time she had multiple CAL 
spots and cutaneous neurofibromas (one of these was biopsied, 
histology of a benign neurofibroma). In October 1979 presented with 
anorexia and weight loss, carcinoma of the stomach was found at 
laparotomy. She died 2 days after a gastro-oesophagectomy with 
pulmonary oedema. No other abnormalities were detected at autopsy. 
Her family history was obtained from her spouse who reported that 
II-1 was the first case of NF-1 in her family. 
III-1 - 8.1.38,48 years. 
Examination of skin normal. 
111-2 - 25.10.39,45 years. 
Examination of skin and iris normal. 
111-4 - Born 1942, died at 3 months. 
Her father did not recall noting CAL spots prior to her death from 
septicaemia. 
III-5 - 2.1.52, died 27 years. 
Medical details obtained from wife. Had numerous CAL spots and 
neurofibromas at time of marriage, age 25 years, but had no other 
NF-1 related problems. Then had recurrent episodes of severe 
depression, was intermittently violent towards his wife; committed 
suicide by hanging in 1979. 
111-6 - 30.1.48,36.4 years. Sewerman; SC: IV, secondary modern 
school education, no qualifications. 
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. 8- 
14 CAL; freckling: axillae, all over trunk; CNF: 5; face: yes; LN: 43; 
GNF: 2; Ht: 162 (3); HC: 55.5 (50-75). 
111-6 was extremely anxious about his appearance and had had several 
of the larger cutaneous neurofibromas removed. 
111-7 - 22.11.49,35.2 years. Sewerman; SC: IV; secondary modern 
school education, no qualifications. 
9 CAL; freckling: axillae and groins; CNF: 4, face: no; LN: 18, GNF: 
2; Ht: 158 (<3); HC: 55 (50). 
No problems directly related to NF-1. Intermittent bouts of 
depression and excess alcohol intake for which he had had psychiatric 
review. 
111-8 - 4.6.52,32.1 years. Housewife; SC: IIIM; secondary modern 
school education, no qualifications. 
9 CAL; freckling: axillae and over whole trunk; CNF: 4; face: no; LN: 
27; GNF: 2; Ht: 148.5 (<3); HC: 54.5 (50) 
Had had several cutaneous neurofibromas removed for cosmetic reasons. 
Unaware of genetic implications of NF-1 and uncertain whether 
children were affected until study assessment. 
IV-1 - 10.9.70,13.8 years. Schoolgirl; SC: IV; secondary modern 
school, no problems. 
21 CAL >1.5 cm, 0 >0.5 cm; freckling: axillae and over whole trunk; 
CNF: 1; face: no; LN: 6; GNF: 1; Ht: 148 (3); HC: 59.5 (>97) 
Correctable divergent squint of left eye secondary to myopia from 
early childhood. When assessed for LN study, optic discs normal and 
no further investigations undertaken. 
IV-2 - 11.12.71,12.6 years. Attending remedial class at 
comprehensive school. 
Normal examination of skin and iris. Ht: 129.5 (<3) 
Excluded from linkage analysis as father's siblings cast doubt on 
paternity of this branch of the family. 
IV-3 - 9.1.73,11.6 years. Attending comprehensive school, no 
problems. 
Normal examination of skin and iris. Ht: 140 (25). 
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Excluded from linkage analysis because of question of paternity. 
IV-5 - 19.4.78,1 6.2 years. Attending remedial class at primary 
school. 
Examination of skin showed 5 extremely pale CAL spots 1 cm in 
diameter. Slit lamp examination normal. Classified as equivocal, 
excluded from analysis. 
IV-6 - 23.5.77,7.1 years. Schoolgirl; SC: IV; remedial class 
education. 
10 CAL >1.5 cm, 0>0.5 cm; freckling: unilateral axillary on left; 
CNF: 2; face: no; LN: 40; GNF: 3; Ht: 115 (25); HC: 51 (25) 
Diagnosed secondary to study. Approximately 6 months after being 
assessed, developed absence attacks and EEG showed modified spike and 
wave activity. Good control achieved with sodium valproate therapy. 
On examination a small plexiform neurofibroma with overlying skin 
hypertrophy was noted below her right ear. 
IV-7 - 6.3.82,2.3 years. SC: IV, achieving normal milestones. 
2 CAL >1.5 cm, 8 >0.5 cm; freckling: none; CNF: 1; face: no; LN: 
present, unable to count accurately; GNF: 3; Ht: 89(25); HC: 50(50). 
Diagnosed secondary to study. Shortly after being seen, had 2 grand 
mal seizures and probably some absence attacks in addition. Sodium 
valproate therapy commenced and no further seizures; EEG normal. 
IV-8 - 25.9.71,12.8 years. Schoolboy; SC: IIIM; comprehensive 
school, no problems. 
6 CAL >1.5 cm, 0>0.5 cm; freckling: none; CNF: 1; face: no; LN: 33; 
GNF: 2; Ht: 133 (<3); HC: 55 (75) 
Diagnosed secondary to study. On examination noted to have large 
area of CAL pigmentation in bathing trunk distribution with a 
plexiform neurofibroma, several cm in diameter, in the middle (over 
the lumbar spine). This was intermittently painful and he was 
therefore referred to a plastic surgeon. Lumbar spine x-ray showed 
no significant abnormality. At operation the lesion was found to 
extend down into the buttocks therefore only the painful area was 
excised. Histology confirmed the clinical diagnosis and there was 
some resolution of pain. 
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IV-9 - 18.2.73, died 7 months. 
No problems until August 1973 when developed severe diarrhoea. On 
hospital admission a suprapubic mass was noted and at subsequent 
laparotomy a tumour invading the bladder, uterus and pelvic wall was 
found. Histology showed an embryonal rhabdomyosarcoma. She died 
soon after the operation. Her mother remembered one CAL spot and the 
hospital notes commented on multiple lesions. Mother was unaware of 
the relationship of her tumour to NF-1. 
IV-10 - 15.5.76,8.1 years. Schoolboy; SC: III; attending primary 
school with no educational problems. 
6 CAL >1.5 cm, 2 CAL >0.5 cm; freckling: none; CNF: 2; face: no; LN: 
26; GNF: 1; Ht: 121.5 (25); HC: 55.1 (97). 
Diagnosed secondary to study. 
IV-11 - 25.1.78,6.4 years. Attending primary school, no educational 
problems. 
Examination showed 1 CAL spot but no other features (slit lamp 
examination performed); Ht: 108.5 (3). 
Excluded from initial linkage study but re-examination one year later 
showed no other lesions, therefore classified as normal in subsequent 
studies. 
IV-12 - 28.10.78,5.7 years. No educational problems. 
Normal examination of skin and iris. Ht: 112.5 (50). 
IV-13 - 5.10.83.0.7 years. Achieving normal milestones. 
Normal examination of the skin. 
NF 8 
111-3 was referred to the study by his neurosurgeon and also 
ascertained via medical records. 
111-3 - 9.12.30,53.5 years. Former senior accounts clerk, made 
redundant in 1980, registered disabled when seen; SC: II; attended 
grammar school, achieved School Certificate and took an accounting 
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course at a College of Further Education. 
16 CAL; freckling: none; CNF: 3; face: no; LN: not examined; GNF: 4; 
Ht: 166 (10); HC: 58 (97). 
NF-1 had been diagnosed in 1961 when a painful neurofibroma had been 
removed from an intercostal nerve. In 1971 he presented with neck 
pain and difficulty in walking and was referred to a neurosurgeon. 
On examination he had a spastic tetraparesis and loss of 
proprioception in the right hand. Myelography showed probable 
neurofibromas at C1 and C2. At operation a large neurofibroma was 
removed at C2 and a much smaller lesion at C1 was left. He had 
complete resolution of symptoms initially but his problems recurred 
in 1973 and the neurofibroma at C1 was removed. His only residual 
problem was loss of proprioception in the right hand. 
He was well until 1974 when he presented with headaches and 
drowsiness. Investigation showed a right frontal tumour and subtotal 
removal was undertaken; histology was reported as showing a 
well-differentiated astrocytoma after which he was treated by 
radiotherapy. Three years later he developed a left hemiparesis, CT 
showed a right parietal lesion; after surgical decompression he was 
managed intermittently on dexamethasone for 7 years until his 
condition deteriorated, at which time CT demonstrated communicating 
hydrocephalus but despite insertion of a ventricular shunt, his 
condition had not improved by 1985. The frontal tumour was 
histologically reviewed at the time of shunt insertion and 
reclassified as meningioangiomatosis. He was seen twice during the 
course of the study and his left hemiparesis was slowly progressing, 
he had developed loss of inhibition and short-term memory. 
The details of his family history were supplied by his sister, 
111-2, an associate specialist in genito-urinary medicine. She 
reported that both herself and III-1 had no features of NF-1 but that 
their father (11-3, date of birth 11.9.91) had been affected. He had 
had no complications of NF-1 but had had multiple CAL spots and 
cutaneous neurofibromas. He died at the age of 45 years from cardiac 
failures secondary to myocarditis. Neither his parents nor siblings 
were reported affected. 
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NF 9 
III-1 was referred to the study by her GP, she was also ascertained 
by the genetic and orthopaedic records. 
III-1 - 6.1.60,24.4 years. Clerical assistant; SC: IIIN; 
comprehensive school education, attained 6 '0' level and 2 'A' level 
passes. 
14 CAL; freckling: axillae; CNF: 2; face: no; LN: 3; GNF: 3; Ht: not 
appropriate; HC: 55 (90). 
NF-1 was diagnosed at 11 years of age when she presented with 
multiple CAL spots and right thoracic scoliosis (curve 550, T5 - T10, 
vertebrae normal). This progessed over the next year to 66° and a 
posterior spinal fusion was performed. The curve was corrected to 
30° and remained stable with good cosmetic effect. III-1 had been 
seen for genetic counselling at 17 years of age. 
On examination the only other feature of note was a large 
plexiform neurofibroma on the right thigh (approximately 20 cm in 
diameter). The skin overlying it was hypertrophied in the centre and 
there was surrounding CAL pigmentation. 
II-1 - 21.10.29,54.6 years. Garage proprietor; SC: IIIM; secondary 
modern school education, no qualifications; reported difficulty in 
learning to read requiring extra help in this area alone. 
15 CAL; freckling: axillae and groins; CNF: 4; face: yes; LN: 17; 
GNF: 2; Ht: not appropriate; HC: 59 (>97). 
NF-1 was diagnosed when his daughter presented with scoliosis. In 
1982 he had a neurofibroma removed from his right upper eyelid and 
had residual slight ptosis. He had been aware of a slight scoliosis 
from the age of 12 years but this had never progressed and on 
examination he had a minimal thoracic scoliosis to the left; no 
investigations were undertaken. 
II-1 reported that both his parents were unaffected. His father had 
died at 34 years from TB (date of birth unknown) and his mother at 63 
years (date of birth unknown) from a myocardial infarction. II-1 was 
classified as a new mutation. 
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11-2 - 6.4.37,47.2 years. Housewife; SC: II; secondary modern 
school education, no qualifications. 
Examination of skin and iris normal. 
111-2 - 19.3.64,20.2 years. University student; SC: I; grammar 
school education, achieved 3 'A' level passes. 
Examination of skin and iris normal; Ht: 180 (75). 
NF 10 
II-1 was referred to the study by his GP and also ascertained via the 
Genetic Clinic records and Dermatology Histology Index. 
II-1 - 24.10.47,36.5 years. Council gardener; SC: IV; secondary 
modern school education, no qualifications. 
4 CAL; freckling: bilateral and around base of neck; CNF: 3; face: 
no; LN: 17; GNF: 1; Ht: 165 (10); HC: 58 (97). 
II-1 had not worried about his skin appearance until after his 
marriage. He was then referred to a dermatologist and the diagnosis 
made (1 cutaneous neurofibroma was removed to confirm diagnosis). He 
had subsequently been referred for genetic counselling. He was 
unwilling for his parents and sister to be reviewed for the present 
study. 
Classified as new mutation. 
I-1 - 8.9.22 
Had previously been examined in the Genetics Clinic, no abnormality 
on examination. 
I-2 - 3.4.23 
No abnormality on examination of skin at Genetics Clinic. 
11-2 - 20.1.53. 
Reported normal. 
III-1 - 16.1.78,6.3 years. 
No abnormality on examination of skin or iris. 
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111-2 -6.5.81,3 years. 
No abnormality on examination of skin. 
NF 11 
II-1 was referred to the study by his GP and independently 
ascertained through Genetic Clinic and general hospital records. 
II-1 - 2.1.73,12.8 years. Schoolboy; SC: III; attending school for 
physically handicapped children, no intellectual but considerable 
psychological problems. 
12 CAL all >1.5 cm; freckling: axillae; CNF: 1; face: yes; LN: left 
eye only examined, LN present (unable to count accurately); GNF: 4; 
Ht: not appropriate; HC: not appropriate. 
CAL spots were noted by his parents from birth. Bulging of the right 
eye was noted at 8 months, paediatric and ophthalmic referral was 
made. Initially thought to be secondary to congenital glaucoma but 
on review it became clear the problem was a plexiform neurofibroma of 
the orbit and the slight increase in intraocular pressure secondary 
to this. This lesion slowly enlarged although only involved the 
orbital area. He had been seen by cranio-facial surgeons in two 
centres and had undergone a number of procedures to reduce the bulk 
of the tissue. Despite this, at the time of assessment, his right 
eye was blind, the lesion still large, and eventual enucleation of 
the whole orbit was planned. 
In addition to this, his parents had also noted bowing of the 
left tibia during the first year of life. At one year he fell and 
fractured this, and when the fracture failed to heal a diagnosis of 
pseudoarthrosis related to NF-1 was made. He had a series of 
unsuccessful corrective procedures and was almost continually in 
plaster from the age of 1 until his below knee amputation in 1984. 
When assessed for the study he was having no problems with mobility 
with his artificial limb. 
Classified as new mutation. 
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I-i - 9.9.48. 
Refused to be seen for study. Had previously been examined in 
genetics clinic and no NF-1 features noted. His wife reported that 
he could not accept his son's problems. They had sought a number of 
second opinions over the years because of this. 
I-2 - 6.6.50. 
Prepared to answer questions but examination not undertaken. Skin 
noted to be normal when seen previously at genetics clinic. 
11-2 - 7.6.79. 
Reported normal. 
NF 12 
The ascertainment of this family was rather complex! Only the 
descendents of 11-6 lived in the area of the population study; 
although 111-8 is the father of IV-7 and IV-8, he is not in touch 
with them. 111-8 was referred to the population study by his GP and 
ascertained by medical records, as was IV-8; IV-7 was ascertained via 
medical records. IV-4 and his branch of the family were ascertained 
via genetic clinic records for linkage studies and the pedigrees 
subsequently found to connect (all the children of 11-6 had been 
adopted). 
111-8 - 7.1.54,31.3 years. Building labourer; SC: IIIN; secondary 
modern school education, no qualifications; experienced difficulties 
in learning to read and required extra tuition at primary school. 
17 CAL; freckling: axillae; CNF: 4; face: no; LN: not examined; GNF: 
2; Ht: 170.5 (50); HC: 59.5 (>97). 
111-8 was diagnosed during a hospital admission for asthma. He had 
had several cutaneous neurofibromas removed for cosmetic reasons. 
His only other complaint was of occasional intense pruritis related 
to his neurofibromas. He was unaware of the inheritance of NF-1. 
IV-7 - 4.10.73,12.1 years. Schoolgirl; SC: IV; attending 
comprehensive school, no educational problems. 
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8 CAL >1.5 cm; 28 >0.5 cm; freckling: axillae and groins; CNF: l; 
face: no; LN: not examined; GNF: 1; Ht: 141 (10); HC: 54 (75) 
IV-7 had also been diagnosed during a hospital admission for asthma. 
No NF-1 related problems. Mother unaware of implications of 
diagnosis. 
IV-8 - 20.4.77,8 years. Schoolboy; SC: IV; remedial class education. 
8 CAL >1.5 cm; 13 CAL >0.5 cm; freckling: axillae and over trunk; 
CNF: 1; face: no; LN: 24; GNF: 2; Ht: 118.5 (10); HC: 51.5 (25) 
Diagnosed at 3 years when referred to a paediatrician for delay in 
speech development. Swelling over lumbar spine with overlying 
hypertrichosis noted, spina bifida occulta queried but x-rays normal. 
On examination for study, the lesion was found to be a plexiform 
neurofibroma. 
IV-4 - 5.2.67,17.3 years. Student on course for people with 
learning difficulties; SC: IV; comprehensive school education, 
required extra tuition with reading. Attained 1 CSE (grade 5). 
12 CAL; freckling: axillae and trunk; CNF: 3; face: no; LN: 21; GNF: 
2; Ht: 151(3); HC: 57(90). 
Diagnosed in 1980 when referred to Growth Clinic for short stature. 
Endocrine investigations normal (including insulin stress test and 
usual parameters of pituitary function). Followed in Growth Clinic 
and growing parallel but below the 3rd centile for height. Family 
referred for genetic counselling from the Growth Clinic. Had 2 
cutaneous neurofibromas removed in 1980 for diagnostic purposes. 
I-1 and 1-2 - The family did not know who had been affected in 
generation I. No accurate details were available of age at or cause 
of death for either I-1 or 1-2. 
II-1 - Disease status uncertain. Said to have died of a "brain 
tumour", age unknown. 
11-2 - Reported normal 
11-3 - 29.12.15, died 64 years. Reported affected by family and 
confirmed via hospital records. At age of 12 years he had broken his 
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right leg, and as the fracture did not heal, had had an amputation 
(no more details available). Died from acute renal failure and a 
chest infection complicating treatment for a fractured left femur. 
11-4 - Reported normal. 
11-5 - 2.1.21,63.4 years. Housewife, SC: IIIM; secondary modern 
school education, no qualifications. 
4 CAL; freckling: axillae and collar-line; CNF: 4; face: no; LN: 13; 
GNF: 2; Ht: 141 (<3); HC: 54 (50) 
Accepted NF-1 as a "family problem" and never sought medical advice, 
other than for removal of a cutaneous neurofibroma on one occasion. 
Experienced pruritis over neurofibromas. 
11-6 - 16.2.23, died 32 years. 
Hospital records reviewed. Definite case of NF-1 with left sphenoid 
wing dysplasia. Presented at 32 years with 9 month history of 
headaches and increasing apathy. Investigation showed a right 
frontal tumour which was partially resected; histology was of a 
pyeloid astrocytoma. Died in post-operative period, no other lesions 
identified at autopsy. 
III-1 - 5.8.44,40 years. 
Examination of skin normal. Children reported normal. 
111-2 - Reported affected by sister. Said to "live like a hermit". 
Refused to be seen. 
111-3 - 22.11.44,39.5 years. Housewife; SC: III; secondary modern 
school education, no qualifications. 
7 CAL; freckling: axillae and neck-line; CNF: 3; face: no; LN: 100; 
GNF: 2; Ht: not available; HC: 54 (50) 
Unaware of exact cause of skin appearance until seen in genetics 
clinic with IV-4. Long-standing lower thoracic kyphoscoliosis not 
investigated until 1976 when presented with dyspnoea and chronic 
cough (heavy smoker). Radiology of spine had shown dysplastic 
vertebrae in area of curve, changes reported as being consistent with 
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NF-1. Chest x-ray showed bilateral emphysema with bullae on the 
right side. 
111-4 - 21.4.48, died at 7 years from Brights disease. Reported 
unaffected by mother. 
111-6,111-7,111-9, III-11 - These children had been adopted 
following their mother's death and no details were available through 
the family or the Cardiff adoption agencies. 111-6 was thought to 
have died in a road traffic accident. 
IV-3 - 16.6.63,20.9 years. On Youth Training Scheme; SC: IV; 
comprehensive school education, attained 1 CSE (grade 5) 
10 CAL; freckling: axillae and over trunk; CNF: 2; face: no; LN: 3; 
GNF: 1; Ht: 157 (3); HC: 57 (97). 
IV-5 - 29.3.70,14.1 years. 
Normal examination of skin and iris. 
IV-6 - 27.9.74,11.1 years. Attending comprehensive school, no 
educational problems. 
2 CAL (1 cm diameter) on examination. Slit lamp examination not 
performed. Classified normal. Ht: 147 (75). 
NF 13 
Family ascertained via III-1 and 111-2, from general hospital 
records. 
I 
III-1 - 19.5.23, died 54 years. 
III-1 had been a long-stay hospital patient in a unit for the 
mentally handicapped prior to his death. His hospital records 
document features of NF-1 and congenital hydrocephalus, cause 
uncertain. He was severely retarded and suffered from epilepsy. It 
is also documented he had kyphoscoliosis but no details are given. 
At the age of 54 he had an acute haematemasis and died despite 
resuscitative attempts, source of haemorrhage not established. 
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111-2 - 12.7.27,58.1 years. Former lift engineer on invalidity 
benefit from 1979; SC: IIIM; attended secondary modern school, no 
qualifications. 
7CAL; freckling: axillae and over trunk: CNF: 3; face: no; LN: not 
examined; GNF: 1; Ht: not appropriate; HC: 59.5 (> 57). 
Diagnosed in 1972 when presented with low back pain. Radiological 
examination had shown Paget's Disease involving the pelvis and 
femora, posterior scalloping of the lumbar vertebrae and compression 
fracture of T11 and 12. No active treatment undertaken and 
intermittent severe back pain since, unable to work because of this. 
No NF-1 related problems. 
II-1 - 14.2.02,83 years. Long-term patient in psychogeriatric unit. 
No details regarding education available. 
Limited examination: 5 CAL; freckling: axillae; CNF: 3; face: no; LN: 
not examined. 
Although 111-2 reported she was affected this had not been 
formally documented in hospital records prior to study assessment. 
She had senile dementia, a history of previous strokes, was immobile 
and confused. She had not had any NF-1 complications. Details of her 
family were obtained from 111-2, who thought his grandparents and 
mother's siblings were unaffected. The cause of death was known for 
11-4 and 11-5, these were tetanus and a road traffic accident 
respectively. 
Classified as a probable new mutation. 
111-3 - Living in New Zealand, reported normal 
NF 14 
Ascertained via III-1 and 111-2 who were referred both by their 
paediatrician and GP. They had been in foster care from the age of 7 
months because of social problems. Their mother (II-1) and her 
family lived outside the study area. 
III-1 - 19.12.74,10.8 years; schoolboy; SC: IV; remedial class 
education. 
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8 CAL >1.5 cm, 4 CAL >0.5 cm; freckling: axillae and groins; CNF: 2; 
face: no; LN: not examined; GNF: 2; Ht: not appropriate; HC: 51.5 
(25). 
III-1 and 111-2 have been under regular paediatric care from birth 
which was at 35 weeks' gestation and the diagnosis of NF-1 is 
mentioned in their notes from the age of 2 years. 
III-1 had been noted to have bowing of the right leg when he 
began walking at one year and was referred for orthopaedic assessment 
in 1977. X-rays showed marked bowing of both the lower tibia and 
fibula with cortical thickening and sclerosis of the medial aspect of 
the lower end of the tibia. The leg had been under observation with 
no active treatment and no change had occurred to the time of 
assessment. 
Pre-school psychological assessment (4 years 4 months) had shown 
an IQ of 87 and a mental age of 3 years 10 months. At the time of 
study assessment he was in a remedial class and having particular 
problems in reading and writing. 
111-2 - 19.12.74,10.8 years; schoolgirl; SC: IV; remedial class 
education. 
6 CAL >1.5 cm, 5 CAL >0.5 cm; freckling: axillae and groins; CNF: 2; 
LN: not examined; GNF: 1; Ht: 139.5 (97); HC: 50 (10). 
111-2 had a post-axial extra digit on her right hand which had been 
removed at birth. She had no NF-1 related problems apart from 
intellectual ones. Pre-school psychological assessment (4 years 4 
months) had shown an IQ of 79, mental age 3 years 7 months. She had 
experienced slightly more problems than her brother in reading and 
writing to the time of assessment. 
II-1 - 21.11.44,41 years. Catering assistant (unemployed); SC: IV; 
secondary modern school education, no qualifications. 
II-1 had not experienced any major NF-1 problems and had been 
diagnosed at the age of 15 years when the family became concerned 
about her appearance. She had a small plexiform neurofibroma, 
approx. 3 cm diameter on her right cheek. She also had very slight 
lateral bowing of her left leg, but did not want this X-rayed. 
Remainder of family - II-1 reported she was the only affected 
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individual in her own family. Her father, I-i, had died from right 
ventricular failure complicating chronic bronchitis and emphysema. 
NF 15 
II-1 and 11-2 were both ascertained by hospital records and 
individually referred by their plastic surgeon and GP respectively. 
Because of social problems, the children of I-1 had been in care or 
adopted from an early age. 
II-1 - 23.12.53,31.5 years. Cleaner (unemployed); SC: V; special 
school education, now literate and leading an independent life. 
16 CAL; freckling: axillae and over trunk; CNF: 3; face: yes; LN: not 
examined; GNF: 4; Ht: not measured; HC: not appropriate. 
II-1 had an extensive plexiform neurofibroma involving all branches 
of the right trigeminal nerve with relative sparing of the orbit; 
this had been present from birth. She had had a number of plastic 
surgical procedures but was still left with severe cosmetic problems 
and had taken an overdose because of this on one occasion. Her 
vision was unaffected. 
In 1981 she developed grand mal seizures which were well 
controlled on phenytoin. 
She had had 2 miscarriages and 2 stillbirths. Details of one of 
the latter were available, the foetus was macerated but no 
abnormalities found and chromosomes were normal. 
11-2 - 7.2.57,28.5 years. Gardener (unemployed); SC: IVM; special 
school education, now literate and leading independent life. 
16 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: 86; GNF: 
2; Ht: 170.2 (25); HC: 55.5 (75). 
Brought up in children's home from 4 years (as had been II-1). NF-1 
was formally diagnosed when he was being investigated for chest pain 
in 1980 (cause uncertain). 
On examination he had a plexiform neurofibroma of the left fourth 
finger with overgrowth of the finger and overlying CAL pigmentation. 
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C 
I-1 - 7.11.33, died 55 years. 
Reported affected by both II-1 and 11-2 independently. Only hospital 
records available from gynaecology reviews. She had had a total of 
14 pregnancies, only 4 of which had resulted in live births. There 
were no specific details about the remaining 10 in the notes. In 
1978 she presented with anorexia, abdominal pain and altered bowel 
habit. A grade 3 carcinoma of the cervix was found and treatment 
unsuccessful. There was no mention of NF-1 in her gynaecology notes. 
No details of her family are available. 
11-3 - 1.8.58,27.3 years. 
Normal cutaneous examination, children reported normal. 
11-4 - 19.6.60,25.6 years. Provisions assistant; SC: III; 
comprehensive school education, no qualifications. Adopted in early 
childhood. 
7 CAL; freckling: groins; CNF: 2; face: no; LN: 15; GNF: 1; Ht: 154 
(10); HC: 53.5 (25). 
Diagnosed secondary to study, no NF-1 related problems. Had had one 
mid-trimester miscarriage. 
II-5 - Lived outside study area, thought to be approximately 24 years 
old in 1985, reported normal by 11-4. 
III-1 - 2.9.84,0.9 years. Normal milestones to date of assessment. 
11 CAL >0.5 cm; 0 >1.5 cm; freckling: none; CNF: 1; face: no; LN: not 
examined; GNF: 1; length: 75 (50); HC: 44.9 (25). 
Diagnosed secondary to study. 
NF 16 
11-4 was referred to the study by her GP. 
11-4 - 5.9.01,83.7 years. 
She was seen at an old people's home where she had been resident for 
a number of years. She was demented, her medical and family history 
was largely supplied by the matron. She had had no major NF-1 
problems but at the time of assessment was under review for 
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post-menopausal bleeding. Her gynaecologist felt investigation was 
not justified and she was being treated empirically with progesterone 
and the bleeding had decreased in volume. The matron reported that 
she complained frequently of pruritis from her neurofibromas. 
On limited examination she had multiple cutaneous neurofibromas 
(grade 4) and axillary freckling. 
The matron said that relatives who visited the home reported no 
history of NF-1; she had asked this specifically in connection with 
my visit. 
Classified as a probable new mutation. 
NF 17 
II-1 and 111-2 were referred by their GP and also ascertained via 
hospital records. 
The other children of II-1 lived outside the study area and were 
visited during 1987 for the purpose of linkage studies (and were not 
used for any other analysis). 
II-1 - 4.2.05,80.4 years. Housewife; SC: IIIN; normal schooling, no 
qualifications. 
2 CAL; freckling: none; CNF: 4; face: no; LN: 20; GNF: 3; Ht: 154 
(10); HC: 55 (75) 
Diagnosed when 111-2 sought medical opinion in 1966. She had had a 
few cutaneous neurofibromas removed for cosmetic reasons and they 
were intermittently itchy. In 1982 she presented with a 2-year 
history of abdominal pain and altered bowel habit. Investigation 
showed a right abdominal mass and at laparotomy a pedunculated 
neurofibroma was found within the terminal small bowel, with a 
separate tumour in the wall of the small bowel proximally. A right 
hemicolectomy was performed and a segmental small bowel resection to 
remove the proximal tumour. Histology showed benign neurofibromas 
and in the wall of the resected bowel there was diffuse neuromatous 
overgrowth with areas of neurofibroma. She had no post-operative 
problems. 
Classified as a new mutation. 
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111-2 - 28.7.33,51.9 years. Never worked secondary to neurological 
problems; SC: IIIN; normal schooling, no qualifications. 
13 CAL; freckling: none; CNF: 3; face: yes; LN: 74; GNF: 3; Ht: 161.5 
(50); HC: 56 (90). 
NF-1 was diagnosed in 1966 when she presented with cutaneous 
neurofibromas, several of which were painful. 3 lesions were 
removed, histology showed benign neurofibromas. In 1984 she 
presented with colicky abdominal pain and investigation showed an 
abdominal mass. At laparotomy a large neurofibroma of the appendix 
was removed, a few smaller lesions on the serosal surface of the 
small bowel were noted. Complete resolution of symptoms post 
operatively. These were the only NF-1 related problems. 
Other medical problems 
(a) Multiple sclerosis - This had been diagnosed when she was 15 
years of age when she presented with an episode of diplopia and loss 
of use of her right arm and left leg. This had partially resolved 
and she had had intermittent relapses from that time. Her most 
recent neurological assessments (in 1979 and 1983) had found few 
objective clinical signs and considered some of her problems were 
functional. On examination for the study she had an intention tremor 
of the right arm, her legs were held stiff but reflexes were normal 
and her gait was ataxic but much worse when being observed. 
(b) Mitral valve prolapse - This was diagnosed in 1979 (on 
echocardiography) during an admission for assessment of (a); this was 
asymptomatic. 
(c) "Bizarre leiomyoblastoma" of uterus. She had had a hysterectomy 
for menorrhagia in 1973, histology showed uncomplicated fibroids and 
in addition one polyp which showed the above histological pattern. 
I-1 - Born 1892, died in 1922 from asthma. Reported normal. 
1-2 - Born in 1876, died in 1952 from carcinoma of the bowel. 
Reported normal. 
11-2-4 - They and their children reported normal. 
11-5 - Reported normal. Died at 23 years from congenital heart 
disease. 
11-6 - He and 2 children reported normal; 
accident. 
11-7 - He and 3 children reported normal; 
myocardial infarction. 
died at 34 years in an 
died at 80 years from 
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III-1 - 3.2.32, died aged 51 years. 
CAL spots noted by mother in early childhood and also a lesion on the 
left chin. She had a series of operations but was left with residual 
tissue; presumed plexiform neurofibroma. 
In 1972 she presented with paraesthesiae and weakness of the left 
arm and leg. Myelogram had shown several small filling defects in 
the upper cervical region. Decompressive laminectomy was performed 
at C1-7 and the lesions were neurofibromas. One small one was 
removed for histological confirmation. In 1982 her symptoms 
recurred, with progressive deterioration and a large neurofibroma was 
removed at C2. Post-operatively she developed obstructive 
hydrocephalus and a pseudomeningocoele in the scar. A 
ventriculoperitoneal shunt was inserted. One month later the 
pseudomeningocoele bulged again and was repaired, shortly after this 
operation she had a cardio-respiratory arrest after which, despite 
restoration of normal heart rhythm and respiration, she remained 
unconscious initially. Over the next weeks and months she showed 
some improvement to the extent of opening her eyes, but it did not 
appear that she had any comprehension. She eventually died in June 
1983. 
111-3 - 5.3.37,50 years 
Normal examination of skin. 
111-4 - 31.8.40,47.3 years 
Multiple CAL spots; freckling: none; CNF: 4; face: no. 
In 1966 had successful removal of a cervical neurofibroma at C2/3 
with complete resolution of neurological symptoms. No other NF-1 
related problems. 
IV-1 - 17.6.60,27.5 years. 
Multiple CAL spots; freckling: axillae, neckline, mammary region and 
groins; CNF: 3; face: no. 
IV-2 - 19.6.61,26.5 years 
Normal examination of skin. 
IV-3 - 8.12.62,24.3 years 
Normal examination of skin 
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IV-4 - 1.12.63. 
Reported normal 
IV-5 - 1.12.63,23.3 years. 
Multiple CAL; freckling: axillae; CNF: 3; face: no. 
IV-6 - 19.5.68,18.7 years 
Multiple CAL; freckling: axillae; CNF: 3; face: no. 
Congenital nystagmus and partially sighted, CT scan in the past had 
not shown evidence of an optic glioma; presumed to be unrelated to 
NF-1. 
IV-7 - 11.7.66,20.3 years 
Normal cutaneous examination. 
IV-8 - 19.5.68,18.5 years 
Multiple CAL; freckling: axillae and groins; CNF: 1; face: no; 
plexiform neurofibroma of right ankle. 
NF 18 
II-1 and III-1 were ascertained via hospital records, III-1 was also 
referred by her GP. 
II-1 - 22.2.12, died 63 years. 
On reviewing his records, NF-1 had been diagnosed incidentally during 
hospital review in 1945 (age 33 years). From 1970 he was 
hypertensive but this was well controlled; urinary VMAs were normal 
on one occasion. He suffered 3 strokes (in 1970,1974,1975) and 
died shortly after the last one. 
III-1 knew very little about her grandparents but thought her father 
was the first case of NF-1 in the family. II-1 was presumed to be a 
new mutation but excluded from analysis. 
III-1 - 4.11.38,46.6 years. Clerical Officer; SC: IIIN; grammar 
school education, no qualifications. 
16 CAL; freckling: axillae, submammary region and groins; CNF: 3; 
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face: no; LN: not examined; GNF: 1; Ht: 152.5 (3); HC: 53 (10). 
III-1 had been hypertensive for 10 years and was well controlled on 
atenolol 50 mg per day. She had been reviewed by a neurologist in 
1984 for paresthesiae in the right fifth finger, no significant 
abnormalities were found on examination or nerve conduction studies. 
Cervical spine x-ray showed spondylosis and it was felt that this was 
the cause of her symptoms. Her symptoms had persisted 
intermittently; neurological examination was normal when assessed for 
study. 
111-2 - 5.3.48,37.7 years. Home care aid; SC: IV; secondary modern 
school education, no qualifications. 
Normal examination of skin. Ht: 165.5 (75). Children reported 
normal. 
NF 19 
11-3 was ascertained via hospital records. 
11-3 - 31.8.47,37.8 years. Housewife (former cleaner); SC: IV; 
secondary modern school education, no qualifications. 
11 CAL; freckling: axillae and submammary regions; CNF: 4; face: no; 
LN: 25; GNF: 2; Ht: 156 (10); HC: 56.5 (97) 
Diagnosis had been made in her late teens and she had experienced no 
major problems. She had had several cutaneous neurofibromas removed 
when they became particularly large. 
On examination the only other abnormality was a right divergent 
squint with ipsilateral myopia, her fundi were normal. 
Classified as new mutation. 
I-1 - Birth date unknown, died aged 57 years; cause of death unknown. 
I-2 - Age unknown accurately (said to be "in her 70s"); 11-2 did not 
want her contacted. Reported normal. 
II-1 - Sister had lost touch with her brother 
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11-2 - Lived in Australia, no medical details. 
Despite the rather vague historical details, 11-3 was adamant that 
neither her parents nor siblings had NF-1. 
III-1 - 4.9.67,17.7 years. Warehouse assistant; SC: IV; 
comprehensive school education, no qualifications. 
Normal examination of skin. 
111-2 - 27.8.68,16.7 years. Unemployed since leaving school; SC: 
IV; comprehensive school education, no qualifications. 
1 CAL spot on examination, irides not examined. Classified normal. 
111-3 - 14.4.76,9.1 years. Schoolboy; SC: IV; attending primary 
school, no problems. 
6 CAL >1.5 cm; 4 CAL>0.5 cm; freckling: no; CNF: 1; face: no; LN: 10; 
GNF: 1; Ht: 123.5 (10); HC: 54 (25) 
His mother first noted one or two CAL spots at birth. Diagnosis was 
formally made in 1981 when he was referred to a paediatrician with an 
unrelated problem. He was under regular review to monitor for the 
development of complications of NF-1. The only other medical 
consultation had been for a right divergent squint which had been 
corrected surgically; when assessed for the eye study his eye 
movements, visual acuity and fundi were normal. 
NF 20 
Both II-1 and IV-1 were referred to the study by their GP; IV-1 was 
also referred by his paediatrician and ascertained via hospital 
records. 111-2 lived outside the study area and was examined in 1986 
for the purpose of linkage studies (not used in other analyses). 
II-1 - 31.8.20,64.8 years. Factory worker; SC: IV; normal 
schooling, no qualifications. 
4 CAL; freckling: axillae; CNF: 4; face: no; LN: 19; GNF: 1; Ht: 
164.5 (75); HC: 56 (90). 
II-1 had been diagnosed at approximately 35 years when she became 
worried about the appearance of her skin. She was on treatment for 
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hypertension which was well controlled. 
On examination she had a plexiform neurofibroma over the left elbow, 
6 cm in diameter. She also had slight conductive deafness in the 
left ear and a cataract in the right eye. 
Classified as a new mutation. 
IV-1 - 15.8.73,11.9 years. Schoolboy; SC: IIIM; attending remedial 
class at comprehensive school. 
17 CAL all >1.5 cm; freckling: axillae; CNF: 1; LN: 13; GNF: 4; 
Ht: 153 (50); HC: not appropriate. 
IV-1 had been diagnosed on the basis of multiple CAL spots at the age 
of 4 years. 2 years later he presented with right sided amblyopia 
(vision 6/60) and disc pallor. CT showed an enlarged chiasm and at 
craniotomy this was found to be due to an optic glioma (biopsy 
confirmed), the right optic nerve was also enlarged. The lesion was 
treated with radiotherapy, his vision improved thereafter and 
remained stable. Examination when assessed for the study (age 12 
years) showed bilateral optic atrophy with 6/12 vision in the right 
and 6/24 in the left eye. 
I-1 - Died 75 years, cause unknown. Reported normal. 
I-2 - 13.6.1896, died 87 years, after fracturing a femur. Reported 
normal. 
11-2 - Died in infancy, cause unknown. 
III-1 - 25.8.44,40.9 years. State enrolled nurse; SC: II; secondary 
modern school education with no qualifications on leaving school but 
had then completed nursing course. 
3 CAL; freckling: submammary region; CNF: 4; face: no; GNF: 2; Ht: 
162 (50); HC: 56.5 (97). 
Had one cutaneous neurofibroma removed while training and diagnosed 
at that time. 
111-2 - 11.8.47,39.5 years. 
Normal cutaneous examination. 
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IV-2 - 22.3.76,9.3 years. Schoolgirl; SC: IIIM; attending primary 
school, no problems. 
6 CAL >1.5 cm; 3 >0.5 cm; freckling: axillae; CNF: 2; face: no; LN: 
12; GNF: 3; Ht: 138 (90); HC: 54.5 (97). 
CAL spots were noted from birth, formal diagnosis made when brother 
had eye problems and a plexiform neurofibroma of the left ankle also 
noted. 
On examination at the time of the study, this was a diffuse swelling 
round the medial aspect of the ankle. Her left foreleg was 2 cm 
longer than the right and her left foot one shoe size larger. 
IV-3 - 18.10.77,7.7 years. Schoolboy; SC: IIIM; attending primary 
school, no problems. 
Normal examination of skin; Ht: 132 (90). 
NF 21 
IV-3 was referred to the study by his GP and ascertained through 
hospital records. 
11-2 and IV-1 lived outside the study area, in Mid-Glamorgan. 
IV-3 - 30.8.68,16.7 years. Shop assistant; SC: IV; comprehensive 
school education, no qualifications. 
30 CAL; freckling: axillae; CNF: 2; face: no; LN: 12; GNF: 1; Ht: 
180.5 (75); HC: 58.5 (>97). 
CAL spots had been obvious from birth and the diagnosis made by the 
GP. At the age of 10 years he had been investigated by a 
neurosurgeon for episodic low back pain; there were no neurological 
signs on examination and myelogram was normal. The pain had resolved 
with no active treatment. He had a neurofibroma removed from his 
left posterior tibial nerve and four lesions from his left median 
nerve at the age of 15 years, with no residual neurological deficit. 
At the time of study he had no NF-1 related problems although a deep 
neurofibroma was noted proximal to the scar on his left arm. 
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Details of generation I and II were obtained from III-2: - 
I-1 - Age at and cause of death unknown; uncertain whether he had any 
NF-1 features. 
I-2 - Died 75 years, cause unknown; reported normal. 
II-1 - Reported normal; did not reply to letter about the study. 
11-2 - Died 70+ years from carcinoma (site unknown). He and son 
reported normal. 
11-3 - Died 70+ years from carcinoma of lung. He and children 
reported normal. 
11-4 - Died from tuberculosis, he and children reported normal. 
11-5 - 17.6.05, died 70 years from bronchial pneumonia; also had 
chronic bronchitis and rheumatoid arthritis. Reported affected by 
family, this was confirmed on reviewing hospital records. 
III-1 - 17.2.36, died 43 years from carcinoma of breast. Reported 
affected by family, confirmed from hospital notes; had had several 
cutaneous neurofibromas removed but no other NF-1 related problems. 
111-2 - 3.4.30,55.5 years. 
Normal cutaneous examination. 
IV-1 - 26.5.63,32.3 years. Housewife; SC: IVM; remedial class at 
primary school only; no qualifications. 
20 CAL; freckling: axillae, groins, submammary regions; CNF: 3; face: 
no; LN: 8; Ht: 167 (75); HC: 56 (90). 
Had had 2 cutaneous neurofibromas removed for cosmetic reasons, no 
other problems. 
IV-2 - 22.8.64,20.7 years. Secretary; SC: IIIN; comprehensive 
school education; obtained '0' level passes in several subjects and 
completed a secretarial course on leaving school. 
14 CAL; freckling: axillae, submammary region and groins; CNF: 2; 
face: no; LN: 8; GNF: 2; Ht: 153 (10); HC: 54.5 (50). 
Had orthopaedic review at the age of 14 years because of a diffuse 
swelling over the medial aspect of the left foot. This had been 
partially excised and histology was of a plexiform neurofibroma. On 
examination for the study there was residual diffuse swelling under 
the scar but this was asymptomatic. 
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V-1- 18.12.83,1.8 years. Normal developmental milestones. 
3 CAL >1.5 cm; 10 >0.5 cm; CNF: 1; face: no; LN: not examined; Ht: 82 
(50); HC: 48 (75). 
V-2 - 15.5.85,0.25 years. 
Normal cutaneous examination. 
NF 22 
II-1 was referred to the study by his GP and ascertained through 
hospital records. 
II-1 - 13.9.18,66.7 years. Retired steel worker; SC: IV; secondary 
modern school education, no qualifications. 
0 CAL; freckling: axillae; CNF: 5; face: yes; LN: not examined; GNF: 
3; Ht: 157.5 (<3); HC: 59.5 (>97) 
NF-1 had been diagnosed when in hospital for an unrelated problem at 
the age of 22 years. He had no NF-1 related complications but 
experienced pruritis from his neurofibromas and was acutely 
embarrassed by his appearance. 
In 1981 (aged 63) had presented with a bloody discharge from his 
right nipple associated with a breast lump. Investigation showed an 
intraduct invasive carcinoma of the breast and a Halstead mastectomy 
was performed; the axillary nodes were involved. He had had a local 
recurrence in 1982 and was treated with tamoxifen with some success, 
but it recurred 6 months later and radiotherapy was undertaken. He 
had then been well until 1985 but at the time of assessment he was 
having treatment for lung secondaries. 
Unable to classify regarding NF-1 inheritance. 
I-1 - No details as had left home when II-1 was very young. 
11-2 - Died 80+ years, cause unknown. Reported normal. No history of 
NF-1 in her extended family. 
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NF 23 
11-2 was referred to the study by his GP. 
11-2 - 24.5.52,33.2 years. Severe mentally retarded, never worked; 
special school education. 
Multiple CAL spots (unable to count); freckling: axillae; CNF: 4; 
face: no; LN: present but unable to count; GNF: 4; Ht: not measured; 
HC: 59 (>97). 
11-2 had been noted to have CAL spots from the age of one year and 
cutaneous neurofibroma from 3 years. He had severely delayed 
developmental milestones and was assessed by a paediatrician at the 
age of 3 years when the diagnosis of NF-1 complicated by severe 
retardation was made. There was no suggestion of other causative 
factors in the perinatal history. No radiological investigations 
were undertaken and 11-2 had not been under regular hospital review 
from that time. He had attended a special school but since leaving, 
apart from a short period of attendance at an Adult Training Centre, 
had been at home. 
On assessment for the study he was severely retarded, mental age 
being subjectively assessed at 2 years. He had a large 
dolicocephalic skull with posteriorly rotated ears but no other 
dysmorphic features. He had a plexiform neurofibroma, 4 cm in 
diameter, in the right lumber region and he walked with a clumsy 
ataxic gait, but detailed neurological examination was impossible. 
It was felt that his mental retardation was particularly severe 
for NF-1 but investigations to rule out underlying CNS abnormalities 
would be of academic interest only. Chromosome analysis on him and 
his parents was normal. 
Classified as a new mutation of NF-1. 
I-1 - 6.8.19,66 years. Retired Tax Inspector; SC: II. 
Normal cutaneous examination. Extended family reported normal. 
I-2 - 12.5.23,61.3 years. Housewife. Normal cutaneous examination. 
Extended family reported normal. 
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II-1 - 15.2.49. 
II-1 was reported normal; he lived in Canada where he worked as an 
anaesthetist. Neither of his children were reported as having 
futures suggestive of NF-1. 
NF 24 
111-5, who lived in the study area, was referred to the study by her 
GP. Although she supplied the pedigree details she refused contact 
to be made with the family. Her son, IV-1, had been adopted by 111-3 
who responded to the newspaper article about the study and was seen 
although she lived outside the study area. 
111-5 - 6.10.46,38.9 years. Moderately retarded, had never worked; 
special school education had been recommended to the family but 
refused and she had attended a secondary modern school; for analysis 
she has been classified as attending a special school because of her 
low intellectual level at assessment. 
16 CAL; freckling: groins; CNF: 4; face: no; LN: 30; GNF: 3; Ht: 
157.5 (25); HC: 56 (90). 
From her sister it was apparent that the family had been aware of the 
diagnosis since childhood but her parents unable to accept her 
intellectual problems. 111-5 was illiterate, extremely anxious and 
her husband answered most of the questions on her behalf. She had 
had a cutaneous neurofibroma removed for cosmetic reasons but no 
other NF-1 problems. At the time of assessment she had had a recent 
onset of deafness in the right ear with discharge; on examination the 
deafness appeared to be a conductive loss but she failed to attend 
for an ENT assessment that had been arranged by her GP. 
111-3 - 6.12.35,50 years. 
Normal cutaneous examination. Ht: 161.9 (50). 
111-3 supplied the remaining family details. 
I-1 and 1-2 - No details available. Disease status unknown. 
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II-1 - 26.3.01, died 48 years. Reported as definitely affected with 
numerous cutaneous neurfibromas but no other health problem before a 
fatal subarachnoid haemorrhage. She had a post-mortem and her death 
certificate states subarachnoid haemorrhage secondary to 
hypertension, atherosclerosis was given as a secondary problem. No 
records were available to see whether the hypertension was a 
long-standing problem or whether it had been investigated. 
III-1 - Died in infancy secondary to convulsions. 
111-2 - 7.1.33. Reported normal by 111-3. Lived in the study area 
but not contacted. 
111-4 - Born 1951, died 19 years. 
111-4 had no known medical problems until she presented at 19 years 
with increasing headache and ataxia. Air encephalogram showed 
obstructive hydrocephalus and a possible filling defect on the left 
side of the fourth ventricle. A subtotal resection of a left 
cerebellar astrocytoma was performed following a shunting operation. 
She died 2 weeks later of bronchial pneumonia. No mention of CAL 
spots in her neurosurgical notes and her sister did not know whether 
she had any NF-1 features, therefore classified as diagnosis 
uncertain. 
IV-1 - 19.5.79,6.5 years. Schoolboy attending a remedial class. 
17 CAL >1.5 cm; 14 >0.5 cm; CNF: 1; face: no; LN: not examined; Ht: 
111.6 (10); HC: 53 (75). 
IV-1 had been cared for by his aunt since infancy as his parents 
could not cope. He had not been formally diagnosed until seen for 
the study. He had an educational assessment at 6 years 1 month and 
on the Wechsler Intelligence Scale showed verbal IQ 94, performance 
IQ 68 and full-scale IQ 79. 
NF 25 
II-8 was ascertained by hospital records. 
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11-8 - 19.11.30,54.6 years. Former cleaner on invalidity benefit 
because of asthma; SC: V; secondary modern school education, no 
qualifications. 
6 CAL; freckling: axillae; CNF: 3; face: no; LN: not examined; GNF: 
1; Ht: 155 (10); HC: 54 (50). 
11-8 had had recurrent hospital admissions for severe asthma since 
childhood. NF-1 had been diagnosed clinically at 39 years and a 
cutaneous neurofibroma removed for confirmation. II-8 thought NF-1 
was "just a skin problem" and was unaware of its complications or 
inheritance. 
Classified as new mutation. 
I-1 - Born 1885 (approximately), died 60 years from a myocardial 
infarction. Reported normal. 
I-2 - Born 1896, died 69 years from carcinoma of the colon. Reported 
normal. 
II-1-7,9 - 11-8 was adamant she was the only affected member in her 
sibship and was not keen for her sibs to be contacted. 
11-5 had died from a myocardial infarction at 40 years of age. 
III-1 - 9.9.58,26.9 years. Data control supervisor; SC: IIIN; 
comprehensive school education; attained several CSE and one '0' 
level pass. 
Normal cutaneous examination; Ht: 155.5 (10). 
111-2 - 16.6.63,22 years; receptionist; SC: IV; comprehensive school 
education, obtained several CSE passes. 
16 CAL; freckling: axillae; CNF: 2; face: no; LN: not examined; GNF: 
1; Ht: 155 (10); HC: 55 (75). 
Multiple CAL spots had been noted by mother in infancy. Formal 
diagnosis of NF-1 was not made until she was seen for the study. 
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NF 26 
Ascertained by II-1 who was referred by his GP and identified through 
the hospital records system. 
II-1 - 8.2.48,37.3 years. Heating fitter (unemployed); SC: IV; 
secondary modern school education, no qualifications. 
2 CAL; freckling: no; CNF: 4; face: no; LN: 2; GNF: 3; Ht: not 
appropriate; HC: 58 (>97). 
The diagnosis of NF-1 had been made at 4 years when he was referred 
to an orthopaedic surgeon with swelling of the left ankle, this was a 
plexiform neurofibroma. He had three operations for removal of this 
during childhood but was still left with residual tissue and 
overgrowth of the left leg; he had epiphyseal plating at the knee to 
prevent further growth at the age of 16 years. On examination for 
the study he had an extensive lesion involving most of his foreleg 
with overlying skin pigmentation, there was a further area of 
involvement just below the groin; his left leg was 4 cm longer than 
the right. The leg swelled during the day and slowed his walking 
pace slightly. He had 5 cutaneous fibromas removed for cosmetic 
reasons in 1978. 
His other medical problems were apparently unrelated to NF-1. In 
1978 he was involved in a road traffic accident and although he 
retained consciousness, had severe facial injury (no notes available 
but right temporal skull fracture from history) requiring 
neurosurgical treatment. In 1980 he developed complex partial 
seizures and CT showed an area of low density in the right frontal 
region; the appearance was thought to be compatible with an area of 
previous infarction. His seizures were reasonably controlled on 
phenytoin. A repeat scan at time of the study showed no alteration 
in findings and lesion presumed to be unrelated to NF-1. 
Classified as new mutation. 
I-i - 18.6.23, died 58 years as a result of an industrial accident. 
Reported normal by 1-2. 
I-2 - 8.6.20,65 years. Normal cutaneous examination. 
11-2 and 11-3 - 27.6.50 and 3.9.52 respectively. They and their 
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children reported normal by 1-2 who was reluctant for them to be 
contacted for the study. 
NF 27 
II-1 was referred to the study by his GP. 
II-1 - 20.10.21,64.1 years. Retired grocer; SC: III; attended 
elementary school, no qualifications. 
13 CAL; freckling: axillae and groins; CNF: 4; face: yes; LN: 
present, not counted; GNF: 3; Ht: 158 (<3); HC: 58 (>97). 
From the time of his parents' death, II-1 had been unable to cope 
with the family business which had been sold and he lived as a 
semi-recluse from then. The family history was supplied by 11-2 as 
the propositus was a rather vague historian. The family were aware 
of the diagnosis in II-1 from childhood, the GP having made the 
diagnosis. He had had no major NF-1 problems and had only had 1 
cutaneous neurofibroma removed from his scalp. He had avoided 
sporting activities because of his appearance. 
Classified as a new mutation. 
I-1 - 10.1.92, died 86 years from chronic chest disease (pathogenesis 
uncertain). Reported normal. 
I-2 - 19.10.92, died 83 years from heart failure. Reported normal. 
There was no history of NF-1 in the extended families of I-1 and 1-2. 
111-2 - 25.6.25,60.3 years. Hotelier; SC: II. 
Interviewed, not examined; no abnormality reported in himself or 
children. 




11-2 was ascertained via the Dermatology Histology Index. 
11-2 - 10.6.59,26.3 years. Shop assistant; SC: IV; comprehensive 
school education, obtained several CSE passes. 
6 CAL; freckling: groins; CNF: 3; face: no; LN: 12; GNF: 1; Ht: 154 
(10); HC: 53 (10). 
Diagnosis of NF-1 had been made at 22 years when referred to a 
dermatologist. Four cutaneous neurofibromas had been removed. 11-2 
had no idea of the genetic implications of NF-1 or its complications. 
Classified as new mutation. 
I-1 - 4.6.34,51.4 years. Normal examination of skin and iris. No 
history of NF-1 in extended family. 
I-2 - 25.12.31,53.8 years. Normal examination of skin and iris. No 
history of NF-1 in extended family. 
II-1-3,6 - The siblings of 11-2 were reported normal. 
III-1 - 23.12.79,5.8 years. Schoolboy; no developmental or 
intellectual problems to date. 
7 CAL >1.5 cm; 4 >0.5 cm; freckling: none; CNF: 1; face: no; LN: 
examination not possible; GNF: 2; Ht: 115 (10); HC: 52 (50). 
III-1 was diagnosed secondary to the study. On examination he had a 
small plexiform neurofibroma with overlying pigmentation on his right 
forearm. 
111-2 - 7.9.85,0.1 years. 
One possible CAL spot noted on anterior chest, classified as 
equivocal. 
NF 29 
II-1 was referred by her GP, 111-3 ascertained via hospital records 
and IV-1 and 2 by their paediatrician. 
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II-1 - 6.2.32,53.8 years. Housewife; SC: IVM; no details of type of 
school attended available. Her husband reported she had been kept 
away from school much of the time as a child; on subjective 
assessment she was illiterate but had coped with bringing up her 
family reasonably well - for the purpose of analysis she was 
classified as requiring special school education but minimally 
retarded. 
12 CAL; freckling: axillae and groins; CNF: 4; face: no; LN: not 
examined; GNF: 4; Ht: 152 (3); HC 53.5 (25). 
At the time of assessment, II-1 was a hospital in-patient and much of 
the history was supplied by her husband. She had cutaneous 
neurofibromas from the time he knew her but her only medical problem 
prior to the 1985 admission had been grand mal epilepsy which she 
developed in her early 20s. This had not been investigated and she 
was well controlled on phenytoin. On examination for the study, the 
only other NF-1 related finding on her skin was a plexiform 
neurofibroma in the left groin, approximately 15 cm in diameter. 
In August 1985 she had presented with symptoms and signs of small 
bowel obstruction. At emergency laparotomy an ileocolic 
intussusception was found and right hemicolectomy performed. She had 
a stormy post-operative period with several hypertensive crises and 
investigation showed bilateral phaeochromocytomas. Bilateral 
adrenalectomy was subsequently performed and a peri-ampullary 
carcinoid lesion was identified and removed at the same time (this 
had been specifically looked for in view of the known association). 
She was eventually discharged on 18th December but was readmitted 
later in the same month with a urinary tract infection. She was 
responding satisfactorily to antibiotics and steroids, then had a 
cardiac arrest from which she could not be resuscitated. The cause 
of death at coroner's post mortem was given as coronary artery 
disease. 
Unable to classify regarding inheritance of NF-1. 
111-3 - 22.3.57, died 23 years from neurofibrosarcoma. 
111-3 had no NF-1 related problems until she presented with severe 
pain secondary to a large paraspinal mass in the lumbar region at the 
age of 23 years. A myelogram was normal. The mass was removed and 
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histology showed a neurofibrosarcoma. She had a cause of palliative 
radiotherapy but died six months later from complications of tumour 
involvement of the spinal cord. 
IV-2 and IV-3 had been in foster care for most of their life as 2 
years after their mother's death their father committed suicide. 
IV-2 - 12.2.78,7.7 years. Schoolboy, attending remedial class. 
13 CAL >1.5 cm; 14 >0.5 cm; CNF: 1; face: no; LN: not examined; GNF: 
2; Ht: 116.5 (10); HC: 52.5 (50). 
Diagnosed in early childhood on the basis of multiple CAL spots and 
under regular paediatric follow-up. No NF-1 related problems other 
than in schooling. 
IV-3 - 14.11.79,5.9 years. Schoolboy, attending remedial class. 
7 CAL >1.5 cm; 4 CAL >0.5 cm; CNF: 1; face: no; LN: unable to 
examine; GNF: 2; Ht: 112.5 (25); HC: 53 (75). 
Diagnosis of NF-1 had been made at 1 year on the basis of multiple 
CAL spots and he had been under paediatric care from that time. A 
recurring problem was of diarrhoea with intermittent abdominal pain 
for which no cause had been identified (including investigations to 
exclude a duodenal carcinoid). On examination he had a small 3 cm 
diameter plexiform neurofibroma under the left nipple. 
1-1,1-2,11-2-5 - The husband of II-1 thought that 11-4 was possibly 
affected but did not know any details regarding his parents-in-law. 
They had lost touch with the parents and siblings of II-1. 
III-1 - Died at approximately 6 years after falling into a fire. Her 
father did not remember her having CAL spots. 
111-2 - 12.7.53,32.2 years. Comprehensive school education, no 
qualifications. Normal cutaneous examination. 
111-4 - 27.11.58,26 years. Comprehensive school education, no 
qualifications. Normal cutaneous examination. 
III-5 - 8.12.59,25 years. Comprehensive school education, no 
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qualifications. Normal cutaneous examination. 
IV-1 - 26.5.74, in foster care in West Wales and under regular 
paediatric review. No features of NF-1 reported to be present by her 
consultant. 
NF 30 
IV-1 was referred to the study by her GP and consultant 
dermatologist. 
IV-1 - 13.3.64,21.5 years. Nursing auxiliary; SC: II; comprehensive 
school education, obtained several CSE passes. 
10 CAL; freckling: none; CNF: 3; face: no; LN: not examined; GNF: 4; 
Ht: 152.4 (10); HC: not appropriate. 
Her mother had noted multiple CAL spots as a baby but not been aware 
of their implication until IV-3 presented with scoliosis and was 
diagnosed. 
IV-1 had no problems until she presented for neurological 
investigation following 2 grand mal fits (aged 17 years). She had 
also complained of occasional mild headaches which had been more 
frequent in the previous six months. On investigation her multiple 
CAL spots were noted, skull x-ray showed evidence of chronically 
raised intracranial pressure and CT severe hydrocephalus of the 
lateral and third ventricles with normal sized fourth ventricle. 
Diagnosis of aqueduct stenosis complicating NF-1 was made. A 
ventriculo-peritoneal shunt was inserted and from that time she had 
had no fits or headaches. She had no other NF-1 related problems and 
was 17 weeks into her first pregnancy at the time of assessment. 
I-1 and 1-2 - Both died at 80+ years, cause unknown. Not thought to 
be affected. 
II-1 - Age at and cause of death unknown. Reported normal. 
11-2 - 13.3.01. Died 82 years of bronchopneumonia, had senile 
dementia. Reported affected by family and "covered in lumps". No 
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mention of NF-i in geriatric notes. 
III-1 - 14.7.34,51.3 years. Shop cashier; SC: IIIN; secondary 
modern school education, no qualifications. 
Face: yes; GNF: 3; Ht: 164 (10); HC: 58 (>97). 
III-1 refused examination saying "it's obvious from my face what's 
wrong .... ". He had about 40 cutaneous neurofibromas on his face and 
his only worry regarding NF-1 was his cosmetic effect. He had never 
sought medical advice about the disease. 
111-2 - 26.11.38,46.8 years. Nursing auxiliary; SC: II; grammar 
school education, obtained school certificate. Lived outside study 
area. 
10 CAL; freckling: none; CNF: 4; face: no; LN: not examined; Ht: 154 
(10); HC: 56 (90). 
Vaguely aware of diagnosis from childhood; diagnosis was made 
formally when IV-3 presented with scoliosis. When she became 
pregnant after this she had a termination because of the risk of NF-1 
to the foetus. 
111-3 - 28.1.41,44.7 years. Long-distance lorry-driver; SC: IIIM; 
secondary modern school education, no qualifications. 
Normal cutaneous examination; Ht: 165 (10). 
IV-2 - 8.4.66. Reported normal, lived outside study area. 
IV-3 - 15.9.68,16.1 years. On Youth Training Scheme; comprehensive 
school education, no qualfications. Recently moved to live with 
III-1. 
7 CAL; freckling: none; CNF: 3; face: no; LN: not examined; GNF: 3; 
Ht: not appropriate; HC: 56 (75). 
CAL spots had been noted by his mother at one year. From 10 years he 
experienced intermittent pain over the thoracic spine and a scoliosis 
developed. On orthopaedic assessment at 12 years he was found to 
have "a short sharp 85° right thoracic scoliosis", with a trapezoid 
shape vertical body at its apex. He had no neurological signs, a 
myelogram showed narrowing of the canal at the apex of the curve and 
bow stringing of the cord across the convexity of the apex. He was 
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initially treated with bracing and at 15 years had a spinal fusion in 
situ, no attempt being made to improve the curve because of the risk 
of neurological damage. Apart from occasional pain, he had no 
problems following surgery, but had a marked residual kyphoscoliosis. 
On examination the only other feature was a6 cm diameter 
plexiform neurofibroma with overlying skin hypertrophy over the 
sacrum. 
NF 31 
11-4 was referred to the study by his GP and ascertained via hospital 
records. 
11-4 - 19.9.56,28.9 years. Barman/cook; SC: IV; secondary modern 
school education, no qualifications. 
7 CAL; freckling: none; CNF: 4; face: no; LN: 12; GNF: 4; Ht: 169.3 
(25); HC: 61 (>97) 
Although his mother was aware of multiple CAL spots from early 
childhood he did not come to medical attention until he presented at 
the age of 20 years with enlargement and pain of several subcutaneous 
lesions on his right arm. Diagnosis of NF-1 was made and 4 
neurofibromas removed from the medial cutaneous nerve of the arm. 
During this admission his blood pressure was noted to be 210/140, 
with grade II hypertensive retinopathy. Investigation of this showed 
a left renal artery stenosis on arteriogram. He was conservatively 
treated for 2 years but as his blood pressure was difficult to 
control, was re-investigated in 1978 and a 50% stenosis demonstrated; 
he had successful saphenous vein bypassing of the left renal artery 
and required no anti-hypertensive medication post-operatively. 
In 1984 he had a painful neurofibroma removed from his left 
posterior interosseous nerve with damage to the nerve; this was 
partially corrected by a subsequent tendon transfer. On examination 
for the study he had grade IV power in the finger and wrist 
extensors. 
Classified as new mutation. 
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I-1 - 18.9.21,64 years. 
Normal cutaneous examination. No history of NF-1 in extended family. 
I-2 - 26.11.21,63.8 years. 
Normal cutaneous examination. No history of NF-1 in extended family. 
II-1-3 - They and their children reported normal by parents. 
NF 32 
11-2 was referred to the study by her GP. 
11-2 - 8.7.72,12.9 years. Schoolgirl attending special school. 
13 CAL >1.5 cm; 9 >0.5 cm; freckling: axillae; CNF: 2; face: no; LN: 
not examined; GNF: 3; Ht: 138.5 (<3); HC: 55 (90). 
11-2 had delayed milestones in early childhood, her speech being 
particularly slow in developing and attended a special school from 5 
years. The diagnosis of NF-1 was made at 10 years when she was 
referred to a paediatrician because of a swelling on her left wrist. 
Multiple CAL spots were noted with 1 hypopigmented patch; a soft, 
poorly-defined swelling on the left radius was noted, bones 
underlying being normal on x-ray and a diagnosis of NF-1 with a 
plexiform neurofibroma made. No investigation into other causes of 
retardation were undertaken. 
On examination for the study, the left wrist lesion was 
approximately 6 cm in diameter with overlying hypertrophy and CAL 
pigmentation; she had a second plexiform lesion on the left thigh 
anteriorally with overlying skin hypertrophy and hypertrichosis. Her 
speech was very slow and her gait clumsy but with no local 
neurological signs.. She was classified as moderately retarded on 
subjective assessment. 
Classified as new mutation. 
I-1 - 31.1.46,39.5 years. 
Normal cutaneous examination. No history of NF-1 in extended family 
of him or his wife. 
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I-2 - 5.1.50,35.6 years. 
Normal cutaneous examination. She had miscarriages in 2 pregnancies 
at 3 months and 5 months, for which there had been no obvious cause. 
II-1 - Had been born prematurely at six months' gestation and died at 
18 hours. 
11-3 - 22.9.78,7.2 years. 
On cutaneous examination had no CAL spots but one area of patchy 
coffee-coloured pigmentation over the fourth and fifth toes of the 
left foot. Classified normal. Ht: 116 (25). 
11-3 had bilateral club feet at birth requiring several corrective 
operations. He had delayed milestones and attended a special school 
but had had no investigations for his retardation. 
NF 33 
IV-4 was referred by his GP and ascertained via orthopaedic records. 
IV-4 - 23.6.59,26.1 years. Cook/waiter; SC: IV; comprehensive school 
education, no qualifications. 
17 CAL; freckling: axillae and groins; CNF: 2; face: no; LN: 43; GNF: 
3; Ht: not appropriate; HC: 59 (>57). 
His mother said that he had multiple CAL spots from the first year of 
life but the diagnosis was not made formally until he was referred 
for investigation of nocturnal enuresis in 1974. An IVP showed a 
thoracic scoliosis but no other abnormality. The scoliosis 
progressed and he was referred for orthopaedic assessment in June 
1975 (aged 16 years); he had a right thoracic scoliosis T8-12,66°, 
with no underlying bony abnormality. This progressed to 95° by May 
1976 and in July he had a posterior spinal fusion. The curve was 
corrected to 56° and has remained stable since. No other NF-1 
problems. 
The family history was mainly supplied by 111-2 on telephone 
interview as she lived outside the study area. 
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I-1,1-2,11-2-7 - No accurate details available but not thought to 
have had NF-1. 
II-1 - 20.4.09, died 66 years from myocardial infarction. Reported 
as definitely affected by 111-2. No known NF-1 complications. 
III-1 - 22.8.31. 
Lives in Norway. Reported normal. 
111-2 - 9.2.35, died 49 years from lung cancer. Emigrated to USA. 
Reported definitely affected with no NF-1 complications. 
111-3 - 20.12.36. Interviewed on telephone. Reported CAL spots from 
childhood and cutaneous neurof ibromas from 12 years. Reviewing her 
hospital notes, she had been formally diagnosed by a dermatologist 
(aged 33 years) when she had had 3 cutaneous lesions removed. She 
reported no NF-1 complications. 
IV-1 - Reported affected by aunt, said to have NF-1 with a related 
problem "with one of his legs". 
IV-2 - Reported normal. 
IV-3 - 1.4.57,28.4 years. Shop assistant; SC: IV; comprehensive 
school education, no qualifications. 
Normal cutaneous examination. 
IV-5 - 10.1.65,20.8 years. Medical student; SC: I; comprehensive 
school education, attained 3 'A' level passes. 
1 CAL spot on cutaneous examination; classified normal. 
V-1 - 23.10.78,6.9 years. 




111-3 was referred by her GP and ophthalmologist. 
111-3 - 3.3.67,18.7 years. School cleaner; SC: V; comprehensive 
school education, no qualifications. 
111-3 answered the study questionnaire but refused full clinical 
examination, the only recordings were face: no; LN: 4; GNF: 3; Ht: 
166.3 (75); HC: 60.5 (>97). 
111-3 had presented to an ophthalmologist at 2.5 years with left 
buphthalmos and goniotomy was performed. Despite this, the 
intraocular pressure remained elevated and she had 3 further 
goniotomies within the next 3 years but the pressure gradually rose 
after each procedure and her vision began to deteriorate. She was 
referred to Moorfields Eye Hospital for a second opinion when her 
multiple CAL spots and family history were noted; the left disc was 
pale with a large cup and the iris flat and featureless. On the 
nasal angle of the eye there were signs of the previous operations 
but on the temple side of the iris the trabecular meshwork was 
covered by a network of pigment. It was felt that this represented a 
congenital anomaly like that seen in cases of NF-1 complicated by 
glaucoma. Conservative treatment was advised with cyclocryotherapy 
if further operations were necessary. The latter was performed in 
1979 and her pressure had been normal from then although her vision 
remained reduced at 2/60. 
111-3 had no other NF-1 related problems. 
The family details were supplied by 11-3. 
I-1 - Born 1896, died 83 years, cause unknown; reported normal. 
I-2 - Born 1896, died 88 years, cause unknown; reported normal. 
II-1 - Date of birth unknown. Lived outsided study area, reported 
normal. 
11-2 - 2.9.21. Lived in Cardiff but family unkeen for her to be 
contacted. Reported normal. 
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11-3 - 25.7.23,62.3 years. Signalman; SC: IIIM; elementary school 
education, no qualifications. 
2 CAL; freckling: none; CNF: 5; face: yes; LN: 13; GNF: 3; Ht: 162.2 
(3); HC: 60.5 (>97). 
11-3 knew that he had NF-1 but was not aware of its implications 
until seen for the study. He had been aware of CAL spots and 2 large 
masses (plexiform neurofibromas on examination) since childhood, one 
on his neck and one just below his right breast. He had had the neck 
lesion partially excised at 19 years (no records available). 
Cutaneous neurofibromas had begun to appear at 13 years. 
On examination for the study he had a scar over the posterior 
aspect of his neck with diffuse underlying swelling and the lesion on 
his chest was approximately 10 cm in diameter with overlying skin 
hypertrophy. 
Classified as new mutation. 
III-1 - 6.5.58,27.5 years. State Enrolled Nurse; SC: II; 
comprehensive school education; obtained several '0' level passes. 
III-1 lived just outside the study area. Cutaneous examination was 
normal; Ht: 167 (75). 
111-2 - 23.8.62. Reported normal by his father; lived in the study 
area but did not reply to letter about the study. 
NF 35 
11-3 was ascertained via hospital records. 
11-3 - 2.3.59,26.7 years. Office clerk; SC: IIIN; comprehensive 
school education, no qualifications. 
15 CAL; freckling: axillae; CNF: 3; face: no; LN: 35; GNF: 1; Ht: 
160.5 (50); HC: 54 (50). 
The diagnosis had first been made when her mother sought paediatric 
review because of multiple CAL spots. She was told the name of the 
disease and reassured it was not a cause for major worry; no 
follow-up was arranged. In 1978 11-3 had 2 cutaneous neurofibromas 
removed because of their unsightly appearance but had no other NF-1 
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problems. She was 4 months pregnant at the time of assessment and 
unaware of the inheritance of NF-i. 
Classified as new mutation. 
I-1 - 23.6.34,51.4 years 
Normal cutaneous examination. No history of NF-1 in extended family. 
I-2 - 5.5.36,49.6 years. 
Normal cutaneous examination. No history of NF-1 in extended family. 
II-1,2,4 - Reported normal by parents. 
NF 36 
III-1 was ascertained via hospital records. 111-6, who lived outside 
the study area, was referred by Professor M. Laurence when he 
attended for genetic counselling. 
III-1 - 9.2.48,37.9 years. Registered disabled, former hospital 
kitchen assistant; SC: V; secondary modern -school education, no 
qualifications. 
7 CAL; freckling: axillae, submammary regions, groins; CNF: 4; face: 
no; LN: 3; GNF: 2; Ht: 151 (3); HC 54.5 (50). 
III-1 was a very anxious lady who had been known to have NF-1 for a 
number of years (from hospital records) but who was not aware of this 
or its implications. No major NF-1 problems and had had a few 
cutaneous neurofibromas removed for cosmetic reasons. 
She said she had been registered disabled because of poor vision 
and right-sided deafness, both of which dated from childhood. ENT 
notes recorded recurrent treatment of right-sided otitis externa, a 
narrow external canal being the only abnormal recorded feature. 
On examination she had a left convergent squint, her vision was 
6/9 in the right eye and 6/18 in the left, which corrected (with 
pinhole) to 6/6 and 6/9 respectively. She did appear to have a right 
sensorineural deafness but failed to attend a neurogenetic clinic 
appointment for review of this. 
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She denied a family history of NF-1 and was unwilling for her 
family (who all lived outside the study area) to be contacted. When 
111-6 was seen in the genetic clinic he gave a different account and 
this proved to be correct from discussions with the family GP and 
reviewing hospital records. Despite this the remaining family 
members were not contacted for the study in respect of III-1's 
wishes. 
111-6 -15.5.55,30 years. Normal cutaneous examination. 
11-4 - 11.1.16, died 68 years from aortic valve disease. 
Reported to be the first case of HF-1 in the family; no accurate 
details about his parents and siblings available. Hospital records 
from 1982 document multiple cutaneous neurofibromatosis. At that 
time he was assessed for dyspnoea and a chronic productive cough; 
examination showed aortic stenosis with incompetence, blood pressure 
was 180/90, with evidence of heart failure on treatment with 
bumetidine K and phyllocontin. 
Investigations were as follows - chest x-ray: prominent left 
ventricle, suspicion of background pneumoconiosis with some 
bronchiectasis; ECG: left ventricular hypertrophy and strain; 
echocardiograph: calcified tricuspid aortic valve with severe 
stenosis, fine fluttering of mitral valve being seen as-evidence of 
aortic incompetence, the left ventricle was markedly dilated with 
left ventricular hypertrophy and a large end systolic volume. In 
October 1984 he died suddenly at home; after post mortem his cause of 
death was shown to be calcified aortic valve disease with unrelated 
pulmonary fibrosis and bronchiectasis. 
111-2 - 7.11.49. Reported affected by 111-6 and this was confirmed 
from hospital records. 
111-2 had a long history of recurrent duodenal ulceration compounded 
by heavy alcohol intake. In November 1982 (age 33 years) he was 
admitted with a haematemesis, endoscopy showed gastritis and a 
duodenal ulcer; this settled with conservative treatment. His 
admission notes document multiple CAL spots and cutaneous 
neurofibromas. He also complained of an enlarging painful mass on 
the posterior aspect of his left forearm. This was subsequently 
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removed and found to be an 8x5 cm mass arising from the radial 
nerve. Histology showed a neurilemmoma with low grade malignancy; 
radiotherapy was not advised. He was kept under review and 
recurrence had not been observed to the time of the study. 
111-3 - 16.3.50. Reported normal. 
111-4 - 14.5.51. She and children reported normal. 
III-5 - 15.5.55. Reported affected. Had attended a special school 
and suffered from epilepsy from the age of 10 years. 
111-7 - 13.5.62, Reported normal. 
IV-1 - 27.1.71,14.8 years; schoolboy attending comprehensive school. 
Normal examination of skin and iris. 
NF 37 
II-16 was ascertained via hospital records. 
II-16 - 20.10.27,58.1 years. Storeman; SC: V; elementary school 
education, required extra tuition until 12 years of age; classified 
as requiring remedial class education. 
9 CAL; freckling: no; CNF: 4; face: yes; LN: 1; GNF 2; Ht: 169.2 
(25); HC: 56.5 (90). 
NF-1 had been incidentally diagnosed during an admission for a 
pneumothorax in 1981; he had had no hospital assessment specifically 
for NF-1. 
Classified as new mutation. 
I-1 - Born 1880, died 62 years from myocardial infarction. Reported 
normal. 
I-2 - Born 1884, died 84 years, cause unknown. Reported normal. 
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II-1-15 - The propositus was the youngest of 15 children and was 
adamant no one else in the family was affected. He was vague about 
the ages and causes of death of those siblings who had died. 
NF 38 
111-2 was referred by his GP and ascertained via hospital and genetic 
clinic records. 11-2 was prepared for her and the 2 children to 
answer questions but not to undergo examination. 
111-2 - 29.8.66,19.3 years. Had not worked since leaving school; 
SC: V; special school education, classified as minimally retarded. 
Face: no; GNF: 3. 
The diagnosis of NF-1 was made in 1975 (age 9 years) when he 
presented to a paediatrician for assessment of grand mal fits. He 
had had delayed motor and intellectual milestones, requiring special 
school education. His seizures were grand mal and apart from 
multiple CAL spots no abnormalities were found on examination. His 
IQ was 76. An EEG was reported to be non-specifically abnormal and 
an isotope brain scan was normal. He was treated with phenytoin and 
ospolot and his seizures were well controlled. On leaving school he 
had been literate but had never worked. He was classified as 
minimally retarded as with different social circumstances he would 
probably have achieved much more. 
I-2 - 2.1.07, died 61 years from leukaemia. Reported affected by 
daughter, no hospital records or details of type of leukaemia traced. 
No antecedent family history available. 
II-1 - Reported normal by 11-2 who was unwilling for her siblings to 
be contacted. 
11-2 - 29.11.34,51.1 years. Housewife; former brewery worker; SC: 
V; special school education, classified as minimally retarded. 
Face: no; GNF: 3. 
Had never had hospital assessment for NF-1 other than being examined 
in the genetics clinic on one occasion when the diagnosis was 
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confirmed. She could not read and could only write her name but as 
she managed to live independently with the 2 children was classified 
as minimally retarded for analysis. 
11-3 - Reported normal by 11-2. 
III-1 - 23.9.63,22.2 years. Had not worked since leaving school; 
SC: V; special school education; classified as minimally retarded. 
Face: no; GNF: 3. 
At 9 months presented with attacks of salaam spasms and EEG showed 
typical hypsarrhythmia with had completely responded to prednisolone. 
Delayed motor and intellectual milestones had followed and she had 
attended a special school; on leaving was able to read and write. 
In 1980 she developed grand mal seizures and was well controlled on 
carbamazepine when assessed for the study. Her mother had been aware 
of a swelling on the left ankle from early childhood and by 16 years 
she was unable to fit into normal shoes. She had 3 partial excisions 
of a plexiform neurofibroma over the next 6 years but when seen there 
was still an obvious residual mass. 
NF 39 
111-2 was ascertained via hospital records. 
111-2 - 29.11.63,22.1 years. Attending college course for people 
with learning difficulties; SC: unable to classify; special school 
education, classified as minimally retarded. 
10 CAL; freckling: axillae and trunk; CNF: 3; face: no; LN: 50; GNF: 
3; Ht: 167.5 (10); HC: 57.5 (97). 
Although he had required special school education no hospital 
paediatric assessment was known to have been made in childhood. 
When seen he was an anxious rather inadequate personality but was 
literate. He was not aware of the diagnosis of NF-1 though this had 
been made when he had had a neurofibroma removed from his right ulnar 
nerve at 13 years. 
On examination he had a6 cm diameter plexiform neurofibroma with 
overlying skin hypertrophy to the right of his umbilicus. 
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I-1 - Age unknown. Reported normal by son who was unwilling for him 
to be contacted. 
I-2 - Birth date unknown, died 60+ years, cause unknown. Reported 
normal. 
II-1-3 - Reported normal, 11-4 unwilling for them to be contacted. 
11-4 - 23.12.34,51.1 years. Fork lift truck driver (unemployed); 
SC: IIIM; secondary modern school; no qualifications. 
3 CAL; freckling: no; CNF: 3; face: no; LN: 20; GNF: 1; Ht: 160 (3); 
HC: 58 (97). 
Diagnosed secondary to study, no NF-1 related problems. Suffered 
from angina. 
III-1 - 12.10.70. Died 2.5 years from bronchopneumonia complicating 
spastic quadraplegia with epilepsy which was said to be caused be 
prematurity. No CAL spots reported by parents. 
111-3 - 26.12.64. Reported normal, unable to contact. 
111-4 - 21.5.74. Reported normal. Mother unwilling for her to be 
examined. 
NF 40 
11-3 was ascertained via hospital records, he was unwilling to be 
seen for the study but allowed his GP to supply information. 
11-3 - 2.5.22,63.1 years. Barman; SC: IV 
Face: yes. 
The diagnosis of NF-1 was made in 1959 by a consultant dermatologist 
when he had a cutaneous neurofibroma removed. He appeared to have 
had no other HF-1 complications. Several of the author's colleagues 
frequented the pub in which he worked and reported his face to be 
covered in neurofibromas. 
His GP stated his father was affected but knew no other details 
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of his case and GP thought that I-1 and 1-2 were unaffected. 
NF 41 
This family was ascertained by III-1, referred by her GP, and IV-1 
referred by the GP, his hospital consultant and identified through 
hospital records. 
III-1 - 17.10.44,40.6 years. Housewife; SC: III; secondary modern 
school education, no qualifications. 
14 CAL; freckling: axillae and groins; CNF: 4; face: yes; LN: 56; 
GNP: 3; Ht: 153 (10); HC: 56.5 (97). 
NF-1 had been diagnosed during-her first pregnancy. She had no major 
complications and her only complaint was of pruritis. She thought 
that NF-1 was just a "skin problem". She had several cutaneous 
neurofibromas removed for cosmetic reasons. 
On examination she had 2 small plexiform neurofibromas, one on 
the medial aspect of the left buttock and another on the right ankle. 
IV-1 - 2.1.67,18.4 years; unemployed; SC: III; remedial class 
education; no qualifications. 
19 CAL; freckling: axillae; CNF: 3; face: no; LN: 80; GNF: 2; Ht: 
157.5 (<3rd); HC: 58 (97). 
Although his mother was aware of the CAL spots during childhood, 
formal diagnosis was not made until 16 years of age when he was 
referred for assessment of short stature and lack of pubertal 
development. Endocrine investigation showed no abnormality and 
pubertal changes began at 17 years of age. His height was growing 
parallel to the 3rd centile. 
11-8 - Born 1918, died 1949 aged 31 years. 
Reported affected by husband. Her main disease related problem had 
been a large swelling on the left arm which had required surgery 
during childhood (no records available, ? plexiform neurofibroma). 
She had died of pulmonary infarction following childbirth. 
Although details regarding her parents and siblings are limited, 
her husband was sure that she had been the first case in the family. 
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Presumed new mutation but excluded from analysis because of limited 
details. 
111-2 - 3.7.42,44.2 years. Lived outside study area. 
Visited for purpose of linkage studies in September 1986. Brief 
examination confirmed multiple CAL spots and cutaneous neurofibromas. 
No major disease complications. 
111-3 - Born 1949, died at six months. Described as a 'blue baby'. 
No other details available. 
IV-2 - 19.6.70; 15 years; attending comprehensive school, no 
educational problems. 
Normal cutaneous examination. 
IV-3 - 15.10.77; 8.9 years. 
Normal cutaneous examination. 
NF 42 
11-6 was referred to the study by her GP. 
11-6 - 14.4.40; 45.6 years. Unemployed chicken sexer; SC: ISM; 
elementary school education, no qualifications. 
7 CAL; freckling: axillae, groins and submammary regions; CNF: 4; 
face: no; LN: not examined; GNP: 2; Ht: 149.5 (<3); HC: 56 (90). 
Although 11-6 had heard the disease mentioned on hospital visits, she 
knew nothing about NF-1 or its genetic implications. From her 
hospital records the diagnosis had been made during investigations 
for chest pain at 43 years. She had no disease complications apart 
from a small plexiform neurofibroma on her abdomen with hypertrophy 
of the overlying skin. 
Classified as new mutation. 
I-1 - 13.12.06, died November 1985 aged 78 years. 
Had a myocardial infarction and cerebrovascular accident in 1985 
following which he became increasingly confused. Examined for signs 
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of NF-1 during terminal admission at the author's request and 
reported normal. 
I-2 - Date of birth unknown. Died aged 74 years in 1982. 
Reported normal by 11-6. Suffered from angina and diabetes, cause of 
death unknown. 
Siblings of 11-6 - 11-6 said she was the only affected member of her 
sibship. Her siblings and their children were in good health apart 
from II-1 who had been treated for carcinoma of the breast, and 11-9 
who was described as 'spastic', being unable to walk or talk. His 
twin, 11-8, had died at 6 months of age, cause unknown. 
III-1 - 2.8.58. Lived outside study area. 
He and his offspring were reported to be unaffected. 
111-2 - 17.10.60. Lived outside study area. 
He and his offspring were reported to be unaffected. 
111-3 - Born 1961. Reported to have died at 1 month although his 
mother was uncertain as to the cause, apart from the fact that he had 
been a poor feeder and was said to have had a large heart. 
111-4 - 23.8.65; 20.2 years. Unemployed; SC: IVM; comprehensive 
school education, no qualifications. 
14 CAL; freckling: axillae, groins and submammary regions; CNF: 2; 
face: no; LN: not examined; GNF: 2; Ht: 152 (3); HC: 55 (75). 
111-3 had never been reviewed for NF-1. Mother had noticed CAL spots 
from infancy and a swelling on the left wrist from 6 years. On 
examination this was a small plexiform neurofibroma. 
111-5 - 26.3.67; 19.7 years; on Youth Training Scheme; SC: IV; 
remedial class education, no qualifications. 
18 CAL; freckling: axillae and groins; CNF: 2; face: no; LN: not 
examined; GNF: 2; Ht: 173 (50); HC: 56.9 (90). 
The diagnosis of NF-1 was formally made when referred for assessment 
of gynaecomastia at the age of 19 years. No underlying abnormality 
was found although it was noted that he was still undergoing pubertal 
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development. Apart from late puberty he had no other NF-1 
complications. 
111-6 - 17.10.68; 17.1 years; on Youth Training Scheme; 
comprehensive school education, no qualifications. 
Normal cutaneous examination. Ht: 168 (25); HC: 54.5 (50). 
111-7 - 16.7.70; 14.9 years; attending comprehensive school; SC: 
IVM. 
9 CAL; freckling: axillae and groins; CFN: 2; face: no; LN: not 
examined; GNF: 1; Ht: 155 (10); HC: 55.5 (90). 
111-7 had never been formally assessed for NF-1 although CAL spots 
were noted in her hospital records from 7 months of age. She had 
been under orthopaedic review when younger for bilateral 
calcaneovalgus deformity and had required lengthening of the left 
Achilles tendon at 6 years. 
On examination, the only other finding of note was a possible 
plexiform neurofibroma on the right chest posteriorly; this was 
approx. 3 cm in diameter with ill-defined margins; the overlying skin 
was reddened. 
NF 43 
11-7 was referred to the study by her GP. 
11-7 - 21.1.15; 70.7 years. Retired home help; SC: IV; elementary 
school education, no qualifications. 
3 CAL; freckling: approx. 30 freckles in left axilla only; CNF: 4; 
face: no; LN: not examined; GNF: 2; Ht: 146 (<3); HC: 54 (50). 
11-7 was a spinster who had not been formally diagnosed until the age 
of 67 years when she had seen a dermatologist. She complained of 
severe pruritis from her neurofibromas and was extremely upset by her 
appearance. No NF-1 complications. 
Classified as new mutation. 
I-1 - 28.5.1874, died 1948 aged 74 years. Died suddenly at home, 
cause unknown, no records available. Reported normal. 
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I-2 - Born 1879, died 1956 aged 77 years. 
Died from carcinoma of the throat, no records available. Reported 
normal. 
Siblings of 11-7 - 11-7 reported she was the only affected family 
member. 
II-1 had died of a myocardial infarction, age uncertain; 11-2 died at 
81 years, cause unknown; 11-5 had died of a cerebrovascular accident 
at 39 years. The remaining siblings of 11-7 and the members of 
generation III were reported to have no health problems. 
NF 44 
IV-1 was referred to the study by his GP. 
IV-1 - 3.11.73,11.9 years; attending comprehensive school, no 
particular problems; SC: IIIM (father a joiner). 
7 CAL; freckling: none; CNF: 1; face: no; LN: present, not counted; 
GNF: 4; Ht: 135 (3); HC: 56 (97). 
The diagnosis of NF-1 was made at 8 months when he presented with 
infantile spasms and was noted to have multiple CAL spots. EEG 
showed hypsarrhythmia. He was treated with ACTH with resolution of 
the attacks and no secondary developmental problems. 
At the age of 4 years he was noted to have problems with vision 
and at ophthalmological assessment he was found to have decreased 
vision in the right eye with optic atrophy. There was no proptosis 
and X-rays of the optic foramina were normal. Diagnosis of optic 
atrophy of unknown aetiology was made. When he was assessed for the 
study, vision in his right eye had decreased from 2/60 to counting 
fingers at 4 feet. Vision in his left eye was normal. On contacting 
the ophthalmologist it became clear he was unaware of the diagnosis 
of NF-1. On re-assessment his optic foramina were still normal on 
X-ray but CT scan showed enlargement of the right optic nerve within 
the orbit and no intracranial extension; the appearance was 
consistent with an optic nerve glioma. 
IV-1 had also had a swelling over the left temple at 4 years of 
age. Excision biopsy in 1983 showed this to be a plexiform 
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neurofibroma. On examination for the study, a2 cm diameter diffuse 
swelling persisted. 
I-1 - Born 1872, died aged 73 years in 1955. 
Reported unaffected, died from carcinoma of the breast. 
I-2 - Date of birth unknown, died at 92 years. Reported unaffected, 
died from an aortic aneurysm. 
II-1 - 16.12.16; died 1971 aged 64 years. 
Reported by daughter to be first case of NF-1 in family. No known 
complications until presented on day prior to death with right 
hypochondrial pain and increasing dyspnoea. Her condition rapidly 
deteriorated with enormous swings of blood pressure and she died 24 
hours later. Autopsy showed acute left ventricular failure and 
haemorrhage into a phaeochromocytoma on the right adrenal. 
Classified as a new mutation but insufficient detail on parents' 
and siblings' birth dates to use in analysis. 
Siblings of II-1 - 11-2,3, and 5 had died from myocardial infarction, 
11-4 suffered from angina. None were reported to have NF-1. 
III-1 - 8.6.40,45.3 years; part-time cleaner; SC: V; secondary 
modern school education, no qualifications. 
5 CAL; freckling: left axillae and submammary regions; CNF: 3; face: 
no; LN: not examined; GNF: 1; Ht: 151 (3); HC: 55 (75). 
III-1 was first diagnosed when her son was an infant although she had 
no idea about the possible implications of the diagnosis. She had no 
NF-1 complications. 
111-2 - Reported normal. Lived outside the study area. 
NF 45 
11-3 was referred to the study by his GP. 
11-3 - 25.3.62,23.4 years. Factory labourer; SC: V; comprehensive 
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school education; obtained 2 CSEs. 
9 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: not 
examined; GNF: 1; HT: 166 (10); HC: 58 (97) 
The diagnosis of NF-1 was made at 6 years of age when he presented 
with short stature and multiple CAL spots. He was also noted to have 
a right 6th nerve palsy and mild conductive deafness on the left, the 
aetiology of both were unknown and had not changed since early 
childhood. 
He had regular paediatric follow-up during childhood and had 2 
cutaneous lesions removed, a neurofibroma at 16 years from the 
abdominal wall and a probable angio-pericystic hamartoma from the 
left ankle at 22 years. 
Classified as new mutation. 
I-1 - 10.7.31,54.2 years. Steelworker; SC: IV; secondary modern 
school education; no qualifications. 
Normal cutaneous examination. 
I-2 - 19.8.35,50 years; part-time escort; SC: IV; secondary modern 
school education, no qualifications. 
Normal cutaneous examination. 
Siblings of 11-3 - Reported normal by parents. 
NF 46 
II-5 was ascertained via hospital records and referred by her 
consultant plastic surgeon and GP with her son 111-3. 
11-5 - 15.2.28,57.2 years. Housewife (former shop assistant); SC: 
IV; secondary modern school education, no qualifications. 
6 CAL; freckling: axillae; CNF: 5; face: yes; LN: not examined; GNF: 
3; Ht: 151 (3); HC: 57.5 (>97). 
11-5 had been diagnosed at 20 years of age and been told the name of 
the disease but no other information. She was extremely disturbed by 
her appearance and had had numerous plastic surgery procedures for 
removal of neurofibromas. She had hypertension which was well 
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controlled on beta blockers; urinary VMAs at the time of the study 
were normal. 
Classified as new mutation. 
111-3 - 12.3.63,22.2 years; unemployed (formerly on YTS Scheme); SC: 
IV; comprehensive school education, attained GCE '0' level passes. 
10 CAL; freckling: axillae; CNF: 3; face: no; LN: not examined; GNF: 
1; Ht: 162.5 (3); HC: 57 (90) 
11-3 had no complications of NF-1 and had not had regular review for 
the disease. He had several neurofibromas removed for cosmetic 
reasons, largely at his mother's insistance. 
I-1 - Reported unaffected. Died of carcinoma of the lung. 
I-2 - Reported unaffected. Died of Parkinsons's disease at 78 years. 
Siblings of 11-5 - 11-5 said she was the only affected member of her 
sibship. 11-2 had died from a brain haemorrhage and 11-3 from 
carcinoma of the lung. 
III-1 and 111-2 - Dates of birth 16.12.61 and 21.2.59 respectively. 
11-5 did not want her other 2 children (III-1 and 111-2-) to be seen. 
Neither they nor their offspring were reported to have any health 
problems. 
NF 47 
11-9 was referred to the study by his GP. 
11-9 - 7.6.18,67.2 years. Retired miner; SC: IIIM; elementary 
school education, no qualifications. 
4 CAL; freckling: none; CNF: 5; face: yes; LN: not examined; GNF: 3; 
Ht: 157 (<3); HC: 58 (97) 
11-9 was unsure when he had first been told of his diagnosis and was 
unaware of possible complications or its inheritance. He had well 
controlled essential hypertension and investigation had excluded a 
phaeochromocytoma when he had first presented in 1974. He had had 
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several neurofibromas removed for cosmetic reasons. 
Classified as new mutation. 
I-1 - Born 1876, died 1954 aged 78 years, cause unknown. Reported 
unaffected. 
I-2 - 29.5.1877, died 1954 aged 77 years, from pneumonia. Reported 
unaffected. 
Siblings of 11-9 - 11-9 reported he was the only affected member of 
his sibship, 8/9 of whom had died from the following: 
II-1 - 24.10.97, died 79 years: pneumoconiosis 
11-2 - 2.10.99, died 50 years: bronchitis 
11-3 - 6.6.01, died 63 years: myocardial infarction 
11-5 - Born 1905, died 37 years: cause unknown 
11-6 - 11.3.08, died 65 years: pneumoconiosis 
11-7 - 4.3.12, died 66 years: CVA 
II-8 - Born 1916, died 1 year: cause unknown. 
III-1 - 7.12.52; 33 years. 
8 CAL; freckling: none; CNF: 2; face: no; LN: 0; GNF: 4; Ht: 151 (3); 
HC: 54 (50) 
III-1 lived outside the study area. Neither she nor her parents were 
aware she had NF-1 until seen for the study. At the age of 3 years 
she had presented with proptosis and papilloedema of the right eye. 
Investigation had showed enlargement of the right optic foramina and 
at craniotomy a right optic nerve glioma was removed. This extended 
back towards the chiasm and she had an enucleation with removal of 
the right optic nerve. She had no further problems and vision in her 
left eye was normal at the time of assessment. Her neurosurgical 
notes do not comment on CAL spots nor of her father having NF-1. 
NF 48 
11-5 was referred to the study by her neurosurgeon 
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11-5 - 23.11.62,22.2 years. On Youth Training Scheme; SC: V; 
remedial class education, no qualifications; formal IQ assessment in 
1984 showed IQ = 82. 
8 CAL; freckling: axillae; CNF: 4; face: yes; LN: 18; GNF: 4; Ht: 158 
(25); HC: 61.5 cm (centile inappropriate for analysis). 
Had delayed milestones as a child and had required speech therapy 
from 3 years of age. At 7 years she developed ataxia and increasing 
headaches, examination showed bilateral papilloedema with a spastic 
paraparesis. Skull x-ray showed signs of chronic raised intracranial 
pressure and a ventriculogram hydrocephalus secondary to aqueduct 
stenosis. A shunt was inserted between the right lateral ventricle 
and upper cervical spine with satisfactory resolution of symptoms. 
In 1981 a ventriculo-atrial shunt had been inserted but the 
indications of this were unclear from the notes. 
In 1984 (aged 21 years) she presented with increasing difficulty 
in walking; examination showed recurrence of a spastic paraparesis, 
in addition her blood pressure was persistently elevated. 
Investigation of her hypertension excluded a phaeochromocytoma 
but isotope scan showed delayed excretion from the left kidney and 
arteriogram showed a renal artery stenosis. Her blood pressure was 
controlled medically during neurosurgical investigation which showed 
that her shunt was not working and this again was revised. Spinal CT 
and a myelogram also showed a dumbell neurofibroma at T3 which was 
subsequently removed. Following recovery from this, a right renal 
angioplasty had been performed. At the time of assessment for the 
study her symptoms and signs were slowly resolving, although she had 
required catheterisation 2 weeks after her spinal operation and this 
had not been able to be removed. Blood pressure was being controlled 
on decreasing doses of acebutolol and captopril. 
Classified as new mutation. 
I-1 - 7.2.17; 68.8 years. Retired labourer; SC: V; elementary 
school education; no qualifications. 
No abnormalities on cutaneous or slit lamp examination. 
I-2 - 13.3.20; 65.8 years. Housewife; SC: V; elementary school 
education; no qualifications. No abnormality on cutaneous or slit 
lamp examination. 
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II-1 - 24.12.42; died 1982 aged 40 years from aspiration pneumonia. 
She had been an alcoholic. No features of NF-1 reported. 
11-2 - 16.9.45.11-2 and her children were reported normal. 
11-3 - 7.11.48; 37.1 years. 
Normal cutaneous examination. Children reported unaffected. 
11-4 - 12.9.59. Reported normal. 
NF 49 
This family were ascertained by 111-4 and 111-5, who had previously 
been referred to the genetics clinic for diagnostic clarification, 
and 111-8 who was ascertained via hospital records. 
All the members of NF 49 lived within the study area except 111-9 and 
his family who had emigrated to Australia. Although few of the 
family had sought medical advice about NF-1 they were aware of the 
diagnosis and its genetic implications, although not of its possible 
complications. 
The family were used in the linkage studies. 
111-4 - 25.2.71; 13.2 years. SC: IIIM; comprehensive school 
education. 
4 CAL >1.5 cm; 6 CAL >0.5 cm; freckling: none; CNF: 1; LN: 0; GNF: 1; 
Ht: not appropriate; HC: 57.5 (>97). 
Multiple CAL spots had been noted from infancy and as she grew short 
stature was also obvious with an initial diagnosis of achondroplasia. 
In 1975 she was referred to the genetics department for evaluation. 
In addition to CAL spots she had limitation of extension of the 
elbows, moderate joint laxity elsewhere, and short broad hands and 
feet. Skeletal survey showed the changes of multiple epiphyseal 
dysplasia (MED). Her mother was found to be similarly affected, she 
reported her father had the same problem. 
111-5 - 27.12.73; 10.4 years. SC: IIIM; no problems during primary 
school education. 
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7 CAL; freckling: axillae: CNF: 1; face: no; LN: one on left iris; 
GNF: 1; Ht: not appropriate; HC: 55 (>97). 
Multiple CAL spots had been present from infancy. At 6 months she 
had also developed small yellow raised areas on her face and skin. 
On dermatological review NF-1 was diagnosed and biopsy of one of 
these lesions showed that the were juvenile xanthogranulomata. In 
1977 she was referred to the genetics department for evaluation. 
Examination showed she had inherited both NF-1 and MED. 
III-8 - 15.8.69; 14.8 years. SC: IIIM; comprehensive school 
education. 
17 CAL; freckling: axillae and groins; CNF: 2; face: no; LN: present, 
unable to count; GNF: 1; Ht: 150.5 (<3); HC: 58 (>97). 
CAL spots were present from infancy but 111-8 had not been reviewed 
in hospital until he presented with pneumonia in 1980. Examination 
and investigation showed signs of a left lower lobe pneumonia and in 
addition the murmur of a patent ductus arteriosus (PDA) with a 
collapsing pulse. He recovered satisfactorily from his pneumonia but 
subsequently became dyspnoeic on exertion and the PDA was ligated in 
1981 with no problems thereafter. 
I-1 - 18.10.11; 72.6 years. Housewife; SC: IIIM (deceased spouse 
had been a miner); secondary modern school education, no 
qualifications. 
2 CAL; freckling: axillae; CNF: 4; face: yes; LN: 29; GNF: 2; Ht: 
157.4 (25); HC: 57 (>97). 
The diagnosis of NF-1 had been made at 50 years when she asked for 
some neurofibromas to be removed for cosmetic reasons. No HF-1 
complications. 
She had recurrent iron deficiency anaemia, barium studies had shown 
no obvious source of bleeding in the gastrointestinal tract. 
I-1 had been adopted and therefore the mode of inheritance of NF-1 
was unknown. 
II-1 - 17.3.42; 42.2 years. Control crossing attendant; SC: IV; 
remedial class education, no qualifications. 
4 CAL; freckling: axillae; CNF: 4; face: no; LN: 46; GNF: 2; Ht: 
147.5 (<3); HC: 58.5 (>97). 
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II-1 had had some neurofibromas removed for cosmetic reasons and 
would not go swimming because of her appearance. 
11-2 - 16.4.43; 41.1 years. Bench viewer in car component factory; 
SC: IIIM; remedial class education, no qualifications. 
7 CAL; freckling: axillae, groins, over trunk; CNF: 4; face: no; LN: 
28; GNF: 2; Ht: 150 (<3); HC: 58 (>97). 
Until he attended the genetics clinic with his daughters, he had been 
unaware that NF-1 had been anything other than a "family trait". 
11-3 - 21.11.44; 39.6 years. Housewife; SC: IIIM; secondary modern 
school education, no qualifications. 
11 CAL; freckling: axillae; CNF: 4; face: no; LN: 50; GNF: 2; Ht: 151 
(3); HC: 55 (75). 
Had a neurofibroma removed for diagnostic purposes in her 20s. Apart 
from anxiety about her appearance, no NF-1 related problems. 
11-4 - 7.12.45; 38.5 years. Maintenance technician with Gas Board; 
SC: IIIM; secondary modern school education, no qualifications. 
No abnormalities on examination of skin or iris. Ht: 173 (50); HC: 
58 (>97). 
11-5 - 24.11.46; 37.5 years. Unemployed component fitter; secondary 
modern school education, no qualifications. 
No abnormalities on examination of skin or iris. Ht: 169 (25); HC: 
56.5 (90). 
11-6 - 4.11.48; 35.6 years. Ran a garage with her husband; SC: II; 
secondary modern school education, no qualifications. 
Normal examination of skin and iris. Ht: 165 (50); HC: 54.5 (50). 
11-7 - 13.10.49; 34.7 years. Greengrocer; SC: II; secondary modern 
school education, attained several CSEs. 
18 CAL; freckling: axillae, groins, submammary regions and over 
trunk; CNF: 3; face: no; LN: 64; GNF: 1; Ht: 161 (50); HC: 54.5 (75) 
Apart from removal of a few neurofibromas for cosmetic reasons, no 
NF-1 related problems. 
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11-8 - 23.10.50; 33.7 years. Maintenance electrician; SC: IIIM; 
secondary modern school education, attained 5 CSEs. 
No abnormalities on examination of skin or iris. Ht: 173 (50); HC: 
57 (90). 
11-9 - 12.7.52. Lives in Australia. Reported affected by mother. 
II-10 - 5.3.54; 30.3 years. Upholsterer; SC: IIIM; secondary modern 
school education, no qualifications. 
No abnormality on examination of skin or iris. Ht: 172.5 (50); HC: 
59 (>97). 
III-1 - 21.6.66; 18 years. On YTS; SC: IV; remedial class 
education, attained 1 CSE pass. 
6 CAL; freckling: axillae; CNF: 2; face: no; GNF: 2; LN: 41; Ht: 166 
(10); HC: 58 (>97). 
111-2 - 29.1.68; 16.4 years. SC: IV; attending remedial class at 
comprehensive school. 
11 CAL; freckling: axillae and groins; CNF: 1; face: no; GNF: 2; LN: 
22; Ht: 161 (<3); HC: 58 (>97). 
111-3 - 8.6.71; 13 years. SC: IV; schoolgirl, attending 
comprehensive school. 
11 CAL; freckling: axillae; CNF: 1; face: no; LN: 34; GNF: 1; Ht: 143 
(3); HC: 56 (97). 
The mother of III 1-3 realised the implications of CAL spots but none 
of them had ever been formally reviewed nor had had any NF-1 
complications. 
111-6 - 1.5.66; 18.4 years. SC: IIIM; secondary school education, 
attained 3 CSE passes. 
Normal examination of skin and iris. Ht: 187 (97); HC: 60.5 (>97). 
111-7 - 27.1.68; 16.4 years. On retail distribution course at 
College of Further Education; SC: IIIM; comprehensive school 
education, needed extra help with reading, attained 3 CSE passes. 
20 CAL; freckling: axillae and groins; CNF: 2; face: no; GNF: 2; Ht: 
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165.5 (10); HC: 57 (90). 
No NF-1 related problems but investigation of intermittent jaundice 
at the age of 16 years had shown a raised unconjugated bilirubin and 
no other abnormalities. The diagnosis of Gilbert's disease had been 
made. 
111-9 - 3.2.78; 6.4 years. SC: IIIN; schoolgirl, no problems at 
primary school. 
11 CAL all >1.5cm; freckling: none; CNF: 1; face: no; LN: 10; GNF: 1; 
Ht: 105.5 (3); HC: 52 (75). 
Mother aware of implications of CAL spots, no formal review for NF-1. 
III-10 - 30.6.81, examined at 2.9 and 4.5 years; SC: IIIN; attending 
primary school with no problems. 
No abnormality on cutaneous and slit lamp examination. Ht: 100 
(>97); HC: 53 (>97). 
III-11-13 - Family uncertain regarding their disease status. 
NF 50 
II-1 was referred to the study by her GP. 
II-1 - 3.12.71; 14 years. SC: IV; schoolgirl receiving home tuition 
because of heart problem, experiencing learning difficulties 
particularly with writing, and had poor concentration. 
10 CAL >1.5 cm; freckling: none; CNF: 1; face: no; LN: 0; GNF: 2; Ht: 
157 (excluded from analysis as scoliosis); HC: 56 (97) 
II-1 had been diagnosed by a paediatrician at 4.5 years of age on the 
basis of multiple CAL spots and had been under regular review from 
that time. She had three main problems which were under review: 
(1) Hypertrophic obstructive cardiomyopathy (HOLM) 
An ejection systolic murmur was noted from early childhood but as she 
was asymptomatic and ECG and chest x-ray were normal it was presumed 
innocent. In 1982 she complained of dyspnoea on exertion and was 
re-investigated. ECG and chest x-ray were again normal but an 
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echocardiogram showed a thickened intraventricular septum. 
Angiography showed a subvalvular gradient of 85 mmHg and virtual 
obliteration of the left ventricular cavity during systole. 
Diagnosis of HOCM was made. She was commenced on propanolol and her 
condition had not deteriorated at the time of the study. Her parents 
were extremely anxious about her heart and insisted on home tuition 
against medical advice. Subsequent echocardiography had not shown 
the severe changes seen on angiography and when assessed for the 
study she was awaiting re-investigation. 
(2) Right thoracolumbar scoliosis 
II-1 was under orthopaedic review for minor scoliosis first noted at 
10 years. There was no underlying vertebral abnormality and the 
curve had not progressed. 
(3) Possible epileptic seizures 
II-1 had one febrile convulsion at 3 years of age. From around the 
age of 10 years she began to have episodes of mumbling with thrashing 
of her limbs during sleep and of sleepwalking on other occasions. 
She had never been incontinent during an attack and had no other ill 
effects from them. An EEG in 1983 showed medium to high voltage 
sharp and slow wave activity appearing at 4-6 cps in all areas. 
Despite this, she had not been treated as it was felt the history was 
uncertain. She was not classified as having epilepsy in the 
complication studies. 
On examination for the study, the only other abnormality noted 
was a small plexiform neurofibroma on the left lower abdomen with 
overlying patchy pigmentation and reddened skin. 
Classified as a new mutation. 
I-1 - 21.12.42; 42.9 years. Unemployed storeman; SC: IV; secondary 
modern school education, no qualifications. 
No abnormality on examination of skin or iris. 
I-2 - 17.4.47; 38.6 years. Housewife; grammar school education; 
attained GCE '0' level passes. 
On examination 1 CAL spot was noted and slit lamp examination was 
normal. Classified normal. 
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11-2 - 4.5.78. Reported unaffected by parents. 
NF 51 
11-2 was referred to the study by her ophthalmologist. 
11-2 - 15.10.80; 5.1 years. SC: IV; schoolgirl, no developmental 
delay, no obvious problems since starting primary school. 
6 CAL; freckling: none; CNF: 1; face: yes, secondary to plexiform 
neurofibroma; LN: 5; GNF: 4; Ht: 103 (25); HC: 51 (excluded from 
analysis because of facial lesion). 
11-2 had a sticky right eye from birth which did not fully resolve 
with antibiotic ointment and at 6 weeks frank swelling of the right 
periorbital region was noted. On paediatric referral CAL spots were 
noted and skull x-ray showed enlargement of the right orbit and 
superior orbital fissure; biopsy of the lesion showed a plexiform 
neurofibroma. The lesion gradually grew in size producing proptosis 
and closure of the right eyelid. By 4 years she had no useful vision 
in the right eye and swelling of the right cheek with overgrowth of 
the maxilla. The superior orbital fissure had widened further and a 
series of plastic surgery procedures were undertaken: bone grafting 
and enlargement of the right orbit, debulking of the facial lesions. 
At surgery most of her facial muscles found to be replaced by 
neurofibromatous tissue. 
On examination for the study, these procedures had obviously 
greatly improved her appearance; she and her family were extremely 
well adjusted to her problems. 
Classified as a new mutation. 
I-1 - 6.10.53; 32.1 years. Stores assistant; SC: IV; comprehensive 
school education; attained several CSE passes. 
1 CAL spot on examination, classified normal. 
I-2 - 12.2.56; 29.8 years. Housewife; SC: IV; comprehensive school 
education, attained several CSE passes. 
Normal examination of skin and iris. 
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II-1 - 8.2.79; 6.8 years. Schoolgirl, no developmental problems. 
1 CAL spot on examination, classified normal. 
NF 52 
11-2 was ascertained via hospital records. 
11-2 - 13.6.55; 30.4 years. Housewife (former shop assistant); SC: 
IV; secondary modern school education, no qualifications. 
9 CAL; freckling: axillae and groins; CNF: 4; face: no; LN: 5; GNF: 
2; Ht: 153 (10); HC: 58 (>97). 
Multiple CAL spots had been present from infancy. The diagnosis of 
NF-1 had been made at 7 years when she began to develop 
neurofibromas. She had several admissions from the age of 20 years 
from the removal of cutaneous neurofibromas for cosmetic reasons. 
She had been myopic from childhood; on examination for the study her 
vision was 6/36 in the right eye and 6/18 in the left, both corrected 
to 6/9. 
She was unaware of the genetic implications of NF-1 or of its 
complications. 
Classified as a new mutation. 
I-1 - 11.10.27; 58.1 years. 
No abnormalities on examination of skin or iris. 
I-2 - 24.12.32; 52.9 years. 
No abnormality on examination of skin or iris. 
II-1 - 5.2.54. Reported normal by parents. 
11-3 - 14.1.59. Reported normal by parents. 
III-1 - 12.9.83; 2.2 years. Under paediatrician for possible delay 
in milestones. Had not walked until 18 months, only 2 words at time 
of study assessment. 
No abnormalities on cutaneous examination. 
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NF 53 
IV-3 was ascertained via hospital records. As these stated his 
mother was affected, the family were contacted through their GP. 
IV-3 - 11.9.74; died 22.11.76, aged 2.3 years. 
Multiple CAL spots had been noticed by the parents from 2 months of 
age. His development was normal until September 1976 when he was 
admitted with urinary retention. After initial catheterisation had 
been able to micturate satisfactorily and was discharged. Six weeks 
later the problem recurred and a firm pelvic mass was noted on 
examination. At laparotomy a large lobulated mass arising from the 
bladder and rectum was found which could only be partially removed. 
Histology was of a malignant rhabdomyosarcoma. He was commenced on 
chemotherapy and his urinary obstruction was temporarily relieved; 
when it recurred his blood urea began to rise and he died only 4 
weeks after the diagnosis had been made. 
I-i - Reported to have had multiple cutaneous "lumps". No other 
details available. Presumed affected. 
II-1 - No details available. 
11-2 - Died 1951, age uncertain. Reported by II-1 to have had 
scoliosis and to have died of chest problems. No other details 
available. Presumed affected. 
III-1 - Born 1938, died within hours of birth, cause unknown. 
111-2 - 4.7.40; 45.4 years. Housewife (former telephonist, husband 
signalman); SC: IIIM; secondary modern school education, no 
qualifications. 
9 CAL; freckling: axillae and groins; CNF: 4; face: no; LN: 2; GNF: 
3, Ht: 146 (excluded from analysis: pseudoarthrosis); HC: 54.5 (50). 
111-2 had been born with a fractured right tibia and fibula, the 
fibula was rudimentary with approx. 5 cm of the lower third missing. 
No mention of NF-1 was found in her orthopaedic notes. Her parents 
had refused orthopaedic advice to have an amputation and she managed 
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with calipers until the age of 39 years when 
below knee amputation. At the time of assesstr 
fully mobile with an artificial limb. 
111-2 had several neurofibromas removed 
She had not been told that NF-1 was related 
her own orthopaedic problem. 
she decided to have a 
ent for study, she was 
for cosmetic reasons. 
to her son' s death or 
111-3 - 13.1.46.111-3 and his children were reported normal, they 
lived outside the study area. 
IV-1 - born 17.6.71 at 31 weeks gestation. Died at 13 weeks from 
respiratory problems. 
IV-2 - 24.11.72; 13 years. Schoolgirl, attending comprehensive 
school. 
No abnormalities on examination of skin or iris. 
NF 54 
The index case was ascertained through hospital records. She had 
been adopted at 8 weeks and no precedent family history was 
available. 
Index case - 29.4.78; 7.6 years. Schoolgirl, attending primary 
school with remedial class help for reading and writing. 
13 CAL >1.5 cm, 6 CAL >0.5 cm; freckling: no; CNF: 1; face: no; LN: 
1; GNF: 2; Ht: 117 (10); HC: 51 (25). 
Her adoptive parents had noted CAL spots at the time of her adoption. 
Diagnosis of probable NF-1 was made when she had an isolated febrile 
convulsion at 18 months and multiple CAL spots were noted. 
After starting school she had a lot of problems, with her teacher 
thinking she was lazy. This led to an assessment by an educational 
psychologist at 7 years 3 months which showed a verbal IQ of 106, 
performance IQ of 70 and full-scale IQ of 87. She was able to read 
appropriately for her age but had major difficulty in copying 
patterns and shapes. Classified as having learning difficulties. 
On examination she had a plexiform neurofibroma, approx. 6 cm in 
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diameter in her left lower thoracic region posteriorly, it was 
covered by an area of hypertrichosis. 
NF 55 
11-3 was referred to the study by his GP. 
11-3 - 4.5.24; 61.6 years. Retired miner; SC: IIIM; elementary 
school education, no qualifications. 
8 CAL; freckling: none; CNF: 5; face: yes; LN: 15; GNF: 2; Ht: 171 
(25); HC: 57 (90). 
11-3 was unaware of the name of his disease and did not understand 
its nature until the time of the study. He had a few neurofibromas 
removed for cosmetic reasons; no other problems. 
On examination he had a plexiform neurofibroma approx. 7 cm in 
diameter on the posterior aspect of his left arm. 
Classified as new mutation. 
I-1 - 8.6.00. Died 1954 aged 54 years from chronic bronchitis. 
Reported unaffected. 
I-2 - 25.7.95. Died 1964 aged 69 years from carcinoma of breast. 
Reported unaffected. 
Siblings of 11-3 - The siblings of 11-3 and their children were 
reported to be in good health and to have no NF-1 stigmata. 
NF 56 
IV-3 was referred to the study by her plastic surgeon. 
IV-3 - 8.4.82; 3.6 years; normal milestones to date. 
3 CAL >1.5 cm; 5 >0.5 cm; freckling: none; CNF: 1; face: yes 
(plexiform neurofibroma); LN: unable to examine; GNF: 4; Ht: 94 (25); 
HC: 52.5 (excluded from analysis, facial plexiform neurofibroma). 
IV-3 was a brow presentation and at birth had generalised facial 
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swelling, this resolved apart from an area on her left cheek which 
persisted and later increased in size. On paediatric referral at one 
year a diffuse swelling extending from the upper cheek to lower jaw 
was noted. This was biopsied and histology was of a plexiform 
neurofibroma. 
At the age of 3 years she had a more extensive plastic surgery 
procedure and the lesion was found to involve the greater auricular, 
trigeminal, facial, hypoglossal and glossopharyngeal nerves, and the 
upper cervical plexus. 
At the time of study assessment, residual swelling was noted on 
the cheek and jaw area with no involvement of the eye. The mother of 
IV-3 was unwilling to accept that the problem was related to NF-1. 
I-1 - Reported affected by 11-3. Died in her 70s, cause unknown. No 
prior family history available. 
II-1 - 11.8.24; 61.3 years. Housewife; SC: V. 
II-1 was unkeen to have a full assessment; brief examination of her 
abdomen showed several CAL spots and multiple neurofibromas. Her 
only reported medical problem was long-standing bilateral deafness 
with tinnitus but no ataxia. Her ENT showed this was sensorineural 
deafness. Examination of her cranial nerves at the time of study 
showed no other abnormalities. She was unwilling to have further 
investigations of her deafness. 
Siblings of II-1 - 111-3 was unable to supply any details about her 
maternal aunts and uncles, only one of whom was said to live in the 
study area. 
III-1 - 6.6.50. Reported normal; family unwilling for him to be 
contacted. 
111-2 - 11.5.57. Reported normal; family unwilling for her to be 
contacted. Under hospital review for psoriasis. Notes do not 
mention any features of NF-1. 
The children of III-1 and 111-2 were reported normal. 
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111-3 - 29.11.51; 34 years. Housewife, previous factory worker; SC: 
V; comprehensive school education, no qualifications. 
Cutaneous examination incomplete: 5 CAL seen above waist, no 
freckling in axillae or submammary regions; CNF: 4; face: no; LN: 5; 
GNF: 2; Ht: 160 (25); HC: 57 (97). 
Diagnosis of NF-1 had been made at 19 years by a dermatologist 
although 111-3 did not really understand the natural history or 
genetic implications of the disease. 
On the upper part of her back she had a large area of CAL 
pigmentation in the centre of which was a plexiform neurofibroma 16 
cm in diameter. 
IV-1 - 26.8.71; 14.3 years. Attending remedial class at 
comprehensive school 
IV-1 would only allow the top half of his body to be examined; there 
were no abnormalities. 
IV-2 - 3.9.78; 7.2 years. Schoolboy, no problems to date. 
Normal cutaneous examination. 
IV-4 - 20.2.84; 1.8 years. Normal development at time of study. 
This child would only co-operate with limited examination, 2 CAL 
spots were seen on his back; classified as diagnosis equivocal. 
NF 57 
II-1 was referred to the study by his GP and consultant surgeon. 
Unfortunately at the time he was contacted for the study he was 
undergoing treatment for carcinoma of the penis and was unwilling to 
be seen. The diagnosis was in no doubt from his hospital records 
which described multiple cutaneous neurofibromas and CAL spots. 
Past medical history from hospital records - 
1974 - presented with rapidly increasing swelling on right side of 
chest and clinically shocked. Found to have haemorrhaged into a 
neurofibroma from a subcostal artery. After resuscitation, lesion 
was removed with no complications. 
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Had a further neurofibroma removed from the right thigh in the same 
year. 
1981 - Shadow on left lung field found on routine chest x-ray. 
Thoracotomy for excision of benign neurofibroma in 1982. 
1985 - presented with indurated area on foreskin. Biopsy showed a 
low grade verrucous squamous cell carcinoma of the penis. Subsequent 
partial amputation of penis. 
Family history - Family of 11-2 lived in Yorkshire, his father, who 
was deceased, was said to have been affected as was one of his 6 
brothers, there are no other family details recorded. 
NF 58 
11-5 was ascertained by hospital records. 
11-5 - 2.3.24; 61.8 years. Spinster who had never worked; SC: IV 
(father had been a miner); elementary school education, described as 
needing extra help, classified as remedial class education. 
CAL spots not counted as incomplete examination; freckling: axillae; 
CNF: 4; face: yes; LN: not examined; GNF: 4; Ht: 150 (3); HC: 57 
(>97). 
11-5 had heard the name neurofibromatosis mentioned but understood 
very little about the disease. She had had only one neurofibroma 
removed for cosmetic reasons. A routine chest x-ray in 1982 had 
shown a mass at the thoracic inlet, isotope scan showed a6 cm mass 
with a whorled appearance and well-defined edge which was thought to 
be typical of a neurofibroma; as she was asymptomatic this was not 
removed. 
In 1983 (aged 59 years) she presented with upper abdominal pain 
and vomiting. A clinical diagnosis of acute cholecystitis was made. 
An ultrasound scan however showed a dilated extrahepatic duct but no 
gallstones. At laparotomy an encapsulated tumour surrounding the 
common bile duct orifice was found and enucleated. Initial histology 
was of an ampullary carcinoma. This was reviewed at the time of the 
study at the author's request by Professor ED Williams because of 
his description of the association between duodenal carcinoids and 
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NF-1. He found that the tumour was a somatostatin-rich duodenal 
carcinoid. 
At the time of her study assessment the patient was asymptomatic 
and urinary VMAs were normal. 
Classified as a new mutation. 
I-1 - 3.9.88. Died 1967 aged 79 years from a CVA. Reported normal. 
I-2 - Died aged approx. 70 years following a fractured neck of femur. 
Reported normal. 
Siblings of 11-5 - 11-5 reported she was the only affected family 
member. I-1 died in childhood, cause unknown; 11-2 died at 26 years 
in an accident and 11-3 had suffered from epilepsy, dying during a 
seizure at 46 years. 
NF 59 
11-2 was ascertained via hospital records. 
11-2 - 14.1.58; 27.9 years. Production line worker in chocolate 
factory; SC: V; comprehensive school education, learning difficulties 
particularly with mathematics, no qualifications. 
13 CAL; freckling: axillae, groins and submammary regions; CNF: 4; 
face: no; LN: 9; GNF: 1; Ht: 155 (10); HC: 58 (>97). 
Diagnosis of NF-1 had been made at 21 years when 11-2 was referred to 
a plastic surgeon for removal of neurofibromas for cosmetic reasons. 
She had no other NF-1 related problems apart from a bony defect of 
the right lamboidal suture on examination. 11-2 reported this had 
first been noted on x-ray after an accident in her teens. 
Classified as new mutation. Her son had been adopted in infancy 
and was therefore not available for assessment. 
I-1 - 23.8.27. Not in contact with family, reported unaffected by 
former wife. 
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I-2 - 12.6.29; 56.5 years. Nursing sister; SC: II; grammar school 
education, attained GCE '0' level passes 
No abnormality detected on examination of skin and iris. 
II-1 - 3.7.55. Lived outside study area, reported unaffected by her 
mother 
NF 60 
II-1 was ascertained through hospital records. 
II-1 - 7.2.46; 39.8 years. Domestic help; SC: IV; secondary modern 
school education, no qualifications. 
11 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: 14; GNF: 
2; Ht: 150 (not used in analysis - scoliosis); HC: 57 (>97). 
II-1 was aware of the diagnosis of NF-1 after dermatological review 
at 38 years. It was however noted in her hospital records at 18 
years when she had a dental surgery procedure for reduction of 
prognathism; there is no evidence in the notes that this problem was 
related to NF-i. 
In 1984 (aged 38 years) she was referred to a dermatologist and 
found to have both NF-1 and psoriasis. Discrete upper thoracic 
scoliosis was also noted; x-ray showed abnormalities at T2-4 with 
fusion of the vertebral bodies and hypoplastic "ribbon" ribs. 11-2 
had been unaware of this prior to 1984 and the lesion was 
asymptomatic. 
On assessment for the study her main complaints were of the 
cosmetic appearance of her neurofibromas and the intermittent intense 
pruritis they caused. 
Classified as a new mutation. 
I-1 - 12.4.14. Died 1.1.81 aged 66 years from car pulmonale secondary 
to chronic bronchitis and emphysema. No features of NF-1 recorded in 
hospital records or reported by his wife. 
1-2 - 11.2.24; 60.9 years. Home help; SC: IV; secondary modern 
school education, no qualifications. 
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No abnormalities on examination of skin or iris. 
11-2 - 10.2.48. Reported unaffected. Family unkeen for him to be 
contacted. 
III-1 - 6.11.69; 16.1 years. Schoolgirl; SC: IV (father: steel 
worker); attending comprehensive school, no educational problems. 
No abnormalities on examination of skin or iris. 
111-2 - 30.11.73; 12 years. Schoolgirl; SC: IV; attending 
comprehensive school, no educational problems. 
12 CAL; freckling: none; CNF: 1; face: no; LN: 10; GNF: 1; Ht: 151 
(50); HC: 55 (90). 
111-2 had no medical problems. Her mother was aware that she had 
probably inherited NF-1 but this was only confirmed formally when she 
was assessed for the study. 
NF 61 
11-2 was referred to the study by her GP. 
11-2 - 5.12.52; 33 years. Housewife; SC: IIIM (husband foreman in 
shoe factory); secondary modern school education, no qualifications. 
15 CAL; freckling: none; CNF: 4; face: yes; LN: 80; GNF: 2; Ht: 154 
(10); HC: 54 (50). 
The diagnosis of NF-1 had been made by her GP when her numerous 
cutaneous neurofibromas began to appear, although her mother did 
report that the CAL spots had been present from one year of age. 
At 24 years she had a sclerosing haemangioma removed from her 
nose. 
On examination she had 2 plexiform neurofibromas, one 3 cm in 
diameter on her forehead and the other 10 cm in diameter just above 
her right buttock. 
Classified as a new mutation. 
I-i - 26.11.23; 62.1 years. Self-employed builder; SC: IIIM; grammar 
school education, no qualifications. 
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No abnormalities on examination of skin or iris. 
I-2 - 5.5.24; 61.7 years. Housewife; secondary modern school 
education, no qualifications. 
No abnormalities on examination of skin or iris. 
II-1,3,4 - 8.8.46,8.1.58,25.11.68 respectively. 
The siblings of 11-2 and the offspring of II-1 were reported to be 
unaffected. 
III-1 - 24.6.74; 11.5 years. Schoolboy; SC: IIIM; no educational 
problems. 
No abnormalities on examination of skin or iris. 
111-2 - 29.5.82; 3.5 years. Schoolboy; SC: IIIM; no educational 
problems. 
1 CAL spot >1.5 cm, unable to co-operate with slit lamp examination. 
Classified as disease status equivocal. 
NF 62 
111-3 was referred to the study by her GP. 
111-3 - 21.10.52; 33.1 years. Unable to work; SC: IV (husband: 
machine attendant); special school education, moderate intellectual 
handicap. 
10 CAL; freckling: axillae, submammary regions and groins; CNF: 3; 
face: no; LN: present, not counted; GNF: 3; Ht: 156 (10); HC: 53 
(10). 
111-3 was illiterate and had been under psychiatric care from her 
early 20s for an anxiety state. She had never been formally assessed 
for NF-1. 
On examination she had a plexiform neurofibroma on her right 
buttock, this was approx. 8 cm in diameter with overlying skin 
hypertrophy. 
The family history was supplied by III-1 who was unkeen that her 
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mother or 111-2 (reported normal) should be contacted. 
II-1 - 24.11.13. Died 13.11.75 aged 62 years from pulmonary embolism 
complicating a deep venous thrombosis. Reported to be affected by 
family and GP although no mention of NF-1 in hospital records. No 
details regarding disease status of his parents or siblings 
available. 
IV-1 - 12.3.76. IV-1 was in foster care, outside the study area, was 
reported to have CAL spots although was excluded from analysis as not 
personally examined. 
NF 63 
11-2 referred himself to the study after reading an article about it 
in the local newspaper. 
11-2 - 2.10.29; 56.3 years. Unemployed, former planning officer with 
Water Authority; SC: IIIM; elementary school education, no 
qualifications. 
14 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: 2; GNF: 
1; Ht: 168.5 (25); HC: 55.5 (75) 
11-2 had never sought medical advice about his minor skin 
manifestations of NF-1. No other medical problems. 
Classified as new mutation. 
I-1 - 16.4.1892, died 1964 aged 72 years from CVA. Reported normal. 
I-2 - 18.9.1893. Reported normal. Family did not want her upset by 
being examined for study. 
II-1 - 2.4.23. Interviewed, not examined. Reported no 
abnormalities. His eldest son (III-1) had died at 32 years from 
renal carcinoma. His other 2 children had no health problems. 
111-4 - 2.6.67; 18.6 years. Student at College of Further Education 
(science technician course); SC: II; comprehensive school education, 
attained several CSE passes. 
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One CAL spot on examination, no neurofibromas or Lisch nodules. 
Classified unaffected. 
111-5 - 29.10.73; 12.2 years. Schoolboy; SC: IIIM; no educational 
problems. 
13 CAL; freckling: axillae and groins; CNF: 1; face: no; LN: 0; GNF: 
1; Ht: 138 (10); HC: 55.5 (90). 
No medical problems, diagnosed secondary to study. 
NF 64 
III-1 and 111-2 were referred by their paediatrician. 
III-1 - 2.8.71,14.4 years. Schoolgirl; SC: IVM (father worked in 
remploy factory); attending comprehensive school, no educational 
problems. 
19 CAL; freckling: axillae and groins; CNF: 1; face: no; LN: 9; GNF: 
1; Ht: 146.5 (excluded from analysis because of possible osteogenesis 
imperfecta (01)); HC: 55.5 (90). 
Diagnosis of NF-1 had been made on the basis of multiple CAL spots at 
6 years of age, when she was referred to a paediatrician because of 
asthma. 
On examination for the study she had no other NF-1 problems but 
had blue sclerae. Her father, 11-5, had 01 type 1 with blue sclerae 
and a history of multiple fractures following minor trauma. Although 
III-1 had only had one fracture (in her foot when she fell off a 
wall) it was felt that she had inherited 01 from her father and NF-1 
from her mother. 
111-2 - 5.2.75,10.9 years. Schoolgirl; SC: IVM; no educational 
problems at primary school. 
15 CAL; freckling: none; CNF: 2; face: no; LN: unable to cooperate 
with examination; GNF: 2; Ht: 122 (3); HC: measurement not recorded 
accurately. 
The diagnosis of NF-1 had been made at 2 years when she had been 
first assessed by a paediatrician for asthma. At 6 years she had one 
neurofibroma removed from her right arm. 
On examination for the study there were no other cutaneous 
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neurofibromas but she had a plexiform neurofibroma, some 4 cm in 
diameter, on the right of her abdomen. Her sclerae were white and 
she had had no fractures. 
I-1 - 18.10.13; died 1976 aged 62 years, from a myocardial 
infarction. Reported unaffected by 11-4 and no features of NF-1 
recorded in hospital notes. 
I-2 - 23.4.14; reported unaffected by 11-4 who did not want her to be 
contacted for the study. 
11-4 - 14.1.50; 36 years. Housewife; SC: IV; secondary modern school 
education, no qualifications. 
9 CAL; freckling: axillae, submammary region and groins; CNF: 3; 
face: no; LN: 4; GNF: 1; Ht: 149 (<3); HC: 58 (>97). 
11-4 viewed NF-1 as a minor skin problem and had no major medical 
problems. She had been on a diuretic for hypertension from her GP 
for one year at the time of study assessment. Her blood pressure was 
well controlled and urinary VMA, organised through the study, was 
normal on one occasion. 11-4 failed to attend for hospital follow-up 
after her initial home assessment. 
Classified as a new mutation. 
Siblings of 11-4 - 11-4 reported she was the only affected family 
member in her generation. II-1 had died of a myocardial infarction 
at 37 years of age. 11-4 did not want her siblings contacted about 
the study. 
NF 65 
The index case was ascertained through hospital records. She refused 
to be seen for the study and the GP could not supply an accurate 
family history; no pedigree therefore available. 
The index case was born on 17.9.59 and NF-1 had been diagnosed at 13 
years when she presented with scoliosis and multiple CAL spots; >6 
spots were counted on the old clinical photos in her orthopaedic 
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records. She had presented with a left upper thoracic scoliosis 
which progressed from 20° to 30° in six months; there was no 
underlying vertebral abnormality. A spinal fusion of Tl-7 had been 
carried out because of the progression, the curve was corrected to 
20° and remained stable until discharge from follow-up 3 years later. 
Her GP reported no major medical problems from that time. 
Although her orthopaedic records record no family history of 
NF-i, it was felt she should not be definitely counted as a new 
mutation. 
The index case was unmarried at the time of the study. 
NF 66 
11-2 was referred to the study by his paediatrician. 
11-2 - 30.8.67,18.4 years. Labourer in shoe factory; SC: IV; 
remedial class education, no qualifications. 
20 CAL; freckling: axillae and groins; CNF: 2; face: no; LN: 30; GNF: 
2; Ht: 162 (3); HC: 55 (50). 
The diagnosis of NF-1 had been made at 15 years when he was referred 
to a paediatrician for assessment of headaches and short stature. 
His history was of classical migraine, the attacks becoming less 
frequent when he stopped eating cheese. His height was below the 3rd 
centile on initial review, with a bone age of 12 years and a normal 
pituitary fossa on x-ray. Growth velocity was normal on follow-up 
and no further investigations were undertaken. 
Classified as a new mutation. 
I-1 - 20.6.38,47.5 years. Miner; SC: IV; secondary modern school 
education, no qualifications. 
No abnormalities on cutaneous or slit lamp examination. 
1-2 - 5.10.39,43.3 years. Home help; SC: IV; secondary modern 
school education, no qualifications. 
1 CAL spot in right axilla; no LN or neurofibromas; classified 
unaffected. 
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II-1 - 23.6.60. Reported unaffected by parents. 
11-3 - 11.1.71. Reported unaffected by parents. 
NF 67 
II-1 was ascertained via hospital records. 
II-1 - 24.8.58; 27.4 years. Production line worker in steel works; 
SC: IV; comprehensive school education, no qualifications; needed 
extra help with reading. 
12 CAL; freckling: groins; CNF: 3; face: no; LN: 0; GNF: 2; Ht: 169 
(25); HC: 58.5 (>97). 
The diagnosis of NF-1 had been made at 20 years of age when he had a 
plexiform neurofibroma partially removed from his left arm. He had a 
further operation for removal of a neurofibroma from his chin at 24 
years but no other medical problems. He was unaware of the 
complications or genetic implications of NF-1. 
On examination he had an ill-defined plexiform neurofibroma, approx. 
8 cm in diameter, on his left arm with overlying CAL pigmentation and 
hypertrichosis. 
Classified as a new mutation. 
I-1 - 21.3.30,55.8 years. Theatre orderly; SC: IV; grammar school 
education, obtained School Leaving Certificate. 
No abnormality on examination of skin or iris. 
I-2 - 18.7.32,53.5 years. Nursing auxilliary; SC: II; secondary 
modern school education, no qualifications. 
No abnormality on examination of skin or iris. 
11-2 - Reported unaffected by parents. 
III-1 - 30.5.83; 2.6 years. Normal developmental milestones. 
4 CAL >1.5 cm, 12 CAL >0.5 cm; freckling: none; CNF: 1; face: no; LN: 
unable to cooperate with examination; GNF: 1; Ht: 84.5 (10); HC: 51.5 
(97). 
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Multiple CAL spots had been noted by parents from birth; they were 
unaware of their implications. 
On examination she had a plexiform neurofibroma on the medial 
aspect of the left foot, the lesion was approx. 4 cm in diameter on 
palpation and the left foot had been a half size bigger than the 
right on measurement for shoes just prior to being assessed for the 
study. Regular paediatric assessment suggested to the GP following 
review for the study. 
NF 68 
IV-2 was referred to the study by his former paediatrician. 
IV-2 - 23.10.67,18.2 years. Unemployed, former shelf filler in a 
shop; SC: IV; comprehensive school education, attained 4 CSE's 
(grades 4 and 5). 
9 CAL; freckling: axillae and groins; CNF: 2; face: no; LN: not 
examined; GNF: 1; Ht: 176 (50); HC: 59 >97) 
NF-1 was diagnosed at 2 years of age on the basis of multiple CAL 
spots. He had no medical problems but had been brought up in a 
children's home from 7 years of age because of parental violence. 
I-1 and 1-2 - This couple had been divorced and III-1 had lost touch 
with I-1.1-2 had died at 78 years of age, cause unknown. They were 
thought not to have had NF-1. 
II-1 - 5.2.19. Died 1969 aged 60 years from carcinoma of the 
stomach. III-1 reported that her father was definitely affected; 
unable to trace hospital records or death certificate for further 
details. Excluded from study of analysis of new mutations because of 
uncertain family details. 
III-1 - 9.8.47,38.4 years. Cashier/clerk; SC: IIIN; grammar school 
education, no qualifications. 
5 CAL; freckling: axillae and submammary regions; CNF: 4; face: no; 




III-1 had been under orthopaedic review during her teens for 
scoliosis but no surgery had been required. No other medical 
problems. 
On examination she had a discrete left upper thoracis scoliosis which 
was asymptomatic. 
111-2 - Reported normal. 
111-3 - Died at 5 months from spina bifida. 
IV-1 - 14.6.66. Reported normal. 
NF 69 
The index case was referred to the study by his GP. When he was 
contacted about the study, the index case did not want to be seen but 
allowed his GP to send a report. He was born on 31.7.42, was a 
bachelor and his parents were said to be unaffected. The diagnosis 
of NF-1 had been made at the age of 18 years by a dermatologist on 
the basis of multiple CAL spots and neurofibromas. He had no medical 
problems other than bilateral Duprytens contracture. 
Classified as a new mutation as his GP was very sure his parents 
were unaffected. No pedigree available. 
NF 70 
This family were ascertained by the British Neurofibromatosis 
Patients Association LINK. 
11-2 - 19.3.55,29.5 years. 
10 CAL; freckling: axillae groins and trunk; CNF 3; face: normal; 
LN: 14; Ht: 154 (10); HC: 56 (90th). 
I-1 - 21.5.24, died aged 56 years from left ventricular failure due 
to ischaemic heart disease. Unable to trace medical records, but 
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family report moderate scoliosis onset 7 years of age and untreated. 
By the time of her death she had developed extensive dermal 
neurofibromas. Reported to be first case of NF-1 in family. 
11-3 - 9.3.58,26.5 years. 
Examination of skin and iris normal. Ht: 186 (>97); HC: 59 (>97). 
11-4 - 11.1.64,21 years. 
10 CAL; freckling: axillae, groins; CNF 4; face: normal; LN: 0; Ht: 
164 (<3); HC: 59 (>97). 
Dermal neurofibroma removed from pressure site on neck aged 14 years. 
No other complications. 
III-1 - 10.2.81,3.6 years. 
9 CAL > 1.5 cm, 4>0.5 cm; freckling: axillae; CNF 1; face: abnormal; 
LN: O (portable examination); Ht: 97.5 (50); HC: 52 (75). 
Bulging of left eye noted at birth, initially thought to be due to 
birth trauma. CAL appeared at 8 weeks and diagnosis made of NF-1 
with probable plexiform neurofibroma of left orbit. This lesion had 
enlarged very slowly as III-1 grew but at the time of assessment he 
still had useful vision in the left eye although the cosmetic 
disfigurement was considerable. CT scans had shown no associated 
sphenoid wing abnormalities and surgery had not been advised whilst 
vision was still present unless cosmetic problems became unacceptable 
to the family. 
NF 71 
This family was ascertained when III-1 was referred to the Swansea 
Genetics Clinic for counselling. 
III-1 - 30.3.67,17.3 years. 
16 CAL; freckling: axillae and groins; CNF 3; face: normal; LN: 7; Ht: 
153 (10); HC: 56 (90). 
Benign neurofibroma removed from neck aged 14 years because of pain. 
Extremely anxious regarding NF-1. 
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I-1 - 30.10.08, died aged 64 years. 
Family reported extensive dermal neurofibromas in adulthood; no other 
complications. Died within hours of myocardial infarction. 
Post-mortem confirmed myocardial infarction but also showed right 
adrenal tumour, histology not given, not known to be previoulsy 
hypertensive. 
II-1 - 29.6.44,40 years. 
21 CAL; freckling: axillae, groins and trunk; CNF 4; face: normal; 
LN: 18; Ht: 145.5 (<3); HC: 55 (75). 
Extremely anxious with numerous complaints of non-organic nature. 
Episodes of ataxia and complaints of leg weakness led to neurological 
investigation in 1983. Cranial CT scan was normal but a myelogram 
showed a small extrinsic cord lesion at L3-4. As her symptoms could 
not be explained by this she remains under observation. 
111-2 - 21.12.68,15.5 years. 
Normal dermatological examination. Ht: 161.5 (3); HC: 53 (10). 
NF 72 
III-1 and 111-2 were co-founders of LINK. 
III-1 - 25.10.46,38 years. 
9 CAL; freckling: groins and axillae; CNF 3; face: no; LN: O; Ht: 
179.5 (75); HC: 59 (>97). 
III-1 was aware of his diagnosis from his early teens and had genetic 
counselling when first married. A small plexiform neurofibroma had 
been removed from his chest wall for cosmetic reasons. 
I-2 - 16.8.1889, died 84 years. 
Described as having extensive cutaneous neurofibromas. No medical 
records available but death certificate recorded cause of death as a 
squamous cell carcinoma of the right ear. No preceding family 
history available. 
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11-2 - 17.10.16, died aged 59 years. 
Described by family as having a lot of cutaneous neurofibromas. Only 
known complication was of obstruction of left external auditory 
meatus by a cutaneous neurofibroma which required removal because of 
deafness. No medical records available regarding cause of death, 
death certificate gives caused as congenital cardiomyopathy. 
11-3 - No accurate details available. Known to have been affected 
and died following myocardial infarction. 
11-5 - 21.4.20,64 years. 
4 CAL; freckling: none; CNF: 4; face: no; LN: 6; Ht: 156.5 (<3); HC: 59 
(>97). 
On examination 5x 12 cm plexiform neurofibroma noted over left 
buttock with slight skin hypertrophy. 11-5 had noticed this 
developing over a 20-year period approximately, but it was entirely 
asymptomatic. Over the last 2 years had noticed deafness in the 
right ear; ENT assessment had shown this to be secondary to a 
cutaneous neurofibroma occluding the right external auditory meatus. 
11-6 - Said to be affected. Family had lost touch with her and her 
offspring. 
11-7 - Said to be unaffected. 
111-3 - 21.10.49,35 years. 
Normal examination of skin and iris. Ht: 169 (90); HC: 54 (50). 
111-4 - 21.3.52, aged 32 years. 
9 CAL; freckling: groins and axillae; CNF: 3; face: no; LN: 18; Ht and 
HC: not appropriate. 
Noted to have bowing of the right leg shortly after birth and 
neurofibromatosis with pseudoarthrosis of tibia and fibula diagnosed 
at 4 months. Treated conservatively until age 6 when had knee 
amputation. As long as she can remember has also had swelling over 
right buttock which on examination was a 25 x 25 cm plexiform 
neurofibroma with skin hypertrophy. 
At the age of 11 she had noticed slight decrease in her vision, 
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more on the right. On investigation she had been found to have 
bilateral optic atrophy and slight enlargement of the right optic 
foramen. A clinical diagnosis of bilateral optic glioma was made and 
she was managed conservatively. Her vision remained stable however 
until 1979 when she noticed some decrease in vision on the right. 
She was fully reinvestigated: V. A. 6/36 right, 6/8 left, skull X-ray: 
enlarged optic foramina R=L=7mm diam.; cranial CT with orbital views 
and coronal sections: slight thickening of left optic nerve only; 
metrizamide cisternogram and carotid angiography with orbital 
venograms normal. It was felt that there was not enough evidence to 
confirm the diagnosis of bilateral optic gliomas and she has remained 
under observation with no further deterioration in vision. 
111-6 - 5.1.51,33.7 years. 
9 CAL; freckling: axille and groins; CNF: 2; face: no; LN: 11; Ht: 
170.5 (50); HC: 59.5 (>97). 
Had one cutaneous neurofibroma removed from trunk because of severe 
pain on pressure. On examination noted to have one hypopigmented 
patch on right arm. 
111-7 - 7.10.52,32 years. 
Normal examination of skin and iris. Ht: 179 (75); HC: 56.5 (90). 
111-8 - 21.1.55,29.7 years. 
Normal examination of skin and iris. Ht: 175.5 (50); HC: 55.5 (75). 
111-9 - 14.6.58,26.3 years. 
Normal examination of skin and iris. Ht: 153.5 (10); HC: 54.5 (50). 
IV-1 - 1.4.76,8.5 years. 
5 CAL >1.5cm, 12 CAL>0.5 cm; freckling: axillae and groins; CNF: 1; 
face: no; LN: O; Ht: 129 (50); HC: 54.5 (97). 
Only problem has been with slight difficulty in reading/writing at 
school. Formal psychological testing age 7.5 years had showed low 
average ability with verbal skills being better than performance 
skills. 
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IV-2 - 19.6.79,5.25 years. 
On examination, 1 CAL >1.5 cm diameter and another less definite area 
on anterior chest wall. Unable to examine with portable slit lamp. 
Nil else. 
Classified as equivocal for chromosome 19 linkage study; 
re-examination at 7 years showed no change, therefore subsequently 
classified as normal. 
IV-3 - 26.3.70,14.5 years. 
Normal examination of skin and iris. Ht: 153 (3); HC: 54 (25). 
IV-4 - 28.1.72, aged 12.7 years. 
Normal examination of skin and iris. Ht: 150.5 (25); HC: 53 (25). 
NF 73 
This family was ascertained via 111-6, a LINK member. 
111-6 - 12.3.48,36.5 years. 
10 CAL; freckling: axillae, groins and all over trunk; CNF: 3; face: 
no; LN: 25; Ht: 170.5 (25); HC: 63 (>97). 
111-6 was diagnosed when his daughter, IV-6, presented with 
pseudoarthrosis. He had problems with reading and writing at school. 
The other problem was long-standing hearing loss in the left ear, 
dating from middle childhood. This was intensively investigated in 
1977 when a left sensorineural deafness was demonstrated, x-rays of 
the internal auditory meati were normal, myodil cysternography showed 
a probable small lateral filling defect, possibly due to an 
intracanalicular acoustic neuroma. However, this investigation was 
repeated a year later and the examination was within normal limits. 
Since that time his hearing has not deteriorated and there were no 
other cranial nerve signs on examination; the provisional diagnosis 
of an acoustic neuroma seems therefore unlikely. 
I-1 - Born 1887, died aged 68 years. Said to have multiple cutaneous 
neurofibromas in later years. Died of cancer of the bowel. No 
precedent family history available. 
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II-1 - 28.9.23,61.2 years. 
7 CAL; freckling: axillae; CNF: 4; face: no; LN: O; Ht: 171 (25); HC: 61 
(>97). 
Neurofibroma removed from left vagal nerve aged 33 years, residual 
vocal chord paralysis. Investigation of abdominal pain in 1974 
revealed a neurofibroma in the stomach. No active treatment, 
problems resolved. 
11-2 - 28.12.20,63.9 years. 
10 CAL; freckling: axillae, groins; CNF: 4; face: no; LN: 6; height: 
173 (50); HC: 60 (>97). 
11-2 had been treated for thyrotoxicosis with radioactive iodine in 
1976 but never had an NF-1 complication. He complained of 
intermittent severe itching from his cutaneous lesions. Examination 
showed a plexiform neurofibroma of the right lower abdominal wall 
10x10 cm diameter, slight thoracic kyphosis and pectus excavatum. 
11-4 - Age unknown. Lives in Eire. Her and 13 children reported to 
be unaffected by family. 
11-5 - 7.1.14,70.9 years. 
2 CAL; freckling: axillae; CNF: 4; face: no; LN: 9; height: 158.5 
(25); HC: 58 (>97). 
Late onset grand mal seizures from 50 years, cause unknown, well 
controlled on standard therapy. 
11-7 - 13.2.15,70 years. 
6 CAL; freckling: axillae and groins; CNF: 4; face: no; LN: not 
examined; height: 158 (25); HC: 56 (90). 
Had had tuberculosis of the uterus when aged 40 years. Said the 
family thought NF-1 was caused by her grandmother eating a lot of 
belly pork when pregnant! 
11-8 - 16.8.19,65.1 years. 
7CAL; freckling: none; CNF: 4; face: no; LN: 5; height: 166 (10); HC: 
58.5 (>97). 
Apart from a partial gastrectomy for peptic ulceration, no medical 
problems. 
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III-1 - 5.7.50,34.4 years. 
Examination of skin and iris normal. Ht: 172 (97). 
111-2 - 28.3.55,29.7 years. 
11 CAL; freckling: axillae; CNF: 2; face: no; LN: 10; height: not 
measured; HC: 57 (>97). 
Had had polio at age of 2 years with residual lower limb weakness. 
Required a right leg caliper and elbow crutches to walk. At the age 
of 12 she had developed scoliosis requiring surgery; the orthopaedic 
surgeon felt that this was due to polio rather than NF-1. Her 
mobility problems persisted at the time of examination but she had 
had no problems related to NF-1. 
111-3 - 19.3.37,47.7 years. 
5 CAL; freckling: axillae and over whole trunk; CNF: 4; face: no; 
LN: 23; Height: 157.5 (25); HC: 56 (90). 
111-5 - 17.7.43, died 31 years. 
Said to have had multiple CAL spots and a few cutaneous neurofibromas 
prior to death from a brainstem tumour (pathology unknown). Also had 
a facial plexiform neurofibroma which had required multiple 
operations. 
IV-1 - 8.4.63,21.7 years. 
6 CAL; freckling: axillae and submammary regions; CNF: 3; face: no; 
LN: 2; height: 160 (25); HC: 55 (75). 
IV-1 had 2 small asymptomatic plexiform neurofibromas on her trunk. 
IV-2 - 11.11.65, died February 1968. 
Had multiple CAL spots. In June 1967 had a right nephroblastoma 
removed but died of multiple metastases in February 1968. 
IV-3 - 11.1.68,16.9 years. 
5 CAL; freckling: axillae and groins; CNF: 3; face: no; LN: 2; 
height: 170 (25); HC: not appropriate. 
IV-3 presented with intermittend headaches and ataxia at the age of 
10 years. Investigation showed a right cerebellar mass and a grade 2 
astrocytoma was completely excised. Follow-up CT scans have been 
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normal and he has had no residual problems. He had a benign 
cutaneous neurofibroma removed from his trunk at 15 years of age. 
IV-4 - 25.1.70,14.9 years. 
9 CAL; freckling: unilateral axillary and bilateral in groins; CNF: 
1; face: no; LN: 3; height: 158 (25); HC: 54.5 (50). 
IV-4 had a small asymptomatic plexiform neurofibroma on her back, 
with overlying skin hypertrophy but no other problems. 
IV-5 - 9.1.70,14.7 years. 
7 CAL; freckling: none; CNF: 2; face: no; LN: 5; height: 148.5 (<3); 
HC: 58 (>97). 
IV-6 - 17.6.72,12.2 years. 
13 CAL all >1.5 cm; freckling: groins; CNF: 1; face: no; LN: 5; 
height: not appropriate; HC: 54 (10). 
Her parents noted curvature of the right leg when one month old. 
This was due to a pseudoarthrosis of the right tibia which, despite 
various procedures, did not unite and she had a below knee amputation 
at 4.7 years. 
IV-7 - 17.2.79,5.6 years. 
IV-7 had 2 CAL spots >1.5 cm but no other features (slit lamp 
examination normal). She was classified as equivocal for the initial 
linkage studies but re-examination 18 months later showed no new 
features and she has been classified as normal from that time. 
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Key to Pedigrees 
N IF 1 Family classification number 




III1 Diagnosis equivocal 
Sex uncertain 
Number and sex of children uncertain 
0 III1 Number of children of given sex, if >1 
No pregnancies 
Deceased 
Spontaneous miscarriage, unless stated in text 
Dizygotic twins 
-Q Illegitimate mating 
Details re marital status and offspring uncertain. 
Spouses/partners of unaffected relatives have only 
O been shown if they were married and had no children, 
if they had been married more than once or if they 






































































































































































































































































































In this section, the four index cases who had a negative family 
history and CAL spots as their only feature are described. Relevant 
details of other family members are supplied in the text, no 
pedigrees are provided. 
DNF 1 
The index case was referred by a consultant neurologist who noted the 
CAL spots on examination when she was referred for an unrelated 
problem. 
Index case - D. o. b. 25.6.60,24.5 years. On examination the only 
abnormality was 4 CAL spots >1.5 cm diameter; there was no freckling, 
neurofibromas or Lisch nodules and no relevant past medical history. 
Family review - The parents of the index case (father aged 61, mother 
62 years) and 3 siblings (sister 35 years, sister 27 years and twin 
brother 24.5 years) were all reported to be in good health with no 
NF-1 features. The index case did not want them to be examined. 
Conclusion - The CAL spots were considered to be a variant of normal. 
DNF 2 
Index case referred to study by his general practitioner. 
Index case - D. o. b. not documented, aged 30 years at time of 
assessment. On examination, 2 CAL spots >1.5 cm in diameter, no 
other features. 
Family review - Negative. 
Conclusion -2 CAL spots as variant of normal. 
DNF 3 
The index case was ascertained through the records of the Prince of 
Wales Orthopaedic Hospital and visited because of the mention of 3 
CAL spots at the time of admission for scoliosis surgery. 
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Index case - D. o. b. 14.9.61,24 years. The index case had surgery at 
the age of 14 years for idiopathic thoracic scoliosis, no underlying 
bony abnormality. She had had no other medical problems. On 
examination she had 2 CAL spots >1.5 cm in diameter and no other 
features. 
Family review - Parents (aged 47 and 46 years), 1 brother (aged 22 
years) reported normal. 
Conclusion - CAL spots as variant of normal with coincidental 
scoliosis. 
DNF 4 
The index case was referred to the study by her paediatrician, the 
diagnosis of NF-1 having initially been queried by her GP. 
Index case - D. o. b. 16.2.85, reviewed at 0.8 years. Normal 
developmental milestones; only problem parents had noted was slight 
ptosis of the left eyelid, this had been present from birth and was 
apparently non-progressive. 
On examination length and weight on 50th, head circumference on 
97th centile for age. 4 CAL spots >1.5 cm in diameter, 6 CAL spots > 
0.5 cm diameter; no other features, slit lamp examination not 
possible. The ptosis of the eyelid was confirmed but there was no 
obvious subcutaneous swelling which might have suggested a plexiform 
neurofibroma. 
Family review - Father - D. o. b. 18.3.46. Examination of skin and 
iris normal. 
Mother - D. o. b. 15.9.49. One CAL spot >1.5 cm diameter, no other 
feature's. 
Brother - D. o. b. 14.1.83. Reported normal. 
Conclusion - Probable new mutation for NF-1 but diagnosis cannot be 
made until other disease features develop. 
368 
Section 3 
In this section the four index cases classified as having other 
forms of neurofibromatosis are described. In the 2 cases where there 
is a possible (ONF 1) or definite (ONF 4) family history, pedigrees 
are supplied. 
ONF i
The index case was referred to the case by her consultant 
neurologist. 
Index case (II-1) - D. o. b.: 15.9.25,64.5 years. II-1 developed 
progressive bilateral deafness with tinnitus from the age of 46 
years. From the age of 60 years she developed episodic vertigo and 
increasing ataxia. Her deafness had been assessed by an ENT surgeon 
originally who diagnosed senorineural deafness of unknown aetiology. 
In 1984 increasing ataxia led to neurological referral. On 
examination she was profoundly deaf, had bilateral horizontal 
nystagmus, an absent left and decreased right corneal reflex and a 
slight right lower motor neurone facial palsy. She was ataxic with 
increased tone and brisk reflexes in the legs. Cranial CT showed 
large bilateral acoustic neuromas but no other abnormality. 
She underwent 2 operations for removal of the acoustic neuromas 
but was left with no hearing, bilateral facial palsies and swallowing 
difficulties. Her ataxia showed no improvement post-operatively. On 
examination for the study, her only cutaneous features were 2 CAL 
spots, LN were not present. 
Family review - 
I-2 - Born 1987, died aged 83 years in 1980. Increasing deafness 
with tinnitus from the age of 40 years. During the last year of life 
she had been bedridden because to ataxia presumed due to "old age". 
Cause of death unknown. No significant preceding family history, her 
husband had had no hearing problems. 
Generation II - Because of the possibility that I-1 had NF-2 her 
siblings were contacted. 11-4 had died of pulmonary TB at the age of 
30 years with no preceding relevant symptomatology. Her remaining 
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siblings all reported no hearing problems and all had normal 
audiological assessments at the time of the study. 
Generation III - The children of II-1 were all asymptomatic but 
underwent examination and screening for acoustic neuromas with 
audiometry, brain stem auditory evoked responses (BAER) and CT scan. 
III-1 - D. o. b. 27.3.47,37 years. Normal cutaneous examination and 
screening investigations. 
111-2 - D. o. b. 9.1.51,33.2 years. 2 CAL spots on examination. 
Decreased right sided caloric response but BAER normal; cranial CT 
with contrast showed possible small right sided acoustic neuroma, not 
confirmed on more detailed CT using air contrast. 
111-3 - D. o. b. 9.4.61,24 years. 1 CAL spot on examination. Normal 
audiometry and BAER testing; cranial CT with contrast showed 
possible small left intra-canalicular acoustic neuroma. 
Other members of generation III - The other members of generation III 
were reported to be asymptomatic. The causes of death in the 4 
deceased individuals were not indicative of being related to NF-2. 
Conclusion - II-1 has NF-2; the problems experienced in diagnosis and 
management are not unusual (Huson & Thrush 1986). Following the 
initial assessment of her children, arrangements were made for them 








The index case was referred to the study by his GP. 
Index case - D. o. b. 19.11.42,42.8 years. The only health problems 
the index case had had were a series of subcutaneous lumps which 
developed from his mid-30s onwards, some of which had given rise to 
severe paraesthesiae if knocked. He had had 6 lesions removed -4 
from his forearms, one from the back of his neck and one from his 
right flank. Histology reports were of neurofibromas for 2, lipomas 
for 3 and non-specific histology for the 6th lesion. 
On examination he had no CAL spots or LN. He had 3 very firm, 
discrete subcutaneous nodules, 2 of which (on his left forearm and 
groin) were acutely painful when pressed. Clinically they were more 
like neurofibromas than lipomas, but further biopsy was not felt to 
be justified. No other abnormalities were found on clinical 
examination. 
Family review - The index case reported that neither his parents nor 
5 siblings had similar problems. 
Conclusion - One neurofibroma can develop as an isolated event in 
otherwise healthy individuals. The index case in ONF-4 however has 
had 2 definite neurofibromas removed and has a further 3 on 
examination, which is unusual. He had no features to suggest he has 
these lesions as stigmata of NF-2. Riccardi (1982) has described a 
form of neurofibromatosis where the individuals develop cutaneous +/- 
spinal neurofibromas in adult life. It may be that the index case in 
ONF-2 falls into this category. 
ONF-3 
The index case was referred to the study by her GP. 
Index case - D. o. b. 29.5.35,50 years. This lady said she had had 
recurrent pain in her lower back since the age of 7 years. This had 
become an increasing problem since the birth of her first child in 
1961 when the pain had begun to radiate into her left buttock and 
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leg. In 1969 (aged 34 years) the pain became more localised to the 
left buttock, more constant in nature, and was worse just before a 
period. She noted two lumps on the upper medial aspect of her left 
leg and was referred to an orthopaedic surgeon. The 2 lesions were 
removed and found to be neurofibromas. From that time the patient 
had had a number of further operations for the removal of many 
similar lesions from the left buttock and perineum. The lesions were 
usually multiple, and aggregating in 'strings' along nerves, with the 
histological appearance of a plexiform neurofibroma. Despite the 
operations there was little relief of pain; a myelogram undertaken 
as further investigation in 1976 was normal. 
At the time of assessment for the study the patient still 
experienced severe left buttock pain radiating down the left leg; 
there were no palpable masses. Neurological examination was normal 
apart from the subjective alteration of appreciation of pin-prick and 
touch in the left leg. A pelvic CT undertaken to further define the 
lesion showed a soft tissue mass deep to the gluteal muscles in the 
fat of the lateral aspect of the ischio-rectal fossa with extension 
into the subcutaneous fat. 
On cutaneous examination there were no features of NF-1. 
Family review - Index case reported no similar problems in preceding 
generations or her siblings. Her children (girls aged 24,22,20 
years, boy aged 16 years) were all personally examined and had no 
NF-1 features. 
Conclusion - The index case has an isolated plexiform neurofibroma 
apparently involving the left-sided coccygeal plexus and possible 
upper branches of the sciatic nerve on the left side. Plexiform 
neurofibromas are unusual occurring in isolation, it could be 
possible that they are similar in aetiology to cases of segmental 
neurofibromatosis; it has been suggested that these represent a 
somatic mutation of the NF-1 gene (Carey 1986). 
ONF 4 
The index case (11-2) was referred to the study by his GP. 
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11-2 - D. o. b. 10.10.25,59.6 years. 
11-2 developed low backache and bilateral sciatica in his mid-teens 
and was initially thought to have 'arthritis'. At the age of 30 years 
he was referred for neurosurgical assessment because of numbness in 
the buttock and because plain X-rays had shown evidence of erosion at 
the pedicles suggesting an expanding spinal cord lesion. Examination 
showed mild diffuse weakness of the lower limbs with decreased right 
and absent left ankle jerk, analgesia over the buttocks and S1 
bilaterally. 
Myelography showed a large lesion in the cauda equina, another in 
the upper lumber/lower thoracic region and possibly an upper thoracic 
lesion. He initially had a massive lesion removed from the cauda 
equina but as the nerve roots tracked through and around the tumour, 
some were damaged. He was left with partial paralysis of the left 
leg and dribbling incontinence. Tumour histology was of a 
schwannoma. 
At a second operation a further tumour was removed from the lower 
thoracic region. He had had two further explorations of the lumber 
region since that time (1963 and 1967) both precipitated by 
increasing pain and weakness. On the first occasion no abnormality 
was found apart from arachnoiditis and on the second a further tumour 
was removed. Following the second operation he had been relatively 
static with regard to his degree of disability. On examination at 
the time of the study, he had no cutaneous features of NF-1. 
Neurological examination showed no abnormality in the cranial nerves 
or upper limbs. He was incontinent of urine with occasional 
incontinence of faeces, had diffuse weakness of his lower limbs, more 
marked distally with absent lower limb reflexes. He reported 
decreased sensation from the buttocks downwards but this was not 
formally examined as he was seen at home. 
Family review 
I-1 and 1-2 - His parents had both died of ischaemic heart disease 
with no neurological symptoms prior to death. 
II-1 and 11-3 - D. o. b. 25.6.23 and 23.9.27 respectively. Reported 
normal. 
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III-1 - D. o. b. 28.9.54,30.8 years. III-1 had developed recurrent 
episodes of pain in the neck from 18 years of age, in 1978 he 
developed paraesthesia in the left hand and weakness of the left leg. 
He was referred to a neurosurgeon and myelography showed an 
extradural spinal tumour in the cervical spine. This was 
successfully removed with complete resolution of his symptoms. 
Histology was of a schwannoma. 
He had had no further problems at the time of assessment. 
Examination showed no cutaneous or neurological abnormalities. 
111-2 - D. o. b. 27.3.56. Reported normal. 
Conclusion - It was felt that 11-2 and his son have a dominent gene 
predisposing to multiple spinal schwannomas. Although this is a 
common feature in families with NF-2, the latter diagnosis seems 
unlikely as neither of the cases have clinical evidence of acoustic 
neuromas, these are usually symptomatic by the mid-20s in patients 
with NF-2 (Kanter et a/ 1980). We therefore concluded that ONF-4 may 









In this section, the 16 index cases in whom diagnoses other than 
NF-1 were made are reported. Relevant details of other family 
members are supplied in the text and there are no accompanying 
pedigrees. 
NNF-1 
The index case was ascertained through hospital records. 
Index case - D. o. b. 9.11.28,57 years. This man had developed 
multiple painless subcutaneous swellings on his trunk from his 30s 
onwards. In 1983 had had been referred for hospital consultation 
when it was felt that the lesions were either neurofibromas or 
lipomas; biopsy was not undertaken as he was asymptomatic. On 
examination for the study, the patient's lesions were thought 
clinically to be lipomas, he had one CAL spot but no other 
abnormalities. Family history was negative. 
Diagnosis - Multiple lipomas. 
NNF-2 - The index case was referred by his GP. 
Index case - D. o. b. 12.7.52,33 years. This man had noted 3 painless 
subcutaneous lumps for approximately 6 years. On examination 3 
lesions were on his left forearm, anterior chest and right hip; they 
were approximately 2 cm in diameter and were thought clinically to be 
typical of lipomas. There were no other cutaneous abnormalities and 
the family history was negative. 
Diagnosis - Multiple lipomas. 
NNF-3 - The index case was referred by her GP. 
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Index case - D. o. b. 18.4.48,37.3 years. 
This lady had recently developed 2 painless subcutaneous 
swellings, one on each forearm. Clinically they were small lipomas. 
No other abnormality on examination. Family history was negative. 
Diagnosis - Lipomas. 
NNF-4 
The index case was referred by his GP. 
Index case - D. o. b. 12.2.20,65.5 years. 
This man had developed multiple painless subcutaneous lesions on 
his forearms and trunk from his late 20s. Clinically these were 
lipomas; no abnormality on cutaneous examination. No significant 
family history. 
Diagnosis - Multiple lipomas. 
NNF-5 
Referred to the study by another patient. 
Index case - D. o. b. 3.8.33,55.5 years. 
This man had a family history of multiple lipomatosis, his mother 
and 2/3 siblings being affected. He had approximately 20 lesions on 
his forearm and trunk; he had had one removed in the past and 
histology showed a lipoma. 
Diagnosis - Multiple lipomas. 
NNF-6 
This case was ascertained via hospital records. 
Index case - D. o. b. 15.7.05,79.8 years. 
NF-1 had been diagnosed on clinical grounds when he had been 
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investigated for haemoptysis in 1976; chest X-ray had showed a 
well-defined right upper lobe lesion and several subcutaneous nodules 
had been noted on his forearms and chest. The chest lesion showed no 
change in 6 months and the patient refused an operation. He had 
remained well and on examination for the study he had 5 painless 
subcutaneous swellings with the clinical appearance of lipomas and no 
other cutaneous abnormality. The patient could not remember his 
parents having similar lesions, although he reported that one of his 
8 siblings did. 
Diagnosis - Multiple lipomas with ? solitary thoracic neurofibroma or 
lipoma. 
NNF-7 
Referred to the study by his GP. 
Index case - D. o. b. 15.11.44,40.6 years. 
This man had developed multiple subcutaneous lesions on his 
forearms and trunk from his early 30s. Clinically they were not 
painful on palpation, had a soft consistency and were 2-3 cm in 
diameter, i. e. they were more typical of lipomas than neurofibromas. 
The only other cutaneous abnormality was one CAL spot. Negative 
family history. 
Diagnosis - Multiple lipomas. 
NNF-8 
Referred by GP. 
Index case - D. o. b. 6.1.47,38.5 years. 
This man had first noticed a painless subcutaneous swelling to 
the right of his lumbar spine at the age of 26 years. He had 
subsequently developed 3 further lesions, none of which caused any 
problems. Clinically they were lipomas rather than neurofibromas and 
there were no other abnormalities on cutaneous examination. 
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His father and 1/3 brothers were reported to have similar lesions. 
Diagnosis - Multiple lipomas. 
NNF-9 
This patient was ascertained via hospital records. 
Index case - D. o. b. 207.35,50.3 years. 
This man had developed multiple painless subcutaneous lesions 
from the age of 26 years. On examination he had 10 lesions, on his 
forearms and trunk, which were thought to be lipomas; no other 
abnormality on cutaneous examination. Family history negative. 
Diagnosis - Multiple lipomas. 
NNF-10 
Self-referral in response to newspaper article. 
Index case - D. o. b. 19.5.28,57.6 years. 
This lady had 2 painless subcutaneous swellings, one on her knee 
and one on the left forearm; clinically they were lipomas. She had 
had them for a number of years and thought that in the past she had 
been told she had NF-1. No other findings on cutaneous examination. 
Family history negative. 
Diagnosis - Lipomas. 
NNF-11 
Referred by GP. 
Index case - D. o. b. 1.12.24,60.8 years. 
This man had started to develop multiple subcutaneous lesions 
from his early 30s. He had had one removed from his right forearm in 
1979 and histology was of a lipoma. On examination he had 
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approximately 30 subcutaneous swellings which were clinically 
lipomas, and no other features. 
The patient reported 1/6 siblings had similar lesions and that 
his son was also affected. Could not recall his parents having 
similar lesions. 
Diagnosis - Multiple lipomas. 
Summary of NNF 1-11 - The clinical distinction between lipomas and 
neurofibromas was found to be relatively straightforward. Although 
only a minority of cases had had biopsy proven lipomas, clinically 
their lesions and those of the other cases were identical. The main 
distinguishing features from cases with NF-1 were that the latter had 
cutaneous as well as subcutaneous lesions; subcutaneous 
neurofibromas were found along the trunks of peripheral nerves and 
were painful on palpation and that subcutaneous neurofibromas were 
firmer than lipomas and had more discrete margins. 
NNF- 12 
Index case was a chronic schizophrenic who was referred by a 
psychiatrist. He had seen the possibility of NF-1 mentioned in her 
clinical notes on a hospital admission in the past and therefore 
referred her to the study. 
Index case - D. o. b. 22.5.28,57 years. On review this lady was found 
to have severe rheumatoid arthritis and her 'lumps' were rheumatoid 
nodules! 
Diagnosis - Rheumatoid arthritis. 
NNF-13 - Referred by GP. 
Index case - D. o. b. not recorded. Age 50 years. This lady had 
multiple small moles on her neck and trunk but no other features. No 
other medical problems and negative family history. 
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Diagnosis - Multiple moles 
NNF-14 
This lady referred herself to the study in response to the newspaper 
article. 
Index case - D. o. b. 5.6.39,46.5 years. 
This lady had had 'lumps' on her skin from childhood. They were 
painless, had increased in number throughout life, and frequently 
became infected. She had been told that she had NF-1 in the past. 
On examination she had approximately 200 cutaneous lesions, 1-2 
cm in diameter, which had a yellowish colouration and a firm 
consistency. These are shown in Figure A-1. There was no abnormal 
skin pigmentation. She clearly did not have NF-1 but as the 
diagnosis was unclear, she agreed to be seen by a dermatologist for 
biopsy. She was seen by Dr P Holt at the University Hospital of 
Wales; biopsy showed a cyst with the histological features of 
steatocystoma multiplex, a cystic disorder centred on sebaceous gland 
elements. This is an autosomal dominant disorder and one of the 
patient's children was similarly affected; the patient reported her 
sister, father and grandmother were also affected. 
Diagnosis - Steatocystoma multiplex. 
NNF-15 
This patient was ascertained via hospital records. 
Index case - D. o. b. 1.6.38,47.4 years. 
Neurofibromatosis had been diagnosed at the age of 15 years when 
she presented with a left thoracic scoliosis and a history of altered 
sensation over the left side of the body of a year's duration. She 
was referred to an orthopaedic surgeon and in turn to a neurologist. 
From the orthopaedic viewpoint she had a thoracic scoliosis, T4 - L1, 
with a curve of 46°, no underlying bony abnormality. The curve did 
not progress on follow-up. On neurological assessment, she was found 
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to have left-sided hyperalgesia with a left extensor plantar 
response. Multiple pigmented lesions were noted on her skin and a 
diagnosis of neurofibromatosis with possible intracranial involvement 
was made. The only abnormality on routine neurological investigation 
was slight increase in CSF protein, it was decided not to perform air 
encephalography but to observe her progress. The patient was then 
lost to follow-up. 
When seen for the study, the patient still complained of altered 
left-sided sensation, but neither this nor her scoliosis had changed 
over the years. In the interim she had developed asthma and 
hypothyroidism and was on routine treatment for both. On examination 
she had multiple small, very dark, slightly raised lesions which were 
thought to be lentigines rather than CAL pigmentation (Figure A-1). 
This was confirmed on biopsy. She also had short stature, even 
accounting for the scoliosis, with a height of 142 cm (<3rd centile) 
and hypertelorism. Neurological examination showed subjective 
sensory changes on the left side with an extensor plantar. 
Cardiovascular examination was normal including ECG. The patient had 
no obvious hearing problems and neither audiology nor 
echocardiography was felt to be justified. 
Putting the clinical features together, the diagnosis of LEOPARD 
syndrome was made; this would not account for the patient's 
neurological problems, the most likely explanation for which were a 
previous cortical infarction. 
The patient reported that her father and one of her 4 siblings 
had similar skin pigmentation but no other abnormalities. 
Diagnosis - LEOPARD syndrome 
NNF 16 
This patient was referred to the study by his consultant 
psychiatrist. 
Index case - D. o. b. 17.10.67,18.2 years. This patient was severely 
retarded, with limited speech and in long term hospital care. He was 
seen with his parents, neither of whom had any NF-1 features; there 
was no other significant family history. 
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The patient's main features were: severe retardation, slightly 
dysmorphic facies, short stature (height 150 cm, <3rd centile) and 3 
large areas of CAL pigmentation with rather jagged edges. There were 
no other cutaneous features. This patient is shown in Figure A-1. 
The diagnosis of NF-1 was excluded on clinical grounds but no 
other diagnosis was made. Further investigation included chromosome 
analysis both of lymphocytes and an involved area of skin, both of 
which were normal. 
Diagnosis - Mental retardation with atypical CAL pigmentation and 
short stature - diagnosis unknown. 
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FIGURE A-1. A. LEOPARD syndrome (case NNF 15) 
B. Atypical areas of CAI. pigmentation in case NNF 16 
in whom no diagnosis was reached. 
C. Steatocystoma multiplex (case '1NF 14) 
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APPENDIX B 
Genotypes for C3, APOC2 and Se polymorphisms in the 9 families used 
















































































































































Study questionnaire used in patient assessment and the computer data 




DIET. OF (E'F ICS, U. H. W. 
Date of assessment: 
General information 
1. Pedigree No. 
®1 Person No. 2 
2. Sex: Ma1e/femle Q3 
3. Disease status: Norm l/Query/Affected 
[] 4 
4. Name: Phase No. 
Address: 
Day Month Year 
5. Date of birth: 
mm 
567 




7. Social class: 
1. Professional 4. Semi-skilled 
2. Intermediate 5. Unskilled 
F-I 8 




8. Civil status: 
1. Single 4. Separated 
2. Married 5. Widowed 9 
3. Divorced 6. Engaged 
7. Other 
9. Method of ascertainment: 
1. Hospital records 7. Neurosurgeon 
2. G. P. 8. Orthopaedic surgeon 
3. Neurologist 9. Plastic surgeon 
4. Paediatrician 10. Denen tologist 
5. Geneticist 11. N. F. Society 
10 
6. General physician 12. Other 
10. G. P. - Name: 
Address: 





1. Have you noticed any small lwms on your skin anywhere? 
Q 11 
(If no, go to No. 22) 
2. How old were you when you first noticed them? 
m 
12 
3. Have you noticed any new ones since then? 13 
(If no, go to No. 17) 
4. Have more developed at some times than others, for example: 
When you were a teenager? (Yes/No/DK) 
14 
When you were pregnant? (Yes/No/DK) 15 
Do they appear at a fairly steady rate? (Yes/No/DK) in 
5. Have any ever disappeared? (Yes/No/DK) 
Q 
17 
6. Have any grown in size very much? (Yes/No/DK) 




7. Do they bother you in any way? No 1Q 
Pruritis 2 19 
Other 3 
8. Do you have any symptoms before a No 1 
new one appears? Pruritis 2 Q 20 
Other 3 
9. Have you ever had one removed? Yes/No 
Analysis, re. removal of NFS: 
None removed 1 Counetic 4 
Diagnosis 2 Secondary to neurological symptom 5 
[] 21 
Malignant change 3 Other 6 
Cafe au lait spots: 
1. Have you any birth marks or brown patches on your skin anywhere? Yes/No 22 
(If No go to No. 27) 
2. When did you first notice them? 
m 23 
3. Have any new ones developed since then? 
[] 
24 
4. When did you last notice a new one? Age 
m 25 
S. [Dive any ever disappeared? Yes/No/DK 
[J 2G 
NTi UROLDGTCAL SYMFIMS 
1. (teadncho- 
Do ycxt suffer from headaches? Yes/No 
If Yes, delineate: 
a) site of headache? 
b) kind of pain? 
C) how long does it last? 
d) how often do they occur? 
e) associated symptom? 
Analysis re. headaches: 
1 No headache 3 Tension 
2 Migraine 4 Other 27 
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2. Vision - Have you any problems with your eyesight? Yes/No 
3. Hearin - have you any problems with your hearing? Yes/No 
Do you have any trouble with dizziness or vertigo? Yes/No 
Do you have any buzzing in your ears? Yes/No 
4. Epilepsy - Have you ever had a fit? Yes/No 
5. Do you have any difficulty in walking? Yes/No 
6. Do you have any weakness in your arms? Yes/No 
7. Do you have any areas of abnormal sensation - like 
pins and needles, or areas of numbness? Yes/No 
Locator tans 
1. Do you have any problems with your joints? Yes/No 
2. Do you have any problems with curvature of the spine? Yes/No 
Gastrointestinal symptans 
1. Do you have any abdcminal (tummy) Pain)? Yes/No 
2_ Are vcur bowels regular? Yes/No 
Clydiovascular syrtmtans 
1. Have you ever had any problems with your heart? 
2. Have you ever had high blood pressure? 
. 1. Do you ever get any pain in your chest? 
4. Do you ever have episodes where your heart beats rapidly? 
5. Do you ever have episodes where you sm-at profusely 
for no apparent reason? 
Yes/No 
Yes/No/ßP never recorded 
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Psychiatric syrrptans 
Have you ever had problems with your nerves? Yes/No 
Birth weight/gestational age 
SToking - Do you smoke? 
(If yes, how many) _ 
Yes/No 
Other problEms 
1. Have you any other symptoms that we haven't mentioned? Yes/No 
2. Have you had any other problems with your health 
that ne haven't mentioned? Yes/No 
(If male, go to No. 30) 
Women only 
How old were you when your periods started? Age 
No. of pregnancies 
28 
No. of livebirths 29 
No. of affected children 30 
No. of miscarriages 
H 
31 
No. of stillbirths 
32 
SOLING AND DL=PON4ýi P 
Mildren <5 years 
1. flow old when they soiled? 
2. How old when they sat unaided? 
3. How old ý%Iien they walked unaided? 
4. How old wizen they first talked? 
Children at school 
1. Which school do they attend? 
2. Are Lhey having any particular problem at school? 
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Adults 
1. Which secondary school did you attend? 
2. How did you get on at school? (Tick) 
No qualifications 0 levels 
CSE's A levels 
I 
3. Did you have'any particular problem at school? 
4. Did you go on to further education? 
1. No 4. Polytechnic 
2. Apprenticeship S. University 
3. College F. E. 6. Other 
Final analysis (schooling) 
Under 5, normal milestones 1 
Under 5, abnormal milestones 2 
No problems at school 3 
33 
Specific problems at school 4 
Analysis of Family Data 
Age of father at conception: 
34 
Age of mother at conception: 
m 
35 
New mutation 1 Mother affected 3Q 36 
Father affected 2 Uncertain 4 
Disease attitudes (only if affected) 
1. How old were you wizen you first realised you 
(or your child) had NF? Age 
2. What happened at that time to make you realise? 
(N. B. Cannent if never seen by a doctor) 
3. Do you understand how NF is passed on in families? 
4. Have you ever asked a doctor for advice about how 
NF is passed on in families? 
5. What have been the rain problems that having NF 




1. Height = cms 
I 37 
2. Centile for 1. 38 
[ 
3. Head circumference = cros 
1-J 
m 39 
4. Centile for 3. 
40 
5. Weight - Kg 
41 
6. Skin pigmentation 
a) No. of CAL spots > 1.5 cros: 42 
b) If < 18 years, No. of CAL spots > 0.5cros <1.5 ans 43 
c) Axillary freckling: None/Bilateral/R/L Q 44 
Average size of freckles = 
d) Other areas of freckling = Yes/No 45 
Sites: 
e) CAL spots overlapping plexiform NFS - see nap. 
7. Neurof ibrams: 
a) Nodular - 
1. None 4. > 100 
46 
2. Few < 
3. Scanty 10-99 





c) Areolar NFs YES/M 
No R. breast 18 
No L breast 
Wfr mn on Iy 
! töw old were you wficn they appeared? 
What happened to them during pregnancy? 
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Neurof ibrorms 
Facial appearance, 'disfiguring' - Yes/No 
Neurofibrams/area: +< 10 
++ 10-50 +++>50 
race = R. Leg = 
Trunk = L. Leg 
R. arm = Soles = 
L. arm = Palms 
404 
Patient's appearance 
Cife au laits 
Draw in on figures if < 18 years. 
Draw in pignentation in relation to plexitotm neurolibra nta 
405 
8. Skeletal examination 
1. Skull - N/ABN 3. Lirtbs - N/A&V 
2. Back - N/Ar . If scoliosis present, note cervical/thoracic/ltmbar 
9. CVS examination 
P= 
Apex = 
If B. P. raised (R 
(L 




FEM. A BRUITS 
10. Neurological Examination 
a) Speech: 
b) Mental state: 









Tone = N/ABN 
Amer = N/A13N 
R. eflcros = N/ABN 
e) Sensation - N/AnN 
III, IV, VI: 
V: 
VII: 
IX, X, XI: 
XI I: 
Coord. = N/AB2 
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11. Lisch nodules 
R eye 
L eye 
Lisch n. R. eye 49 
Lisch n. L. eye 
m 50 
Final analyses. ccnmlications 
1. Neurological: 
None 1 NF with neurol carplication 7 
Epilepsy 2 Definite low IQ 8 
Optic gliona 3 Learning difficulties etc. 9 
Accoustic ne.. irana 4 Other 10 
Meningiaa 5 
Other tumours 6 
51 
2. Skeletal abnonrnlities 
Noranl 1 
Skull defects 2 
t--ý 
1 52 ý"J 
Pseudoartroses 3 
Scoliosis/kyphosis 4 
3. Other NF cai7, lications 
None 1 Hypertension unrelated to 4 5 
Visceral tumours 2 Cardiovascular problems 6 S. 
Constipation 3 Other 7 
Endocrine complications 4 
Naked eye Slit lamp Slit 1arrp 




1. Study area: Yes/No 
2. Pedigree number 
Person number 
3. Name: 
4. Sex: M/F 
5. Status: UN/RN/Q/A 
6. Date of birth: -/-/- 
7. Social class: - 
8. Civil status: - 
9. Education: - 
10. Height 
11. Centile for (10) L/N/S 
12. Head circumference 
13. Centile for (12) L/N/S 
14. Weight 
15. Skin pigmentation: 
a) No of CAL spots > 1.5cm 






d) Age CALs first noted 
e) Have any disappeared? Y/N/DK 
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16. a) Dermal neurofibromas - 
b) Age at first appearance - 
c) Symptoms - 
d) Any symptoms before a neurofibroma appears? 
e) Removal of NFs 
f) Facial appearance 0/N 
g) Did more appear when pregnant? Y/N 
h) Areolar neurofibromas Y/N 
i) Plexiform neurofibromas Y/N 
j) Site of (i): 1. Face - 
2. Trunk - 
3. Limb - 
k) Age at appearance of (i) 
1) Skin hypertrophy overlying (i) Y/N 
m) Bone hypertrophy associated with (i) Y/N 
n) Hair overlying (i) Y/N 
o) Operation for removal of (i) Y/N 
17. Lisch nodules: No. right eye - 
No. left eye - 
18. Neurological complications 
19. Skeletal abnormalities - 
20. Other NF complications - 
21. Genetics: a) Status - 
b) Father - 
Mother - 
c) Age at diagnosis 
d) Diagnosed 2° to study Y/N 
e) Genetic counselling Y/N 
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22. Grade of NF -- 
23. Method of ascertainment - 
24. GP analysis -- 
25. Regularly followed-up for NF Y/N 
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